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Abstract 
Cnot1 was identified as a candidate colorectal cancer (CRC) gene in multiple Sleeping 
Beauty-based screens. Multiple somatic mutations in CNOT1 in CRC have been 
documented. Depletion of CNOT1 in the SW480 CRC cell line resulted in a dramatic 
decrease in cell viability, suggesting that CNOT1 may act as an oncogene. CNOT1 is a 
scaffold of the CCR4-NOT complex, which regulates mRNA expression at several levels. 
Examination of global gene expression in CNOT1-depleted SW480 cells revealed 
dramatically increased expression of TXNIP, which can initiate apoptotic pathways in 
response to extreme endoplasmic reticulum (ER) stress. We hypothesized that CNOT1 
might protect cell viability by limiting TXNIP expression. In support of this idea that 
upregulation of TXNIP was responsible for decreased cell viability seen in CNOT1-
depleted cells, we found that enforced expression of TXNIP in HEK293 cells resulted in 
decreased cell viability. Also, analysis of TXNIP expression in parallel with cell apoptosis 
in CNOT1 depleted cells revealed that upregulation of TXNIP occurs well before a 
measurable increase in cell apoptosis, suggesting that elevated TXNIP may contribute to 
apoptosis seen in CNOT1-depleted cells. To substantiate this connection we investigated 
the mechanism by which CNOT1 regulates TXNIP levels. We found that depletion of 
CNOT8, a deadenylase subunit of the CCR4-NOT complex, also results in decreased cell 
viability and increased TXNIP expression. Further, CNOT1 depletion results in increased 
TXNIP mRNA stability. These results argue that CNOT1 limits TXNIP expression via 
regulation of mRNA deadenylation and stability. TXNIP is activated to promote 
apoptosis by extreme ER stress in part by means of relief of miR-17-mediated 
degradation of TXNIP mRNA. In support of this, we found that miR-17 overexpression 
downregulates TXNIP mRNA in SW480 cells. We also found that limiting TXNIP 
expression increases cell viability under condition of ER stress. CNOT1 acts as an 
adapter between the miRNA RISC and deadenylase subunits of the CNOT complex. 
Thus, we hypothesized that increased activity of CNOT1 may facilitate the degradation 
of TXNIP by miR-17. Further analyses suggested that CNOT1 might limit ER stress and 
activation of the unfolded protein response (UPR) pathways. Based on the results above, 
we proposed the following model. As cancer cells are often subject to extreme stresses, 
increased activity of CNOT1 may protect against the effects of severe ER stress through 
directly limiting TXNIP transcript levels and preventing ER stress leading to apopotsis, 
thus conferring a growth advantage to cancer cells.  
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Chapter 1 
Introduction 
Epidemiology and Challenges in Colorectal Cancer Treatment                                    
Colorectal cancer (CRC) is the third most common cancer in men (663,000 cases) 
and the second in women (571,000 cases) worldwide. About 608,000 deaths from CRC 
were estimated to occur worldwide, accounting for 8% of all cancer deaths, making it the 
fourth most common cause of death from cancer (Ferlay et al., 2010). In the United 
States, CRC is the third leading cause of cancer death accounting for 142,820 new cases 
and 50,830 deaths in the year 2012 (Siegel et al., 2013). In China, the incidence rate of 
CRC is relatively lower than western countries. However, the rate has increased 
dramatically in recent years partially due to the changes in lifestyle and environmental 
pollution. In 2008, China reported 220,000 new cases and 109,000 deaths from CRC, the 
highest number to date in each category of CRC. These statistics highlight the significant 
impact of CRC on our society and thus the importance of new diagnostic and therapeutic 
tools for this cancer.  
Up to 95% of all CRCs are gland-forming adenocarcinomas derived from the 
crypt epithelium (Parkin et al., 2001). Other types of malignancy account for the 
remaining 5% of CRC, including mucinous tumors, signet ring tumors, adenosquamous 
carcinoma, and undifferentiated carcinoma (Jessurun et al., 1999). CRC often causes no 
symptoms until it reaches an advanced stage. Symptoms may be present, but are 
nonspecific and vague, including a change in bowel habits, weight loss, abdominal pain, 
hematochezia, melena, fatigue and weakness (Benedix et al., 2010). The diagnosis of 
CRC is usually made on the basis of histopathology of surgical or biopsy specimens. 
Imaging, including CT and MRI scans of the abdomen and pelvis and lung, is used to 
accurately stage patients. CRC tissues are usually graded as well-, moderately- and 
poorly-differentiated based on how closely the tumor cells resemble normal epithelial 
cells. Once the diagnosis of CRC is made, the disease should be staged. Accurate staging 
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leads to both proper management and prognostic significance for the patient. The two 
most common staging systems to define the extent of invasion of CRC are the Dukes' and 
the TNM staging system. In the TNM staging system, patients are stratified according to 
the depth of tumor penetration (T), number of positive lymph nodes (N) and extent of 
distant metastasis (M) (Edge et al., 2009). Although pathological staging is useful in 
determining the treatment strategy and predicting the prognosis of CRC patients, it has 
some disadvantages. For example it cannot distinguish stage II patients who will relapse 
from those who will be cured by surgery alone. A novel staging system integrating the 
genetic changes in specific cancers may be more effective in selecting therapy and 
predicting prognosis (Eschrich et al., 2005).  
The last decade has witnessed new strategies for the diagnosis and treatment of 
CRC which have improved patient survival. All treatment decisions are determined on an 
individual basis based on the stage, differentiation, pathological type of cancer as well as 
patient’s age, general health, and other medical conditions. Surgery, radiation, 
chemotherapy or a combination of these approaches are among the options available to 
treat patients with CRC. Surgery is the most common treatment for all stages of CRC and 
is the only potentially curative treatment (Lee et al., 2007). Chemotherapy is widely used 
for treatment of stage III CRC post-surgically to prevent the recurrence of disease. It can 
also be used as the primary therapy for advanced CRC when surgery is not indicated 
(NCCN 2012). The use of adjuvant chemotherapy in stage II disease remains unclear and 
controversial (André et al., 2004). Surgery alone is the predominant therapy for stage II 
CRC patients as large clinical trails have not demonstrated a significant benefit to a 
surgery plus chemotherapy regimen in treating stage II disease. However, up to 25% of 
stage II CRC patients rapidly relapse following surgery alone therapy. Thus, there is a 
subset of stage II patients who would benefit by more aggressive therapy. This highlights 
the importance of genetic studies to distinguish this group of high-risk patients from low 
risk patients. The options for treatment of advanced disease are still limited. Even given 
the most effective regimen, 50% of stage III patients relapse (NCCN 2012).  For stage IV 
patients, the situation is even worse. The overall survival is only around two years 
following treatment with surgery combined with standard FOLFOX chemotherapy and 
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bevacizumab (NCCN 2012). These limitations and challenges in CRC management 
highlight the importance of research, especially genetic research, in improving outcomes 
in CRC patients, for example, in the identification of biomarkers for further stratifying 
patients and as targets for emerging novel therapeutic strategies.  
The Biology of the Human Intestinal Tract  
The human intestinal tract extends from the stomach, the small intestine, and 
proceeds to the large intestine, and terminates at the anus. The small intestine is 
composed of the duodenum, jejunum and ileum, and is about 20-25 feet long on average, 
and is the site where most of the digestion and absorption of nutrients is carried out. The 
large intestine, about 5 feet long, consists of the caecum with appendix extension; the 
ascending, transverse, descending and sigmoid colon; and the rectum. The large intestine 
is horseshoe shaped and extends around the small intestine. A major physiological 
function of the large intestine is to absorb water from the remaining indigestible food 
matter and temporarily store waste matter. Besides nutrient digestion and absorption, the 
intestinal tract, in particular the large intestine, also plays important roles in 
immunological defense, water homeostasis, and entero-endocrine signaling, and other 
functions.  
The intestinal wall is composed of four layers, which are the serosa, muscularis, 
submucosa and mucosa from outside to inside (intestinal lumen). Each layer has different 
tissues and functions. The serosa layer consists of connective tissue and acts as a 
covering for the digestive tube. The muscularis layer surrounds the submucosa and is 
responsible for intestinal peristalsis.  Rich in vessels like arteries, veins, lymphatics and 
nerves, the submucosa layer provides the intestine with blood supply and is the location 
of a varaiety of non-epitheliual cells (e.g., fibroblasts, cells of the innate and adaptive 
immune systems) that comprise the intestinal stroma. The mucosa is the innermost layer 
of the intestinal tract which is lined by absorptive and secretory epithelium. The 
epithelium consists of a simple columnar epithelium layer with millions of “crypts of 
Lieberkuhn” that are finger-like invaginations of the epithelium into the underlying 
connective tissue (Figure 3). There are four classes of terminally differentiated cells in 
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small intestinal crypts. The enterocytes, the most abundant cell type in the intestinal 
epithelium, are absorptive cells while the other three classes are all secretory: goblet cells 
secrete mucus; enteroendocrine cells are smaller and secrete various gut hormones 
(peptides and catecholamines) that regulate numerous important biological processes; and 
Paneth cells secrete digestive enzymes, growth factors and especially diverse host 
defense (antimicrobial) proteins such as α-defensins, secretory phospholipase A2 and 
various proinflammatory cytokines (e.g. TNF-α, IL-1β) to protect the constantly 
renewing crypt from harmful invaders. The composition of cell types in the colon is 
similar to that of the small intestine, except for the absence of villi and Paneth cells.   
All types of terminally differentiated cells originate from the differentiation of 
progeny of intestinal stem cells (ISCs) which are located at the base of the crypt in both 
the small and large intestine. In the small intestine, ISCs are interspersed with Paneth 
cells (Sato et al., 2011). Under normal conditions, the intestinal epithelial cells are 
renewed every 2-7 days, which is fueled by stem cells (Figure 4, Medema et al., 2011). 
ISCs are responsible for generating the entire crypt-villus structure. In the small intestine, 
Paneth cells migrate downward to reside at the bottom of the crypt and live for 6-8 
weeks. Slightly higher up the crypt are the transit amplifying (TA) cells and committed 
progenitor cells that undergo differentiation into the enterocytes, goblet cells, and 
enteroendocrine cells as they migrate from the base of the crypt towards the lumen. When 
the migration of these differentiated cells reaches the villus tip (small intestine) or 
intercrypt table (colon), they undergo apoptosis and are shed into the intestinal lumen.  
There are two hypothetical models of stem cells in the intestine (Clevers et al., 
2013). The “+4 model” refers to a common intestinal stem cell origin at position 4-5, 
directly above the Paneth cell compartment. Potten et al. showed that the radiation-
sensitive, label-retaining +4 cells were actively proliferating with 24 hour cell cycles. The 
other model is termed as “the stem cell zone model” which is based on the finding that 
the crypt base is not solely populated by postmitotic Paneth cells. Instead, a population of 
slender crypt-base-columnar (CBC) cells was wedged between the Paneth cells located at 
position 1-5, which were radiation-sensitive but not label-retaining and were called 
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intestinal stem cells (Cheng and Leblond, 1974). Although the identity of intestinal stem 
cells is still controversial, it is agreed that intestinal stem cells reside in a niche that 
provides them with essential signals from important morphogenetic pathways such as 
WNT, NOTCH, and BMP (Figure 5, Heath JK 2010, Crosnier et al., 2006, Reya and 
Clevers 2005). 
 
Figure 1. The anatomy of the gastrointestinal tract. (Nucleus Medical Art, Inc. 2008) 
 
Figure 2. The multi-layered organization of the mature GI tract. (Heath JK 2010). 
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Figure 3. The organization of the small intestinal crypt-villus and the colon crypt. Both the 
colon crypt (left) and the small intestinal crypt (right) are shown. (Medema and Vermeulen, 
2011).  
 
Figure 4. Organization of the intestinal epithelium and the crypts of Lieberkühn and cell 
lineage determination in the intestinal epithelium. (Heath JK 2010).  
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Important Signaling Pathways in Intestinal Crypt Renewal 
Specifically, several key regulatory signals have been reported to be involved in 
intestinal stem cell renewal and differentiation, including the WNT, bone morphogenetic 
protein (BMP), and NOTCH pathways (Heath JK, 2010, Reya and Clevers, 2005). 
Furthermore, evidence suggests there is a close interaction between several key pathways 
in directing intestinal epithelial stem cell renewal and differentiation (Figure 4).  
WNT Signaling Pathway  
WNT signaling is crucial in controlling cell proliferation/regeneration in the 
intestinal epithelium and the maintenance of intestinal stem cells (Polakis, 2007). WNT 
proteins are extracellular glycoproteins produced by epithelial cells in the crypt, which 
bind the Frizzled and the low density lipoprotein receptor-related protein 5 (Lrp5) 
receptors on the surface of intestinal epithelial cells. β-catenin is the key effector of the 
canonical WNT signaling pathway. In the absence of WNT binding, cytoplasmic β-
catenin levels are normally kept low through continuous degradation, which is controlled 
by the APC/Axin/CK1/GSK3 destruction complex. This complex binds to newly 
synthesized β-catenin and phosphorylates it, thereby targeting phosphorylated β-catenin 
for ubiquitination-mediated proteolysis. When WNT proteins bind to the Frizzled/LRP 
receptor complex at the cell surface, the destruction complex is inactivated, resulting in 
the accumulation of β-catenin in the cytoplasm. The accumulated β-catenin then 
translocates into the nucleus to bind with Tcf/Lef transcription factors, leading to 
transcriptional activation of important target genes involved in cell proliferation and 
oncogenesis such as Cyclin D1 and c-MYC (Komiya et al., 2008, Cadigan et al., 2012). 
The expression level of components of the WNT signaling is highest at the bottom of 
intestinal crypts. Canonical WNT signaling plays a major role in maintaining intestinal 
stem cell fate and stimulating progenitor cell proliferation (Reya and Clevers, 2005). For 
example, in Tcf4-/- mice, the proliferating compartment between the villi was entirely 
absent, suggesting an essential role for Wnt in maintenance of crypt progenitors (Korinek 
et al., 1998). Dysregulation of the WNT signaling pathway was shown to cause aberrant 
proliferation of colonic crypts and is the rate-limiting step in CRC development. For 
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example, in 80% of CRCs both APC alleles are inactivated. Furthermore, mutations in 
other canonical WNT pathway components have also been observed in CRC. For 
example, somatic mutations in AXIN1 (Jin et al., 2003) and the TCF4 transcription factor 
have been observed in a subset of CRCs (Angus-Hill et al., 2011). Activating mutations 
in the β-catenin gene (CTNNB1) that protect the protein from APC-mediated degradation 
are also observed in CRC and adenomas (Kaler et al., 2012).     
NOTCH Signaling Pathway 
Another important signaling pathway for intestinal homeostasis and 
differentiation is the NOTCH signaling pathway. NOTCH signaling mediates cell-cell 
interactions in animal development and is known to regulate the proliferation and 
differentiation of intestinal stem cells. Mammals express four transmembrane Notch 
receptors (Notch1-4) and five canonical transmembrane ligands (Delta-like [DLL] 1,3, 
and 4, Jagged-1, 2) (Espinoza et al., 2013). In canonical NOTCH signaling, when 
NOTCH receptors bind to their ligands expressed on neighboring cells, this initiates 
proteolytic cleavage of the receptors by α-secretase and γ-secretase to release NOTCH 
receptors’ intracellular domain (NICD). The cleaved receptors then translocate into the 
nucleus and form complexes with RBP-jκ and induce transcriptional activation of 
NOTCH target genes such as transcription factor hairy/enhancer of split (Hes1) which is 
important for NOTCH induced repression of differentiation. Knockout of Hes1 in 
intestinal tumor cells in Apc-mutant mice was reported to reduce tumor cell proliferation, 
while promoting differentiation toward epithelial lineages (Ueo et al., 2012). Crucial 
components of the NOTCH signaling pathway have been shown to localize to the 
proliferative zone of the intestinal crypts but only weakly in the intestinal villi (Jensen et 
al., 2000, Riccio et al., 2008). NOTCH signaling promotes progenitor cells’ 
differentiation into the absorptive cell lineage rather than the secretory cell lineage 
(Jensen et al., 2000, Riccio et al., 2008) through inhibition of the transcription factor 
atonal homolog 1 (Atoh1) which appears to be required for secretory cell differentiation 
(VanDussen and Samuelson, 2010). Thus, disruption of NOTCH signaling results in 
increased Atoh1 expression and secretory cell hyperplasia, whereas hyperactive NOTCH 
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signaling results in decreased Atoh1 expression and increased numbers of absorptive 
enterocytes (VanDussen et al., 2012). Importantly, NOTCH signaling does not act alone 
but interacts with other key signaling pathways, such as WNT signaling, to promote 
functional signaling networks required for development and tissue homeostasis. In 
addition, there may be a cross-talk between the Notch and RAS signaling pathways, in 
which RAS activating mutations can activate Notch signaling while Notch activation is 
required for RAS-mediated transformation (Saif and Chu, 2010). NOTCH signaling also 
has been shown to be a key participant in epithelial-to-mesenchymal transition (EMT) 
that is an important process for metastatic disease (Saad et al., 2010).  
BMP Signaling Pathway 
The bone morphogenetic protein (BMP) pathway, originally identified as factors 
inducing cartilage and bone formation, also has been shown to play a key role in 
gastrointestinal cell development and in maintaining tissue homeostasis (Itoh et al., 
2000). BMPs belong to the transforming growth factor beta (TGFβ) superfamily, which 
share intracellular signaling through the SMAD proteins. The action of BMP is mediated 
by type 1 (BMPRI) and type 2 (BMPR2) serine/threonine kinase receptors. In the 
canonical BMP pathway, the binding of BMP to BMPRI results in activation of BMPRI, 
leading to phosphorylation of SMAD proteins (SMAD1, SMAD5 and SMAD8). The 
phosphorylated BMP-SMADs form a complex with a co-SMAD (SMAD4) and 
translocate into the nucleus. Once in the nucleus, the SMAD complex cooperates with 
other transcription factors to modulate target gene expression. BMP signaling within the 
intestine is quite complex as BMPs and their receptors are expressed in both epithelial 
and mesenchymal compartments. It has been suggested that BMP2 and BMP4, expressed 
by the mesenchymal cells, can halt proliferation at the crypt-villus border, as BMPs are 
active at the top of the crypt where differentiation occurs. Though also produced at the 
crypt base, they are kept in check by BMP inhibitors such as Noggin. BMP signaling has 
been reported to antagonize WNT signaling along the crypt-villus axis to inhibit intestinal 
stem cell activation and expansion. This signaling pathway has also been shown to be 
involved in lineage fate decisions of secretory cells (He et al., 2004, Derynck et al.,2003). 
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The human adult colonic epithelium undergoes perpetual regeneration fueled by 
intestinal epithelial stem cells and progenitor cells, which is a highly coordinated process 
regulated by different signaling pathways. Disrruption of the signaling pathways critical 
for stem cell renewal may result in a series of diseases in GI tract, including CRC.  
Hereditary and Sporadic CRC   
CRC can be subdivided into hereditary or sporadic cancers depending on the 
presence or absence of familial genetic predisposition. Around 30% of diagnosed CRC 
are considered to be hereditary, while the majority of the CRC cases (70%) occur in 
sporadic forms (Figure 5, Lynch et al., 2003).  
 
Figure 5. The fraction of colon cancer cases that arise in various family risk settings. (Burt, 
2000) 
Hereditary CRC 
Around 30% of the diagnosed CRC cases are considered to be hereditary, 
including dominantly inherited CRC syndromes, such as Familial Adenomatous 
Polyposis (FAP), Hereditary Non Polyposis Colorectal Cancer (HNPCC), and MUTYH 
Associated Polyposis (MAP), which together account for 5-10% of cases and CRC in 
patients from families with familial susceptibility (~25-30% of cases) (Chapelle et al., 
2004).  
FAP is an autosomal dominant syndrome which causes 0.5-1.0% of CRCs and 
affects approximately 1 in 10,000 births (Fearon et al., 2011, Rustgi et al., 2007). FAP 
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patients usually carry germline mutations in APC, typically frameshift or nonsense 
mutations. FAP is characterized by hundreds to thousands of adenomas in the colon and 
rectum, which start to appear in the patient’s second decade of life. Some of these 
adenomas inevitably progress to adenocarcinoma and metastatic disease unless the 
patient undergoes prophylactic colectomy. Hence, FAP patients are recommended have 
endoscopic screening from 10 years old. Genetic studies of FAP led to understanding the 
role of APC somatic mutations in also causing sporadic CRCs.  
Also known as Lynch syndrome, HNPCC is an autosomal dominant condition 
which causes ~2-5% of CRCs and is a genetically heterogeneous disease (Fearon, et al., 
2011). HNPCC patients have germline mutations in genes involved in DNA mismatch 
repair (MMR), with the majority of known HNPCC mutations being found in the genes 
MSH2 and MLH1. Tumors from HNPCC patients also often contain microsatellite 
instability (MSI). There is a more rapid transition from adenomatous lesion to carcinoma 
compared to sporadic cancers, as affected cells accumulate mutations swiftly due to 
impaired DNA repair mechanisms. HNPCC patients have an 80% lifetime risk of 
developing CRC that typically develop in patients in their 40’s, compared with an 
average incidence age for sporadic CRC in the 60’s. HNPCC also increases the risk of 
other cancers such as gastric, ovarian, endometrial, renal and hepatobiliary cancers (Johns 
Hopkins Medicine CRC).  
Genetic Alterations in Sporadic CRC  
The majority of CRC (~70%) is considered sporadic, reflecting no (or very little) 
family history of the disease. Sporadic CRC are different from dominant hereditary 
syndrome forms in that they arise from an accumulation of somatic mutations in rate-
limiting tumor suppressor genes and oncogenes rather than inheriting germline mutations 
(Rustgi et al., 2007). Both sporadic and inherited CRC emerge from normal colonic 
epithelium as a result of a sequence of genetic mutations and genomic alterations 
(including epigenetic changes) that lead to uncontrolled cell division and tumor 
formation. Identification of the genetic abnormalities that accumulate in a step-wise 
manner has led to the well-known model of the adenoma-carcinoma sequence initially 
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characterized by Fearon and Vogelstein (Figure 6, Fearon et al., 1990). This model 
describes the stepwise progression from normal glandular epithelial cells to benign 
neoplasia (adenoma) to carcinoma and eventually metastatic cancer and correlates 
specific genetic events with evolving tissue morphology. In the model that accounts for 
~80% of CRC, mutations in the APC gene result in the activation of WNT signaling, 
which promotes the formation of small adenomas in the form of polyps. Subsequent 
mutations in KRAS, BRAF, P53, and other genes promote the progression to carcinomas, 
and finally additional mutations drive tumor metastasis (Walther et al., 2009). As 
discussed below, many additional mutations that confer a selective advantage for tumor 
growth are required for the development of a CRC. The progression from adenoma to 
invasive carcinoma can take years or even decades (Walther et al., 2009). This concept 
not only provides an excellent model to study the genetics of invasive cancer, but also 
affords a means of preventing CRC by endoscopic removal of precursor lesions (Jass et 
al., 2007). 
 
Figure 6. Schematic representation of the Vogelstein model of colonic carcinogenesis. (Johns 
Hopkins Medicine CRC) 
Identification and characterization of genes that drive cancer processes are critical 
for the development of cancer diagnostic and therapeutic modalities. Over the past three 
decades, molecular genetic studies have revealed some critical mutations at high 
frequency underlying the pathogenesis of the sporadic and inherited forms of CRC, 
including APC, K-RAS, and TP53. 
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APC has been reported to be involved in multiple critical cellular functions. The 
best-established role for APC in CRC is as a major negative regulator of the canonical 
WNT signaling pathway. Germline mutations in APC play a key role in FAP. More than 
95% of known mutations in APC in FAP patients are frameshift or nonsense mutations 
that lead to premature truncation of protein synthesis (Segditsas et al., 2006). FAP 
individuals who inherit germline mutations in APC develop thousands of colorectal 
adenomas by their teens with the inevitable progression of some of these to carcinoma, 
unless the intestine is surgically resected (Kinzler and Vogelstein, 1996). In addition to 
the role in FAP, APC plays a very prominent role in sporadic CRC. Loss of function 
mutations in APC occur in over 80% of sporadic CRC (Kinzler and Vogelstein, 1996). 
Nearly all somatic mutations lead to premature truncation of the APC protein (Segditsas 
et al., 2006). Somatic APC mutations are an early and rate-limiting event in the 
development of most adenomas (Powell et al., 1992). The inactivation of both alleles of 
the APC gene can be detected in most of the intestinal tumors at early stages of 
development (Powell et al., 1992), in agreement with Knudson's two hit hypothesis. 
However, accumulated mutations in additional genes are required for progression of the 
early lesions to cancer. 
Activating mutations in K-RAS (Kirsten rat sarcoma viral oncogene homolog), a 
member of the RAS family of proto-oncogenes, represent a second genetic alteration 
which occurs early in the evolution towards intestinal cancer (Plesec et al., 2009). The 
RAS family of small-G proteins function as molecular switches downstream of multiple 
receptor tyrosine kinase (RTK) growth factor receptors, such as the epidermal growth 
factor receptor (EGFR) family (Malumbres et al., 2003, Zhao et al., 2008). The product 
of the proto-oncogene K-RAS is involved in transduction of the MAPK (mitogen 
activated protein kinase) signaling pathway. K-RAS mutations in specific codons occur in 
approximately 40% of CRC and lead to the constitutive activation of the 
RAS/RAF/MEK/ERK signaling pathway, resulting in the transduction of signals 
involved in cell proliferation and apoptosis inhibition and thus, contributing to malignant 
transformation (Kim and Lance, 1997). K-RAS mutations contribute to colorectal 
adenoma progression but are not required for adenoma initiation, which is supported by 
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the fact that K-RAS mutations are found in at least 50% of colorectal adenomas larger 
than 1 cm and in carcinomas (Vogelstein et al., 1988). K-RAS mutations occur after APC 
mutations in the adenoma-to-carcinoma progression sequence, but are still a relatively 
early event in tumorigenesis. Acquired K-RAS mutations are maintained throughout 
carcinogenesis, as evidenced by the concordance of K-RAS mutation status in primary 
and metastatic colorectal cancer (Artale et al., 2008). 
The phosphatase and tensin homologue (PTEN) gene codes for a lipid 
phosphatase which functions as a negative regulator of the phosphoinositide-3-kinase 
(PI3K)/ v-akt murine thymoma viral oncogene homolog 1 (AKT) pathway. The loss of 
PTEN, which occurs through different mechanisms, probably acts to enhance effects 
downstream of the K-RAS protein via PIP3-mediated activation of AKT that acts on 
downstream anti-apoptotic factors and the mTOR pathway, resulting in persistent 
oncogenic signaling (Cully et al., 2006, Chalhoub et al., 2009). Germline PTEN 
mutations are found in Cowden syndrome, leading to hyperactivity of the mTOR 
pathway, and an increased risk of some benign GI tumors but not an elevated risk of CRC 
(Hobert et al., 2009). Some studies suggest that PTEN protein expression may be lost in 
15-20% of CRCs (Laurent-Puig et al., 2009). Other studies indicate that loss of PTEN 
protein expression measured by IHC occurs in 30% to 45% of CRCs (Loupakis et al., 
2009).  
Loss of heterozygosity (LOH) is a key mechanism for inactivating one allele of 
certain tumor suppressor genes in cancer. Approximately 70% of CRCs are characterized 
by loss of the short arm of chromosome 17 (17p) (Fearon et al., 1990, Vogelstein et al., 
1988). LOH at this locus correlates with the transition from benign adenoma to invasive 
cancer (Vogelstein et al., 1988, Baker et al., 1990). The TP53 gene is thought to be the 
main target of 17p LOH (Baker et al., 1990). In addition to 17p LOH, the function of 
TP53 may be lost due to intrachromosomal somatic mutations. Approximately 85% of 
TP53 mutations in CRC are missense defects, which most often occur at codons 175, 
245, 248, 273, and 282 (Wood et al., 2007, Baker et al., 1990). The few nonsense and 
frameshift mutants encode a truncated TP53 product. TP53 is regarded as the "guardian 
  16 
of the genome" due to its functions in cell-cycle checkpoints at the G1/S and G2/M 
boundaries, in promoting apoptosis, and in restricting angiogenesis (Vousden et al., 
2009). TP53 mutations and LOH of TP53 alterations have been reported in 4-26% of 
adenomas, approximate 50% of in situ carcinomas, and in 50-75% of adenocarcinoma 
(Kaserer et al., 2000). This result is indicative of the central role of loss of TP53 function 
in the adenoma to carcinoma transition. Selection for TP53 mutations in CRC may be due 
in part to the loss of TP53 function in regulating key target genes, including p21, BAX, 
and MDM2 (Vousden et al., 2009). Loss of function in TP53 may facilitate continued 
growth and the acquisition of invasive properties in the face of stresses, including DNA-
strand breakage, telomere erosion, hypoxia, and reduced nutrient exposure, that might 
otherwise severely limit tumor cell survival and maintenance at the adenoma-carcinoma 
transition.  
However, these documented high frequency mutations do not completely explain 
all CRCs, since more mutations need to be acquired in addition to these high frequency 
mutations in the progression to highly invasive carcinomas. Moreover, some CRCs lack 
these high frequency mutations. Therefore, genome-wide analyses of somatic mutations 
in CRC were performed to obtain a deeper understanding of genetic alterations in CRC. 
The first genome-scale study of somatic mutations in CRC was conducted by the 
Vogelstein group at Johns Hopkins University (Wood et al., 2007). They identified a 
small population of genes that were frequently mutated in CRCs. These were called 
“mountains”, including genes such as APC, KRAS, and TP53. Surprisingly, their study 
identified a much larger population of genes mutated at a lower frequency, hence the 
term “hills” (Figure 7, Wood et al. 2007). They then analyzed the influence of the low 
frequency mutations in signaling pathways by determining whether the genes within 
specific pathways were mutated more often than predicted by chance. They found that 38 
pathways were preferentially mutated in CRC. Within the 38 pathways, many of them 
were involved in the PI3K signaling. Additional pathways altered in CRC were related to 
cell adhesion, the cytoskeleton, and the extracellular matrix. These findings suggest that 
tumor growth in individual human CRCs may be driven by some genes that are mutated 
at a low frequency though affecting important signaling pathways. 
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Figure 7. Human colorectal cancer genome landscape. (Wood et al. 2007). 
To identify a more complete list of genes dysregulated in CRC, large-scale exome 
and genome sequencing studies of human CRCs have been conducted by multiple groups 
(Cancer Genome Atlas Network 2012, Han et al., 2013, Schee et al., 2013). These studies 
have revealed that there are hundreds to thousands of DNA alterations in the average 
CRC genome, and that there are roughly 80–100 genes that are commonly altered by 
non-synonymous mutations, and roughly 15 mutations in candidate ‘driver’ genes per 
cancer genome. Somatic mutations can be classified as either driver mutations or 
passenger mutations. Driver mutations confer a growth advantage to the cells carrying 
them in the neoplastic process and are positively selected for during tumorigenesis. They 
reside, by definition, in the subset of genes known as ‘cancer genes’ that are causally 
implicated in cancer development. Passenger mutations provide no positive or negative 
selective advantage to the tumor but are retained by chance during repeated rounds of cell 
division and clonal expansion (Grady et al., 2013, Wood et al., 2007). However, the 
‘passengers’ can be converted into ‘drivers’ under certain selective environments, such as 
chemotherapy (Roche-Lestienne et al., 2002, Mullighan et al., 2008). The number of 
driver mutations in an individual cancer is a central conceptual parameter of cancer 
development, but is not well established. On the basis of age-incidence statistics it has 
been suggested that common adult epithelial cancers such as breast, colorectal and 
prostate cancers require 5-7 rate-limiting events, possibly equating to drivers, whereas 
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cancers of the haematological system may require fewer (Stratton et al., 2009). These 
estimates are supported by experimental studies which show that engineering changes in 
the functions of at least 5 or 6 genes in normal primary human cells are necessary to 
convert them into cancer cells (Schinzel et al., 2008). However, recent analyses of 
somatic mutation data from cancers indicate that the number of drivers might be as many 
as 20 driver mutations in individual cancers  (Beerenwinkel et al., 2007). Ultimately, 
direct estimates of the number of drivers in individual cancers will be provided by 
identifying all the cancer genes and systematically measuring the prevalence of genomic 
mutations and epigenetic alterations in them.  
While identifying the whole constellation of genomic abnormalities is significant, 
identifying those that are cancer drivers is even more meaningful. It appears that most 
somatic mutations in cancer genomes are likely passenger events (Greenman et al., 
2007). A major challenge to all systematic mutation screens will, therefore, be to 
distinguish the driver mutations hidden within a much larger number of passenger 
mutations within the human cancer genome (Voidonikolas et al., 2009). Researchers have 
been tackling this challenge by improving experimental conditions and developing more 
sophisticated statistical models and functional analysis strategies. Performing an unbiased 
forward genetic screen in mice provides the tools to generate tumors and analyze their 
genetic composition, while reducing the background of passenger mutations. A 
successful strategy for such a genetic screen has been developed using the Sleeping 
Beauty transposon system to induce tumors in transgenic mice (Starr et al., 2011). 
Sleeping Beauty Transposon-Based Forward Genetic Screens 
The Sleeping Beauty (SB) transposon system is composed of a Sleeping Beauty 
transposase and a synthetic DNA transposon. The resurrected transposase gene was 
named "Sleeping Beauty" because it was brought back to activity from a long 
evolutionary silencing (Ivics et al., 1997). It was re-constructed from extinct (fossil) 
transposase sequences belonging to the Tc1/mariner class of transposons found in the 
genomes of salmonid fish, which have been inactive for more than 10 million years due 
to accumulated mutations (Doak et al., 1994, Radice et al., 1994). The transposon 
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component of the SB system was isolated from the genome of another salmonid fish, 
Tanichthys albonubes. The transposon was designed with an expression cassette of 
interest flanked by inverted repeat/direct repeat (IR/DR) sequences of about 340 base 
pairs each. Similar to other Tc1/mariner-type transposases, the SB transposase catalyzes 
the excision of DNA sequences within the IRs and the reintegration of this sequence into 
a recipient DNA in a cut-and-paste manner. SB transposons integrate nearly randomly 
into chromosomes at TA-dinucleotide base pairs, making it act as an effective tool for 
random mutagenesis, although the sequences flanking the TAs may influence the 
probability of integration at a given site (Figure 8, Geurts et al., 2006). As a result, DNA 
cargo in a chromosomally integrated transposon can be expressed over the lifetime of a 
cell.  
The SB transposon system has several advantages over other mutagenesis 
systems. First, transposition efficiency of the SB transposase is greatly enhanced, 
enabling highly efficient transgenic integration and expression (Mates et al., 2009, 
Grabundzija et al., 2010). Second, SB-based vectors are likely superior in safety for two 
main reasons. SB shows a random genomic insertion profile without overt preference for 
integrating into genes and their transcriptional regulatory regions (Grabundzija et al., 
2010, Ammar et al., 2012). In addition, the IRs sequence of SB vectors has negligible 
enhancer/promoter activity (Moldt et al., 2007, Walisko et al., 2008). Third, there are no 
SB-related sequences in mammalian genomes, thereby precluding potential cross-
mobilization between endogenous and exogenously introduced transposons  (Newman et 
al., 2008). 
Since the SB transposon system can mediate efficient integration and stable long-
term expression of a precisely defined DNA sequence, over the past decade, this system 
has been widely used in studying functional genomics, insertional mutagenesis, 
transgenesis, and somatic gene therapy. 
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Figure 8. Mechanism of SB-mediated transposition. (by Perryhackett on Wikipedia) 
Large scale sequencing of cancer genomes has revealed a vast array of somatic 
mutations in breast, colon, lung and pancreatic cancers (Wood et al., 2007, Ding et al., 
2008, Jones et al., 2008). Distinguishing driver mutations from passenger mutations 
which are in a much larger number within the human cancer genome has been a major 
task for biologists. The SB transposon-based unbiased forward genetic screen in mice 
provides a tool to generate tumors and identify potential driver mutations, while reducing 
the background of passenger mutations, because the tumor formation process could select 
and enrich for the driver mutations.  
An SB-based screen is initiated by breeding mice carrying SB transposon and 
transposase transgenes together. Further, tissue-specific expression of the transposon can 
be achieved using conditional expression alleles of the transposase that are activated by a 
tissue specific Cre recombinase. In addition, the system can be used in mice of 
differential susceptibility to sporadic cancers. For example, this permits the identification 
of genes important for tumor development in wildtype mice but also permits the 
identification of genes that cooperate with known cancer genes, such as APC. The 
mutagenic SB transposon was designed to create both loss- and gain-of-function 
mutations similar to those that drive tumorigenesis in sporadic human cancers. Recent 
modifications to the system using an inducible, tissue-specific transposase under the 
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control of a tissue-specific Cre recombinase allele have been shown to produce a wide 
range of epithelial-derived carcinomas (Dupuy et al., 2009) and tissue-specific cancers 
including GI neoplasms (Starr et al., 2009). Tumors from these mice are isolated and 
genomic DNA is extracted. Next generation sequencing is then used to identify 
transposon insertion sites in the tumors and bioinformatics tools are employed to identify 
high frequency common insertion sites (CIS) (Starr et al., 2009). A CIS is defined by 
analyzing transposon insertions in many tumors and identifying genomic loci that contain 
transposon insertions at a higher rate than would be expected by chance. The presence of 
a CIS indicates that a transposon-mediated mutation in that locus probably has 
contributed to tumor development. By analyzing the genes within the CIS, one can 
identify candidate cancer genes which need to be further validated by biological 
investigations. Cancer genetic fingerprints are obtained that can be characterized by 
networks of interacting cancer-gene mutations. These genes can be queried in relevant 
human cancers (Hackett et al., 2013). The process of devising and executing a forward 
genetic screen using the SB transposon system to identify candidate cancer genes is 
illustrated in Figure 9. 
 
Figure 9. Using SB system for cancer gene screens in mice. (Hackett et al., 2013) 
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Due to the characteristics of the SB system, there are several advantages of using 
the SB system to identify candidate cancer genes. First, the transposon can easily be 
located in the genome because its sequence is known. Second, transposition can be 
directed to almost any cell type. Third, the transposon is capable of introducing both 
gain- and loss-of-function mutations (Bergemann et al., 2012).  
The SB transposon-based screens have been successful in a number of studies that 
yielded lists of CIS genes which are potential cancer genes in colon (Starr et al., 2009, 
March et al., 2011), liver (O'Donnell et al., 2012), pancreatic (Pérez-Mancera et al., 
2012) and skin (Quintana et al., 2013) cancers. Following functional characterization will 
be helpful in understanding the roles of these novel candidate cancer genes in different 
types of cancers. In addition, the use of this technique may lead to the eventual design of 
new therapies aimed to eliminate the results of these specific genetic mutations. 
The CCR4-NOT (CNOT) Complex and CNOT1 
Cnot1 (Table1) and other subunits of the CNOT complex, including Cnot2, 
Cnot4, Cnot6, Cnot6l, and Cnot8, were identified as CIS associated candidate cancer 
genes in CRC and other types of cancers in multiple SB screens in mice (Koso et al., 
2012, March et al., 2011, Pérez–Mancera et al., 2012, Rahrmann et al., 2013, Starr et al., 
2009, Starr et al., 2011, Wu et al., 2012). The updated information of CIS candidate 
genes in all published SB-based screens in different cancer types is available on the 
website of the Candidate Cancer Gene Database (CCGD) which is maintained by Dr. 
Starr’s group at the University of Minnesota (http://ccgd-starrlab.oit.umn. 
edu/search.php).  
The CNOT complex is a multicomponent complex evolutionarily conserved from 
yeast to human, which has a crucial role in regulation of gene expression at multiple 
levels (Collart et al., 2004). To date, the structural components and dynamics of this 
complex are still not completely known. The human CNOT complex is thought to be 
composed of 11 subunits (Figure 10, Boland et al., 2013). CNOT1 functions as a modular 
scaffold to provide binding sites for other CNOT subunits. Deadenylation is one of the 
main functions of the CNOT complex. The CNOT complex contains four deadenylases, 
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CNOT6 and its paralog CNOT6L, and CNOT7 and its paralog CNOT8, which are 
categorized into the exonuclease–endonuclease–phosphatase (EEP) and Asp-Glu-Asp-
Asp (DEDD) families of nucleases based on their nuclease domains (Lau et al., 2009). 
All four deadenylases have deadenylation activity. Different deadenylase subunits have 
been shown to have various target genes and deadenylases of the same category have 
partial redundancy in function (Lau et al., 2009). The conserved core of the CNOT 
complex consists of two major modules: a catalytic module comprising the middle region 
of CNOT1 and two deadenylases (CNOT6 or CNOT6L, and CNOT7 or CNOT8), and the 
NOT module which minimally consists of the CNOT1 C-terminal region, CNOT2 and 
CNOT3. The integration of additional subunits has been shown, including CNOT4, 
CNOT5, CNOT9, CNOT10 and CNOT11 (Boland et al., 2013). The catalytic module is 
responsible for the deadenylation of specific mRNAs. The precise function of the NOT 
module remains largely unclear. It has been shown to regulate the stability and activity of 
the catalytic module and plays a crucial role in the recruitment of the CNOT complex to 
mRNAs by microRNAs (Wahle et al., 2013). In addition to the role in mRNA 
deadenylation/degradation, the CNOT complex is also involved in the transcriptional 
repression of nuclear receptor-mediated transcription in a ligand-dependent manner via 
CNOT1 and CNOT2 (Winkler et al., 2006). The CNOT complex also plays a role in 
protein ubiquitination/degradation via the CNOT4 subunit with an E3 ligase activity 
(Collart et al., 2004). Furthermore, the CNOT complex is associated with various other 
functions in cells, such as translational repression (Cooke et al., 2010), DNA repair 
(Mulder et al., 2005) and histone methylation (Mulder et al., 2007). Given the diverse 
activities associated with the CNOT complex, it plays a role in a wide range of biological 
processes, including cell proliferation, apoptosis, oogenesis and embryogenesis, 
spermatogenesis, bone formation and energy metabolism (Collart et al., 2012).  
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Figure 10. A proposed model for the human CCR4-NOT complex. (Bartlam et al., 2010) 
Cnot1 (Table1, Figure 11) was identified as a CIS candidate cancer gene in CRC 
and other types of cancers in multiple SB screens in mice (Koso et al., 2012, March et al., 
2011, Pérez–Mancera et al., 2012, Rahrmann et al., 2013, Starr et al., 2011). 
 
 
 
 
 
Table 1. Cnot1 was identified as CIS candidate cancer gene by multiple SB screens. 
                 
Figure 11. Map of SB insertions in Cnot1 in ApcMin
 
screen. (Starr et al., 2011) Yellow and blue 
markers represent sites of transposon insertions on the same and opposite direction of Cnot1 
gene, respectively, in GI tumors. 
The human CNOT1 gene is located over 100kb on the long arm of chromosome 
16 at position 16q21. CNOT1 mRNA has three splicing variants, NM_016284.4, 
Cancer Type Study 
Colorectal Cancer Starr et al., 2011 
Colorectal Cancer March et al., 2011 
Pancreatic Cancer Pérez–Mancera et al., 2012 
Nervous System Cancer Koso et al., 2012 
Nervous System Cancer Rahrmann et al., 2013 
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NM_206999.2, and NM_001265612.1, encoding three protein isoforms NP_057368.3, 
NP_996882.1 and NP_001252541.1, respectively (Table 2). The variant NM_016284.4 
(CNOT1L) encodes for the longest isoform of 2376 amino acids (aa) (Figure 13). The 
variant NM_206999.2 (CNOT1S) differs in the 3’ UTR compared to variant 
NM_016284.4. The encoded isoform NP_996882.1 is 1551aa and has a distinct C-
terminus. The variant NM_001265612.1 (CNOT1M) uses an alternate splice site in the 
coding region, but maintains the reading frame, encoding an isoform NP_001252541.1 
that is 2371aa.   
Transcript variant mRNA length (nt) Protein isoform 
Protein length 
(aa) Abbrevation 
NM_016284.4 8476 NP_057368.3 2376 CNOT1L 
NM_206999.2 5221 NP_996882.1 1551 CNOT1S 
NM_001265612.1 8461 NP_001252541.1 2371 CNOT1M 
Table 2. Splicing variants and protein isoforms of CNOT1. 
Multiple somatic mutations in CNOT1 in different types of cancers, in particular 
CRC, have been documented by several projects. The COSMIC database documented 49 
mutations in CNOT1 among 610 cases (8%). In the TCGA database, CNOT1 mutations 
were identified in 11 out of 212 cases (5.2%) (Cancer Genome Atlas Network, 2012). In 
a study by Seshagiri et al (Seshagiri et al., 2012), CNOT1 mutations were identified in 9 
out of 72 cases (12.5%) (Figure 12). Some mutations, such as R1733H and R1640Q, 
occurred multiple times. For all three databases, CNOT1 is mutated most frequently in 
CRC. Most of these mutations are missense mutations and no specific cluster or hotspot 
was observed. The high CNOT1 mutation rate in CRC suggests a correlation of CNOT1 
genetic alteration with CRC development.  
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Figure 12. Mutations in CNOT1 identified in CRC samples by TCGA and Seshagiri et al. 
The longest CNOT1 isoform is composed of 2376 amino acids which can be 
divided into N-terminal, middle and C-terminal regions. The CNOT1 N terminus consists 
of two HEAT-repeat domains. The CNOT1 middle region contains a MIF4G domain and 
a domain of unknown function (DUF3819). The CNOT1 C terminus contains the NOT1 
superfamily homology (SH) domain (Figure 13).  
 
Figure 13. Diagrams of CNOT1 with N-terminal, middle and C-terminal regions. (Boland et 
al., 2013) 
CNOT1 is essential for the assembly of the complete CNOT complex (Boland et 
al., 2013). The N terminus of CNOT1 provides binding sites for the CNOT10–CNOT11 
module with functions that are largely unknown (Boland et al., 2013). The catalytic 
module comprising deadenylases centers on the middle region of CNOT1, which is 
critical for deadenylation of specific mRNAs. For example, the MIF4G domain (residues 
1093-1317) in middle region of CNOT1 binds to CNOT7 directly through a pre-formed 
interface and leaves the CNOT7 catalytic site fully accessible to RNA substrates (Petit et 
al., 2012). The the middle region of CNOT1 is also important for interaction with RNA 
binding proteins. For example, residues 800-1015 of CNOT1 are critical for binding with 
the ZFP36 ring finger protein (ZFP36). Disruption of the ZFP36-CNOT1 interaction 
impairs mRNA deadenylation in vitro and in vivo (Fabian et al., 2013). The C terminus of 
CNOT1 is the scaffold of the NOT module which minimally consists of CNOT2 and 
CNOT3.  The NOT module has been shown to regulate the stability and activity of the 
catalytic module and play a crucial role in the recruitment of the CNOT complex to 
mRNAs by microRNAs (Wahle et al., 2013). GW182, a RISC complex component, 
directly binds to the CNOT1 C terminal domain to recruit the CNOT deadenylase 
complex (Fabian et al., 2011). 
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Due to the central role of CNOT1 in the integrity and function of the CNOT 
complex, disruption of CNOT1 has been shown to attenuate deadenylation mediated by 
the CNOT complex (Ito et al., 2011, Fabian et al., 2013, Boland et al., 2013). Biological 
functions of CNOT1 have not been well studied, in particular in cancer. Some studies 
showed that depletion of CNOT1 could cause significant apoptotic cell death in a 
caspase-4 dependent manner in Hela cells (Ito et al., 2011). Depletion of another CNOT 
subunit, CNOT2, also has been shown to cause cell apoptosis (Sonnichsen et al., 2005, 
Ito et al., 2011). Deadenylase CNOT6L is required for cell proliferation via regulation of 
mRNA levels of the cell cycle inhibitor p27Kip (Morita et al., 2007). CNOT7 and CNOT8 
are important for cell proliferation in MCF7 breast cancer cells (Aslam et al., 2009). 
These results suggest that the integrity and the deadenylation function of the CNOT 
complex are critical for cell survival. Futhermore, CNOT1 mediates repression of 
estrogen receptor α (ERα)- and retinoid X receptor (RXR)-mediated transcription via 
direct recruitment of the CNOT complex to hormone-regulated promoters. In support of 
this notion, knockdown of CNOT1 by siRNA results in induction of ERα target genes, 
TFF1 and c-MYC, in MCF-7 cells (Winkler et al., 2006). 
Moreover, the disrupted deadenylation function of the CNOT complex can cause 
up-regulated mRNA levels of a large group of genes (Aslam et al., 2009). When these 
mRNAs are translated in the endoplasmic reticulum (ER), it may cause overproduction of 
proteins, inducing a cellular stress condition called ER stress. This is supported by an Ito 
et al study showing that depletion of CNOT1 and CNOT2 in Hela cells can cause 
activation of unfolded protein response (UPR) pathways, which is a cellular response to 
ER stress (Ito et al., 2011).  
Mechanisms of mRNA Decay 
One of the main functions of the CCR4-NOT complex and CNOT1 is regulation 
of mRNA deadenylation and turnover. Control of mRNA decay is a fundamentally 
important step in determining the amount of protein produced from the mRNA by 
translation. Microarray analyses have revealed that 40-50% of changes in gene 
expression in response to cellular signals occurs at the level of mRNA stability, allowing 
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rapid regulation of gene expression in response to different cellular conditions (Fan et al., 
2002, Cheadle et al., 2005). Polyadenylation and deadenylation of an mRNA transcript 
are key processes that regulate its stability and degradation.  
During the process of maturation, almost all eukaryotic precursor mRNAs 
undergo cleavage/polyadenylation at their 3' ends, with the exception of histone mRNAs, 
which are cleaved but not polyadenylated (Gilmartin et al., 2005). During transcription, 
the mRNA transcript is cleaved at a site 10-30 nucleotides downstream of the poly(A) 
signal (AAUAAA), and then a poly(A) tail of 200-300 nucleotides long is added to the 3' 
end by polyadenylate polymerase. The poly(A) tail and the poly(A)-binding proteins 
(PABPs) bound to it aid in protecting mRNAs from degradation by exonucleases 
(Mandel et al., 2008).  
In eukaryotes the 5’ cap and the 3’ poly(A) tail interact with the cytoplasmic  
proteins eIF4E and PABPs, respectively, to protect the transcript from exonucleases and 
to enhance translation initiation. To initiate decay, either one of these two structures must 
be compromised. Decay of most mRNAs is initiated by shortening of the poly(A) tail at 
the 3’ end, referred to as deadenylation (Shyu et al., 1991). The deadenylation process is 
considered as the rate-limiting step and is also the most efficient step in controlling 
mRNA decay (Decker and Parker, 1993). Many cellular factors and mechanisms are 
devoted to modulating the rate of deadenylation, including deadenylases which carry out 
the deadenylation of target mRNAs. There are three main categories of eukaryotic 
deadenylases, including the PAN2-PAN3 complex, the CNOT complex and the PARN 
(poly(A)-specific ribonuclease), each with unique properties (Yamashita et al. 2005). The 
CNOT complex has been described above. PAN is a heterodimeric complex consisting of 
catalytic PAN2 and regulatory PAN3 subunits (Uchida et al., 2004). It was reported that 
mammalian PAN2-PAN3 carries out the initial shortening of the tail of a β-globin 
reporter transcript from the usual 200 nucleotides to a length of ~80 nucleotides 
(Yamashita et al. 2005). At this point, the deadenylation is handed over to the CNOT 
complex. Whether PAN2-PAN3 has a role in deadenylating all mRNAs in higher 
eukaryotes is still unclear as it seems likely that this function can be carried out by other 
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deadenylases (Yamashita et al. 2005). PARN has cap-dependent deadenylase activity, 
i.e., its processivity is enhanced by the presence of a 5’cap and inhibited by cap-binding 
proteins (Balatsos et al., 2006). PARN is essential for embryogenesis in many higher 
eukaryotes including mammals. For example, PARN was reported to be implicated in the 
mass deadenylation of maternal mRNAs in Xenopus laevis oocytes during maturation 
(Korner et al., 1998). Following deadenylation, two mechanisms can degrade an mRNA: 
the 5’-to-3’ and 3’-to-5’ exonucleolytic degradation pathways. In the 5’-to-3’ pathway, 
the 5’ cap is removed by the DCP1–DCP2 complex which is involved in early steps of 
poly(A)  tail  metabolism. Following decapping, the 5'-3' exoribonuclease 1 (XRN1) 
degrades the mRNA transcript (Fenger-Gron et al., 2005). Alternatively, the 
deadenylated mRNA can be degraded in the 3’-to-5’ direction by the exosome, a multi-
subunit complex that consists of 6 core subunits proteins with RNase activity. Following 
3’-to-5’ decay, the 5’ cap on the remaining oligomer is hydrolyzed by the scavenger 
decapping enzyme DcpS (Garneau et al., 2007). These two pathways are not mutually 
exclusive and both are involved in the decay of unstable mRNAs in mammalian cells 
(Figure 14). 
 
Figure 14. Mechanisms of normal mRNA degradation. (Garneau et al., 2007) 
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mRNA deadenylation/decay represents an important checkpoint for regulation of 
post-transcriptional gene expression. The mRNA deadenylation determinants are found 
predominantly in the 3’UTR, such as AU-rich elements  (ARE) and microRNA target 
sites (Sandberg et al., 2008), but they are also found in the 5’ UTR and coding regions.  
About 12% of mammalian mRNAs, especially those encoding cytokines, proto-
oncogenes and transcription factors, bear important regulatory ARE signals in their 
3'UTRs (Khabar et al., 2005). The AREs typically contain one or several AUUUA 
pentamer repeats within a U-rich region of the 3'UTR. Both the AREs sequences and the 
flanking sequences can influence the overall effect on mRNA stability (Stoecklin et al., 
2003). RNA binding proteins (RBPs) can bind to the ARE element to regulate ARE-
mediated mRNA decay by either inhibiting or activating deadenylation (Barreau et al., 
2006). RBPs are key components in RNA metabolism, regulating the temporal, spatial 
and functional dynamics of RNAs (Barreau et al., 2006). Most mRNAs are associated 
with multiple RBPs, while a RBP can bind to multiple mRNA targets, suggesting the 
potential for a multidimensional network of post-transcriptional regulation of RNA 
metabolism. RBPs play diverse roles in mRNA decay. Some RBPs accelerate decay of 
target mRNA transcripts through promoting deadenylation, including ZFP36, butyrate 
response factor 1 (BRF1), AU-rich binding factor 1 (AUF1) and KH-type splicing 
regulatory protein (KSRP). To promote deadenylation of target mRNA transcripts RBPs 
can recruit the CNOT complex to target transcripts to carry out the removal of the 
poly(A) tail. In this process, CNOT1 provides a platform that recruits other subunits of 
the CNOT complex, including deadenylase subunits, to target transcripts (Sandler et al., 
2011). For example, Nanos2 plays a key role in the sexual differentiation of germ cells 
through regulating the expression levels of several important genes, such as Sycp3, Stra8 
and Dazl. It can bind to the CNOT1 protein directly, in turn recruiting the deadenylase 
subunits to the Nanos2-RNA complex to execute deadenylation of these mRNAs (Suzuki 
et al., 2010). PUM1 can promote HMOX1 mRNA deadenylation through binding to its 
ARE and recruiting the CNOT complex (Miller et al., 2011). ZFP36 is an RNA binding 
zinc-finger protein which binds the ARE of TNF-α mRNA and accelerates its degradation 
through recruiting the CNOT complex (Sandler et al., 2011). The disruption of the 
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interaction between RBPs and the CNOT complex may interrupt RBP-mediated mRNA 
degradation. For example, the depletion of CNOT1 by siRNA could result in a 
dramatically decreased decay of globin-ARE reporter mRNA by ZFP36 (Sandler et al., 
2011). The defects in RNA metabolism caused by aberrations in RBP-mediated mRNA 
decay contribute to a broad spectrum of human disorders including cancer (Dean et al., 
2004). Besides the CNOT complex the deadenylase PARN is also involved in ZFP36-
directed deadenylation in vitro (Lin et al., 2007). On the other hand, ELAV like RNA 
binding protein 1 (ELAVL1) can stabilize mRNAs containing AREs in their 3’UTR, such 
as c-fos, GM-CSF and EGF, by blocking the recruitment of deadenylases or the exosome 
(Fan et al., 1998).  
MicroRNAs (miRNAs) are a large family of single-stranded small non-coding 
RNA molecules (~22 nucleotides in length) found in plants and animals, which function 
in transcriptional and post-transcriptional regulation of gene expression. The human 
genome may encode over 1000 miRNAs, which may target about 60% of mammalian 
genes (Friedman et al., 2009). miRNAs are encoded by the eukaryotic genome from 
either their own genes or from introns or even exons of other genes. miRNA genes can be 
transcribed as independent units, or, in some cases, together with its host gene, providing 
a means for coupled regulation of both the miRNA and protein-coding gene (Lee et al., 
2004). In the canonical maturation pathways, miRNA genes are transcribed by either 
RNA polymerase II or RNA polymerase III into primary miRNA transcripts (pri-
miRNA) which are usually capped and polyadenylated and spliced (Lee et al., 2004). The 
pri-miRNA is next endonucleolytically cleaved by the nuclear microprocessor complex 
Drosha–DGCR8 in the nucleus to produce a hairpin structure of about 70 nucleotides, 
termed a precursor-miRNA (pre-miRNA). The pre-miRNA is then exported from the 
nucleus by the Exportin-5–Ran-GTP complex to the cytoplasm. In the cytoplasm, the pre-
miRNA hairpin is cleaved by the RNase III enzyme Dicer in a complex with the double-
stranded RNA-binding protein TRBP, yielding an imperfect miRNA:miRNA* duplex 
about 22 nucleotides in length (Lund et al., 2006). Although either strand of the duplex 
may potentially act as a functional miRNA, only the functional strand of the mature 
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miRNA is loaded together with Argonaute (Ago) proteins into the RNA-induced 
silencing complex (RISC), whereas the passenger strand is degraded (Figure 15).   
 
Figure 15. The canonical pathway of microRNA processing. (Winter et al., 2009) 
miRNAs result in gene silencing either through translational repression and/or 
degradation of target mRNAs (Eulalio et al., 2008). These two mechanisms may 
represent two distinct independent pathways: the ability of miRNAs to expedite 
deadenylation does not depend on decreased translation; in some cases translational 
repression by miRNAs require a poly(A) tail (Wu et al., 2006). miRNAs accomplish their 
regulatory function through the RISC complex. miRISCs facilitate degradation of 
miRNA targeted mRNAs via deadenylation followed by Dcp1-Dcp2 complex-directed 
decapping, and subsequent exonucleolytic digestion (Chen et al., 2009). The core RISC 
contains at a minimum a specificity-determining miRNA, an Ago protein bound to 
miRNA, and a GW182 protein. Target recognition by a RISC is determined mainly by 
the base-pairing between the 5’ portion of the miRNA and the 3’UTR of target mRNAs 
(Bartel et al., 2009). Ago proteins bind the mature miRNA and facilitates its interaction 
with a target mRNA. Some Ago proteins, such as Ago2, can cleave target transcripts 
directly by their PIWI domain when the match-up of miRNA with target mRNA is 
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pri-miRNA cleavage by the Drosha–DGCR8 microprocessor complex. 
The pri-miRNA is next endonucleolytically cleaved by the nuclear micro-
processor complex formed by the RNase III enzyme Drosha (RNASEN) 
and the DGCR8 (DiGeorge critical region 8) protein (also known as Pasha 
(Partner of Drosha) in D. melanogaster and C. elegans)36 (Fig. 2a). DGCR8/
Pasha contains two double-stranded RNA-binding domains and is essen-
tial for miRNA processing in all organisms tested37–40. An average human 
pri-miRNA contains a hairpin stem of 33 base-pairs, a terminal loop and 
two single-stranded flanking regi ns upstream and downstream of th  
hairpin. The double-stranded stem and the unpaired flanking regions 
are critical for DGCR8 binding and Drosha cleavage, but the loop region 
or the specific sequences are less important for this step41–43. A single 
nucle tide polymorphism in a miRNA precursor stem can block Drosha 
processing44. Nevertheless, many miRNA sequence aberrations observed 
in human tumours alter the secondary structure without affecting proc ss-
ing, and reveal the structural flexibility of the microprocessor34.
The two RNase domai s of Drosha cleave the 5´ and 3´ arms of the pri-
miRNA hairpin39, whereas DGCR8 directly and stably interacts with the 
pri-miRNA and functions as a molecular ruler to determine the precise 
cleavage site41. Drosha cleaves 11 base pairs away from the single-stranded 
RNA/double-stranded RNA junction at the base of the hairpin stem.
Drosha-mediated cleavage of the pri-miRNA occurs co-transcriptionally 
and precedes splicing of the protein-encoding or non-coding host RNA 
that contains the miRNAs. Splicing is not inhibited by Drosha-mediated 
cleavage, because a continuous intron is not required for splicing45,46.
microRNA-specific regulation of the microprocessor complex. 
Drosha-mediated pri-miRNA processing was recently shown to be 
subject to regulation by miRNA-specific mechanisms. Drosha forms 
two different complexes, a small microprocessor complex that contains 
only Drosha and DGCR8 and processes many pri-miRNAs, and a larger 
complex that contains RNA helicases, double-stranded RNA binding 
proteins, heterogeneous nuclear ribonucleoproteins and Ewing’s sarcoma 
proteins38. The RNA helicases p72 and p68 are part of the large Drosha 
complex and might act as specificity factors for the processing of a sub-
set of pri-miRNAs (Fig. 2b). Expression levels of several miRNAs are 
reduced in homozygous p68−/− or p72−/− knockout mice, whereas other 
miRNAs remain unaffected47.
Drosha-mediated cleavage can also be regulated for individual miR-
NAs: the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) 
binds specifically to pri-miR-18a and facilitates its processing. Loss of 
hnRNP A1 diminishes the abundance of mature miR-18a (Fig. 2c), but 
hnRNP A1 does not have any impact on other miRNAs that are located 
in the same miR-17 genomic cluster, demonstrating the extraordinary 
specificity of miR-18a biogenesis48. hnRNP A1 binds to the conserved 
loop of the pri-miR-18a and changes the hairpin conformation to create 
a more favourable cleavage site for Drosha49. About 14% of the human 
pri-miRNA loops are conserved between different species and could 
provide anchor points for similar regulatory mechanisms.
Transforming growth factor-β (TGF-β) and bone morphogenetic 
factors (BMPs) induce the maturation of miR-21 by regulating the 
microprocessor activity. TGF-β and BMP bring about the recruitment 
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Figure 1 The ‘linear’ canonical pathway of microRNA processing. The miRNA 
processing pathway has long been viewed as linear and universal to all 
mammalian miRNAs. This canonical maturation includes the production of 
the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and 
cleavage of the pri-miRNA by the microprocessor complex Drosha–DGCR8 
(Pasha) in the nucleus. The resulting precursor hairpin, the pre-miRNA, is 
exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm, the 
RNase Dicer in complex with the double-stranded RNA-binding protein TRBP 
cleaves the pre-miRNA hairpin to its mature length. The functional strand of 
the mature miRNA is loaded together with Argonaute (Ago2) proteins into the 
RNA-induced silencing complex (RISC), where it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, 
whereas the passenger strand (black) is degraded. In this review we discuss 
the many branches, crossroads and detours in miRNA processing that lead to 
the conclusion that many different ways exist to generate a mature miRNA.
Editing is defined as a post-transcriptional change of RNA sequences 
by deamination of adenosine (A) to inosine (I), altering the base-
pairing and structural properties of the transcript. Editing of miRNA 
transcripts by ADAR1 and ADAR2 was first described for miR-22 
(ref. 116) followed by miR-151, miR-197, miR-223, miR-376a, miR-
379 and miR-99a (ref. 117), as well as miR-142, miR-223, miR-1-1 
and miR-143 (ref. 118). In pri-miR-142, A-to-I editing inhibits its 
cleavage by the endonuclease Drosha and results in its degradation 
by the ribonuclease Tudor-SN, which preferentially cleaves double-
stranded RNA containing inosine–uracil pairs118,119. However, edit-
ing of other pri-miRNAs was shown to enhance their processing by 
Drosha120. Editing can also influence further downstream processing 
steps: pri-miR-151 editing abolishes its cleavage by Dicer in the cyto-
plasm. It remains to be established whether miRNA editing events 
are predominantly nuclear or cytoplasmic and whether they occur 
on the pri-miRNA or on the precursor miRNA (pre-miRNA)121. In 
addition o altering miRNA processing, miRNA editing can have 
an impact on miRNA target specificity. For example, a single A-to-I 
change in the miR-376 precursor redirects the mature miRNA to 
a new target, resulting in altered protein expression in mice122. In 
summary, miRNA editing can influence processing at multiple steps 
or can change the miRNA complementarity to target sequences, 
increasing the diversity of the cellular miRNA pool.
BOX 1 microRNA editing
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perfect, such as in the case of miR-196 downregulating the HOXB8 mRNA (Soraya et al., 
2004). However, the vast majority of miRNAs are only partially complimentarity with 
the 3’UTR of their targets, so in most cases, Ago has to recruit additional proteins to 
achieve translational repression and mRNA decay (Bartel et al., 2009). Generally, Ago 
proteins recruit GW182 proteins to miRNA-targeted mRNAs in which the C-terminal 
region of Ago directly binds to the GW-rich regions of GW182 in the N terminal 
(Takimoto et al., 2009). Three GW182 paralogs exist in vertebrates (TNRC6A/GW182, 
TNRC6B, and TNRC6C) (Eulalio et al., 2009). The binding of the RISC to the target 
transcript can result in the recruitment of deadenylation factors mediated by GW182 
(Fabian et al., 2011). Human GW182 proteins recruit the PAN2-PAN3 and the CNOT 
complexes through direct interactions with PAN3 and CNOT1 by the middle and C-
terminal regions of the silencing domains, respectively. Therefore, GW182 proteins 
provide a docking platform through which deadenylase complexes gain access to the poly 
(A) tail of miRNA targets to promote their deadenylation. In this process, CNOT1 
mediates the interactions between GW182 and the additional subunits of the CNOT 
complex that provides a major contribution to miRNA-mediated mRNA degradation 
(Piao et al., 2010). The CNOT complex recruited by GW182 can also act to repress 
translation initiation (Pasquinelli et al., 2012). Thus we hypothesized that the genetic 
alterations in CNOT1 may impair the miRNA-mediated post-transcriptional regulation of 
genes, contributing to the development of CRC. Supporting this idea, knockdown of 
CNOT8 and CNOT1 expression and the overexpression of CCR4 or CAF1 mutants could 
significantly reduce miRNA-mediated deadenylation and mRNA decay, but not 
translational repression (Piao et al., 2010, Fabian et al., 2009). The PAN2-PAN3 
complex has also been shown to be involved in but not essential for degradation of 
miRNA targets, as inactivation of the PAN2-PAN3 complex slows down the initial 
deadenylation, but deadenylation and decay still occur, minimally affecting miRNA 
target levels at steady state (Chen et al., 2009). How and if PARN is involved in miRNA-
mediated deadenylation still remains to be established.  
ER Stress and the Unfolded Protein Response 
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The CNOT complex and CNOT1 are widely involved in RBP- and miRNA-
mediated mRNA deadenylation/decay. Therefore, the disruption of the function of the 
CNOT complex and CNOT1 may lead to an altered gene expression profile. In addition, 
an enlarged pool of mRNAs may be translated in the endoplasmic reticulum (ER). In the 
ER the nascent polypeptides are folded into specific tertiary structures essential to their 
functions. When the requirement for proper folding of nascent polypeptides exceeds the 
protein folding capacity of the ER, unfolded or misfolded proteins will accumulate in the 
ER lumen, inducing a situation termed ER stress. When ER stress occurs, cells will 
activate an elaborate adaptive response known as the unfolded protein response (UPR) 
(Ron, et al., 2007). In eukaryotic cells, canonical branches of the UPR are mediated by 
three ER membrane-associated proteins, PKR-like eukaryotic initiation factor 2a kinase 
(PERK), inositol requiring enzyme 1α (IRE1α), and activating transcription factor-6 
(ATF6) (Tsai et al., 2010) (Figure16). In a ‘‘stress-free’’ ER, these three trans-membrane 
proteins are bound by a chaperone, glucose-regulated protein, 78kDa (GRP78/BiP), in 
their intraluminal domains and rendered inactive. Accumulation of improperly folded 
proteins in the ER results in the dissociation of GRP78/BiP away from these UPR sensors 
(Bertolotti et al., 2000). This event leads to oligomerization and activation of PERK and 
IRE1α and translocation of ATF6 to the Golgi apparatus where it is processed into an 
active transcription factor, resulting in the activation of a series of downstream signaling 
events (Ron et al, 2007). Together these three arms of the UPR can mitigate ER stress by 
reducing protein synthesis, facilitating protein degradation, and increasing production of 
protein folding chaperones, which helps cells to restore homeostasis.  
The IRE1α pathway is the oldest branch of the UPR in an evolutionary sense. The 
endoribonuclease activity of IRE1α cleaves a 26 base-pair segment from the mRNA of 
the X-box binding protein-1 (XBP1), creating an alternative message that is translated 
into the spliced active form of the transcription factor sXBP1 (Calfon et al., 2002). 
sXBP1, alone or in conjunction with ATF6, launches a transcriptional program to 
produce chaperones and proteins involved in ER biogenesis, phospholipid synthesis, and 
ER-associated protein degradation (ERAD). Thus, sXBP1 activates one of the major 
pathways for enhancing the folding capacity of the ER to deal with ER stress. 
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Hyperactivated IRE1α has been reported to increase TXNIP mRNA stability by reducing 
levels of miR-17, a TXNIP destabilizing microRNA. In turn, elevated TXNIP protein 
activates the NLRP3 inflammasome, causing procaspase-1 cleavage and interleukin 1β 
(IL-1β) secretion (Lerner et al., 2012).  
Under ER stress, ATF6 translocates to the Golgi apparatus, where it is processed 
by Golgi proteases (S1P, S2P) to release the active transcription factor. Activated ATF6 
then moves to the nucleus and functions as a transcription factor to promote the 
transcription of genes containing ER stress elements (ERSE), UPR elements (UPRE), and 
cAMP response elements (CRE) in their promoters. As a result, ERAD and production of 
the ER degradation-enhancing mannosidase-like protein (EDEM) are boosted by these 
events, facilitating clearance and degradation of misfolded proteins from the ER lumen. 
Furthermore, ATF6 can upregulate XBP1 mRNA transcription levels. Currently, ATF6 
and sXBP1 are viewed as the predominant regulators of the transcriptional response 
programs triggered by the activation of the UPR (Tsai, et al., 2010).  
Activation of the third arm of the UPR through PERK results in phosphorylation 
of eIF2α (eukaryotic translational initiation factor 2α) at serine 51, which converts eIF2α 
to a competitor of eIF2b, resulting in reduced global protein synthesis. In addition, this 
branch of the UPR can also lead to activation of activating transcription factor-4 (ATF4), 
nuclear erythroid 2 p45-related factor 2 (NRF2), and nuclear factor kappa b (NF-κB) 
through several distinct mechanisms. ATF4 is produced through enhanced translation and 
induces expression of genes involved in apoptosis (CHOP, C/EBP homologous protein), 
ER redox control (ERO1, endoplasmic reticulum oxidoreductin), and glucose metabolism 
(GCK, glucokinase). One consequence of ER stress is the accumulation of reactive 
oxygen species (ROS) that promotes a state of oxidative stress. The UPR has 
incorporated an antioxidant defense system via activation of the NRF2 and ATF4 
transcription factors, coordinating the convergence of ER stress with oxidative stress 
signaling, and orchestrating the transcription program of the antioxidant response 
element-dependent genes, including hemeoxygenase-1 (HMOX1), thioredoxin reductase 
1 (TXNRD1), and the glutathione S-transferases (GSTP1). 
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Figure 16. Unfolded protein response in mammalian cells. (Schönthal et al., 2011) 
Through activation of these three UPR pathways, cells can deal with a moderate 
level of ER stress and restore homeostasis. However, the UPR does not always result in 
successful alleviation of ER stress and reestablishment of a functional equilibrium in the 
ER. When driven by severe or prolonged stress signals, the UPR can also induce cell 
apoptosis through several mechanisms (Tabas et al., 2011). The IRE1α mediated UPR 
pathway is a critical lever in the UPR that controls commitment to cell death or promotes 
survival (Ron et al., 2007). IRE1α leads to activation of the apoptosis signaling kinase 1 
(ASK1) and downstream kinases through binding TRAF2, leading to activation of the c-
Jun N-terminal kinase (JNK) pro-apoptotic signaling pathway that promotes apoptosis by 
switching on the pro-apoptotic B-cell CLL/lymphoma 2 (BCL-2) family proteins BCL2-
associated X protein (BAX) and BCL2-antagonist/killer 1 (BAK) (Zong et al., 2003). 
IRE1α also has been reported to upregulate thioredoxin-interacting protein (TXNIP) 
levels by reducing levels of miR-17. In turn, elevated TXNIP protein activates a series of 
pro-apoptotic pathways, such as activation of interleukin-1 beta (IL-1β) (Lerner et al., 
2012). In addition，IRE1α can also induce the preferential degradation of a pool of 
mRNAs through a mechanism known as regulated IRE1-dependent decay (RIDD) 
(Hollien et al., 2009). Hyper activation of the PERK pathway can induce expression of 
CHOP, a pro-apoptotic transcription factor, which regulates the transcription of BCL2 
family members and other pro-apoptotic genes (Zinszner et al., 1998). In addition, 
activation of both the PERK and IRE1α pathways lead to activation of the NF-κB 
signaling pathway (Tam et al., 2012).  
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There is evidence that chronic ER stress and activation of the UPR are important 
in the pathogenesis of a number of diseases, including cancer, neurodegenerative 
diseases, diabetes, and inflammatory disease (Hosoi et al., 2010, Lerner et al., 2012). 
Some cancer cells, unlike normal cells, harbor a chronically activated protective module 
of ER stress components in order to manage intensified protein synthesis or to adapt to 
hostile microenvironmental conditions, such as hypoglycemia, hypoxia, acidosis, or 
chemotherapy, which are known triggers of ER stress (Luo et al., 2013). The genetic 
alterations resulting in better management of ER stress in tumor cells may confer growth 
advantage to cancer cells and contribute to cancer progression. Therefore, we hypothesize 
that the increased activity of CNOT1 may help cancer cells to limit the production of 
proteins in the ER, thus reducing the levels of ER stress. 
In accordance with the previously described balance of this cellular system, two 
opposing approaches are offered in order to therapeutically target ER stress. On the one 
hand, experimental efforts are aimed at supporting pro-survival modules and/or blocking 
the pro-apoptotic components in order to increase cellular survival. For example, in type 
2 diabetes where chronic ER stress may lead to the destruction of pancreatic β-cells, 
controlling ER stress may help to protect β-cells and delay the development of diabetes 
(Lerner et al., 2012). On the other hand, efforts to further aggravate pre-existing ER 
stress and enhance pro-apoptotic processes could be beneficial in the case of malignant 
neoplasms. For example, deterioration of chronic ER stress in cancer cells by therapeutic 
reagents may induce ER stress mediated cell apoptosis selectively in tumor cells which 
have higher levels of ER stress than normal cells (Schönthal et al., 2011).  
Thioredoxin-Interacting Protein (TXNIP) 
When unfolded proteins accumulate to irremediably high levels within the ER, the 
UPR becomes hyperactivated to cause programmed cell death. TXNIP that is rapidly 
induced by IRE1α is a critical node in this ‘‘terminal UPR.’’ TXNIP was originally 
identified in HL-60 leukemia cells treated with 1,25-dihydroxyvitamin D3 and was 
termed as vitamin D up-regulated protein 1 (VDUP1) (Chen et al. 1995). This gene 
encodes for an inhibitor of the antioxidant protein Thioredoxin (TRX), which directly 
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interacts with TRX and blocks its reducing activity and inhibits the interaction between 
TRX and other factors, such as ASK-1 and PAG (Junn, et al., 2000). TXNIP is also 
reported to exert functions through redox independent mechanisms. TXNIP has been 
reported to be involved in multiple cellular processes, including cell growth and 
apoptosis (Jeon, et al., 2005), metabolic regulation (Patwari, et al., 2009), and 
inflammatory response (Zhou, et al., 2010). TXNIP expression is regulated by multiple 
mechanisms, such as glucose, HDACs, KLFs, and PPARs. Its expression is also 
upregulated by various cellular stresses, including ER stress, oxidative stress, and 
irradiation (Han et al., 2003). Further, NRF2, an important transcription factor known to 
regulate anti-oxidant responses, also upregulates TXNIP expression levels (Adair-Kirk et 
al., 2008). As described before, TXNIP levels are also upregulated by activation of IRE1α 
that destabilizes miR-17.  
As a tumor suppressor, TXNIP has been reported to cause cell cycle arrest and 
apoptosis. To induce cell growth arrest, TXNIP translocates to the nucleus where it 
regulates cell proliferation by multiple mechanisms, including increasing the stability of 
the cell cycle inhibitor p27kip, upregulating levels of the CDK inhibitor p16, and reducing 
RB phosphorylation (Jeon et al., 2005). TXNIP can also promote apoptosis through 
redox-dependent and -independent mechanisms. Thioredoxin (TRX) inhibits apoptosis 
via inhibiting ASK1 and PTEN (Saitoh et al., 1998). TXNIP inhibits the interaction 
between TRX and ASK1, relieving the constitutive inhibition of ASK1 and the released 
ASK1 induces apoptosis through activation of the JNK and p38 signaling pathways 
(Tobiume et al., 2001). A recent report described how TXNIP promotes NLR family, 
pyrin domain containing 3 (NLRP3) inflammasome activation and IL-1β maturation that 
can lead to apoptosis in response to different cellular stresses (Zhou, et al., 2010).  
TXNIP has been identified as a novel tumor suppressor based on its effects on 
regulating both cell growth and death (Han et al., 2003, Goldberg et al., 2003). TXNIP 
has dramatically reduced expression in multiple tumors including renal, breast, lung, 
gastric, colon, and hepatocellular carcinoma (Cadenas et al., 2010，Dutta et al., 2005, 
Takahashi et al., 2002). The enforced expression of TXNIP inhibited the proliferation of 
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cancer cells including gastric cancer, and promyelocytic leukemia, and suppressed tumor 
growth and metastasis in transplantation models (Han et al., 2003，Wang et al., 2002，
Goldberg et al., 2003). TXNIP has also been shown to play an important role in several 
pathologic conditions besides cancer, including diabetes, cardiovascular disease, and 
chronic inflammation.   
It has been shown that miR-17 destabilizes TXNIP mRNA (Lerner et al., 2012). 
miRNAs recruit the CNOT complex through direct binding to CNOT1 to deadenylate 
target mRNAs. Therefore, we hypothesize that increased activity of CNOT1 as well as 
the CNOT complex may contribute to the regulation of TXNIP levels by miR-17.  
Summary 
Identification of driver mutations in CRC is important in overcoming the 
challenges in CRC management and improving patients’ outcome. In the hundreds of 
DNA mutations in each CRC genome, only a small portion are driver mutations, whereas 
most of them are passenger mutations.  Therefore, a major challenge in CRC genetic 
studies is to distinguish driver mutations hidden within a much larger number of 
passenger mutations. To identify candidate CRC driver mutations, we performed a 
Sleeping Beauty transposon-based forward genetic screen in mice and we found a list of 
CIS candidate CRC genes. One of the top CIS candidates is Cnot1 which encodes for the 
scaffold factor of the CNOT complex that is a multicomponent complex widely involved 
in post-transcriptional gene expression regulation. One of the main functions of the 
CNOT complex is regulation of mRNA deadenylation which is the rate-limiting step and 
the most efficient step in controlling mRNA decay. RBPs and miRNAs can recruit the 
CNOT complex to target transcripts to promote deadenylation of target mRNA through 
direct binding to CNOT1. Aberrations in the deadenylation function of the CNOT 
complex have been shown to cause altered gene expression profiles and reduced cell 
viability. Furthermore, multiple somatic mutations have been documented in CRC by the 
TCGA and COSMIC databases. Based on the SB-based screens, somatic mutations and 
function of the CNOT complex, we hypothesize that genetic alterations in CNOT1 may 
contribute to CRC development through affecting deadenylation of mRNA transcripts. 
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Notably, the functions of CNOT1 and the CNOT complex in cancer development have 
not been adequately studied. Therefore the objective of this study is to characterize 
CNOT1 in the development of CRC and investigate the underlying mechanisms.   
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Chapter 2  
Results 
Loss of CNOT1 Results in Decreased Cell Viability  
Cnot1 was identified as a candidate colorectal cancer (CRC) gene in the ApcMin 
(Starr et al., 2011) and LSL-p53R270H (Starr T.K., unpublished data) Sleeping Beauty 
(SB)-based screens. To determine the contribution of genetic alterations in CNOT1 to 
CRC we evaluated cell viability in CNOT1-depleted SW480 human CRC cell line and a 
non-intestinal cell line HEK293. The SW480 cell line is APC deficient as it lacks one 
allele and has a truncating mutation at position 1338.  This APC status is similar to the 
status of Apc in most adenomas formed in the ApcMin mouse strain used in the original SB 
screens that identified Cnot1 as a CIS associated candidate CRC gene. ApcMin mice carry 
an inactivating germline mutation in one allele and the second allele is inactivated in 
most adenomas. For these studies SW480 and HEK293 cells were transfected twice, 48 
hours apart, with either a pool of four siRNA oligos targeting distinct regions in the 
CNOT1 mRNAs, or a non-targeting control siRNA, or transfection reagent only (mock 
transfected), or not transfected. The effectiveness of depletion was confirmed by qRT-
PCR (Figure 17A). CNOT1 expression was reduced to 35% and 33% of the expression 
levels in control SW480 cells and HEK293 cells, respectively. Cell viability was 
evaluated daily for 6 days after the second transfection using the MTT assay. Over the 6-
day interval, depletion of CNOT1 by siRNA resulted in a dramatic decrease in cell 
viability in SW480 cells (Figure 17B) as well as HEK293 cells (Figure 17C).  
To examine the means by which CNOT1 depletion causes decreased cell viability 
we examined the levels of apoptosis in CNOT1-depleted SW480 cells using an Annexin 
V fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI) double staining flow 
cytometry assay, where AV-FITC staining identifies cells in the early stages of apoptosis 
which have undergone translocation of phosphatidylserine to the external surface of the 
plasma membrane lipid but still have intact plasma membranes and thus are impervious 
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to PI staining. AV-FITC-PI staining was determined on day 6 (3 days after the first 
transfection) and day 7 (1 day after the second transfection). No changes in apoptosis 
were seen on day 6 but on day 7 CNOT1 depletion resulted in a greater than two fold 
increase in apoptosis, from 7 to 19% of total cell population, with a corresponding 
decrease in unstained live cells from 78 to 64% (Figure 18A, B and C). These results 
show that depletion of CNOT1 causes decreased cell viability in SW480 and HEK293 
cells and increased apoptotic cell death in SW480 cells. 
A. 
 
 
 
 
 B.                                                                   C. 
  
Figure 17. CNOT1 depletion leads to decreased cell viability in transformed cell lines 
SW480 and HEK293. (A) Cells at 70% confluence were transfected with siRNA oligos targeting 
CNOT1, non-targeting siRNA, transfection reagent only (mock transfected), or not transfected, 
twice, 48 hours apart, at a final concentration of 50 nM. CNOT1 levels were determined by qRT-
PCR.  Relative CNOT1 mRNA levels represent the expression of CNOT1 in CNOT1 siRNA-
treated cells relative to control siRNA treated. Values represent the average of three (SW480) or 
two (HEK293) experiments ± SD. (B and C) Cells were plated at 5000 (SW480) or 2500 
(HEK293) cells per well in triplicate in 96 well plates 24 hours after the second transfection. Cell 
Cell line Relative CNOT1 mRNA levels 
SW480 35.89± 3.09%  
HEK293 33.81± 0.99%  
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viability was measured by MTT assay on days 1-6 after the second transfection. (B) SW480 cells. 
(C) HEK293 cells. Each data point represents mean ± SD of three replicates from a representative 
experiment. Significance of differences in cell viability on day 6 was determined by one-way 
ANOVA. * = p < 0.05 between CNOT1 and all controls.   
A.     
 
B. 
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C.  
 
Figure 18.  CNOT1 depletion leads to increased apoptosis in SW480 cells. SW480 cells were 
transfected with siRNA oligos targeting CNOT1 or non-targeting siRNA as in Figure 17. Cell 
apoptosis was determined by an annexin V fluorescein isothiocyanate (AV-FITC) and propidium 
iodide (PI) double staining flow cytometry assay at 72 hours (day 6) after the first transfection 
and at 24 hours (day 7) after the second transfection. (A and B) Representative dot plots of AV-
FITC-PI staining in SW480 cells on day 6 (A) and day 7 (B). The number in each quadrant 
indicates the percentage of cells stained with specific combination of dyes. Lower right quadrant 
represents cells stained by AV-FITC alone that are early apoptotic cells. (C) Quantitative analysis 
showing AV-FITC stained apoptotic cells as percent of total cells. Values represent mean ± SD of 
three independent experiments. Significance of differences was determined by one-way ANOVA. 
***=p < 0.001, * = p < 0.05. 
Loss of CNOT1 Results in Extensive Changes in Gene Expression 
CNOT1 is a member of the CCR4-NOT complex, which regulates mRNA 
expression at several levels. Therefore, to begin to determine the means by which CNOT1 
depletion might promote decreased cell viability we examined global gene expression in 
CNOT1-depleted SW480 cells using an Illumina Human HT-12 v4 BeadChip array. High 
quality total RNA was isolated from CNOT1-depleted and control SW480 cells.  RNA 
Integrity Number (RIN) values were ≥ 9.8 (Figure 19A). qRT-PCR confirmed 90% 
knockdown of CNOT1 mRNA levels (Figure 19B). Analysis of gene expression 
identified 266 genes with statistically significant, greater than or equal to two-fold, 
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change in gene expression. Of these 183 (69%) were up-regulated and 83 (31%) were 
down-regulated (Figure 19C, Table 4). Expression levels of five top changing genes, 
TXNIP, DKK1, EMP1, BTG1 and IGFBP3, were confirmed by qRT-PCR to validate the 
results of the microarray (Figure 19D). Ingenuity Pathway Analysis (IPA) was used to 
identify pathways and processes associated with changes in gene expression in CNOT1-
depleted cells. IPA analysis generated three networks with scores of 10 or more.  These 
networks represent molecules interacting with protein products of genes that change 
expression in CNOT1-depleted cells. The functions associated with these networks are 
associated with tumor morphology, cellular growth and proliferation, cellular death and 
survival and cell development consistent with an effect of CNOT1 depletion on cell 
viability (Figure 20A, B, C and D, Figure 33).  
  A.                                                       B. 
          
   C.                                                       D. 
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Figure 19. Depletion of CNOT1 in SW480 cells causes an altered gene expression profiles. 
SW480 cells were transfected with either CNOT1 siRNA or a non-targeting siRNA control at 50 
nM final concentrations, twice, 48 hours apart. Total RNA was extracted 72 hours after the 
second transfection from three pairs of biological replicates of CNOT1-depleted and non-
targeting control treated SW480 cells and hybridized to an Illumina Human HT-12 v4 BeadChip 
array to determine the gene expression profile. To improve reproducibility each of the 6 
independent RNA samples was hybridized twice. (A) The integrity of RNA samples was 
determined using an Agilent Bioanalyzer Lab-on-a-chip system to generate an RNA Integrity 
Number (RIN) representing the ratio of 28S/18S RNA as well as other features. All samples met 
the standard of quality with a RIN > 8. OT3 = non-targeting control siRNA. (B) Validation of 
knockdown of CNOT1 in RNA samples by qRT-PCR. (C) Heatmap presentation of the 266 genes 
showing significant differences in expression (fold change ≥ 2, p<0.05) between CNOT1-depleted 
and control cells. Relative gene expression is shown as Z-score. Genes are shown on the Y-axis 
and siRNA treatments on the X-axis. The quality control and normalization were performed using 
the R-based package: lumi and limma. (D) The results of the array analysis were validated via 
measuring the mRNA levels of five of the genes with highest fold changes in the microarray by 
qRT-PCR. For all qRT-PCR assays, values represent mean ± SD of three independent 
experiments. Statistical significance was determined by a t-test. ** = p < 0.01, * = p < 0.05. 
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Figure 20. IPA analysis of gene expression in CNOT1-depleted SW480 cells. Networks based 
on genes that change expression in CNOT1-depleted cells (Network Eligible molecules) were 
generated by Ingenuity Pathway Analysis (IPA). The three top scoring networks are shown (A, B 
and C). The score is calculated using the Fishers Exact Test to determine the likelihood of the 
network containing a given number of Network Eligible molecules by chance. The score =  
-log (Fisher's Exact test result). (D) The functions and scores of the three networks are shown. 
CRC Liver Metastases With High CNOT1 Expression Levels Show Upregulation Of 
Proliferation Related Genes 
To determine if these changes are relevant to human cancers we analyzed gene 
expression in 20 human CRC liver metastasis samples and 5 unrelated normal samples.  
High quality RNA was isolated from flash frozen tissue using RNAIceLater (Ambion) 
and RNeasy (Qiagen) kits. This RNA was sequenced by the University of Minnesota 
BioMedical Genomics Center using the Illumina HiSeq 2000 platform. Sequence was 
assembled and analyzed by Dr. Ying Zhang at the University of Minnesota 
Supercomputing Institute. Fragments per kilobase of exon per million fragments (FPKM) 
gene expression values were obtained. Levels of CNOT1 expression vary by 3-fold 
among the metastasis samples.  Levels in the normal samples fall around the average of 
the normal samples with all normal samples falling within two standard deviations. To 
identify genes whose expression correlated with highest levels and lowest levels of 
CNOT1 expression we used Geneset Enrichment Analysis (GSEA) (Subramanian et al., 
2005).  The three samples with highest CNOT1 expression were designated CNOT1-Hi 
and the three samples with lowest CNOT1 expression were designated CNOT1-Lo.  A 
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complete ranked expression dataset was generated in which genes were ranked according 
to ratio of expression in CNOT1-Hi samples to CNOT1-Lo samples (CNOT1-Hi/CNOT1-
Lo). This ranked dataset was compared to genesets derived from Merlos-Suárez (Merlos-
Suárez et al., 2011). Merlos-Suárez et al sorted mouse intestinal crypt cells based on 
expression of EphB2 to define gene programs for normal crypt cell populations. Genes 
enriched in EphB2Hi cells defined the intestinal stem cell (ISC) signature. Genes 
expressed at equal levels in EphB2Hi and EphB2Med defined a proliferation signature. 
Genes differentially expressed in EphB2Lo cells defined a late progenitor, transit 
amplifying population.  We found that genes in the proliferation geneset were enriched in 
the CNOT1-Hi samples while CNOT1-Lo genes were not enriched in any of the three 
crypt populations (Figure 21A, Table 5A).  The CNOT1-Hi/CNOT1-Lo dataset was also 
compared to genesets of candidate CRC genes identified by SB transposon mutagenesis 
of mouse intestine (Figure 21B an C, Table 5B and C). It was found that genes up-
regulated in CNOT1-Hi tumors, but not in CNOT1-Lo tumors were enriched in candidate 
cancer genes (CIS genes) identified by Sleeping Beauty mutagenesis. These results are 
consistent with in vitro results in which loss of CNOT1 resulted in decreased cell 
viability. However, three metastasis samples had CNOT1 expression levels significantly 
lower than normal samples. As the anchor protein of a multifunctional complex CNOT1 
may potentially regulate many cellular processes.  The fact that both CNOT1-Hi and 
CNOT1-Lo are found in metastasis samples but associated with different expression 
patterns suggests that CNOT1 affect on CRC may differently dependent on genetic 
context. 
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Figure 21. Geneset Enrichment Analysis of human metastasis CRC samples. CNOT1-
Hi/CNOT1-Lo expression dataset (see text for details) was analyzed for enrichment in crypt 
proliferation genes and CRC candidate cancer genes identified by SB screens. Genesets consist 
of: (A) genes differentially expressed in proliferating crypt cells (Merlos-Suárez et al., 2011); (B) 
top CIS-associated genes identified in a wild-type background (Starr et al., 2009), in an ApcMin 
background (Starr et al., 2011), and a p53-mutant background (Starr T.K., unpublished data); (C) 
top 200 CIS-associated genes identified in SB screen using a 120 k window (March et al., 2011). 
(D) Normalized enrichment score (NES) and nominal p value (Nom. p value) are shown for each 
comparison. 
CNOT1 Limits the mRNA Expression Levels of TXNIP in SW480 and HEK293 Cell 
Lines. 
Because of connections seen between CNOT1-Hi expression and cancer-related 
phenotypes, we chose to investigate the mechanism by which CNOT1 expression protects 
cell viability. Microarray analysis revealed dramatically increased expression of 
Thioredoxin-interacting protein (TXNIP) (7.45-fold). TXNIP has been identified as a 
tumor suppressor in human breast, colon, lung and liver cancers through inhibition of cell 
proliferation and arrest of the cell cycle at G0/G1 phase and its expression is decreased in 
several cancers including CRC (Jeon, et al., 2005, Han et al., 2003, Goldberg et al., 2003, 
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Zhou, et al., 2010, Sheth et al., 2006). In addition, in pancreatic beta cells, activation of 
TXNIP by oxidative or ER stress initiates apoptotic pathways (Lerner et al., 2012, Zhou 
et al., 2010, Oslowski et al., 2012). As cancer cells are often subject to extreme stresses 
we hypothesized that CNOT1 might protect cell viability by limiting TXNIP expression. 
In accordance with the array results CNOT1 depletion results in increased TXNIP 
expression by qRT-PCR in CNOT1-depleted SW480 cells and HEK293 cells (8.8 and 
2.85 fold, respectively) (Figure 22 A and B). Increased expression of TXNIP in SW480 
cells was detected as early as 2 days after the first siRNA transfection (Table 3). In 
addition, overexpression of the longest CNOT1 transcript variant (NM_00126561, 
CNOT1L) in HEK293 cells results in a decrease in TXNIP expression to about 70% of 
controls  (Figure 22C). These results indicate that CNOT1 limits TXNIP mRNA levels in 
these two cell lines. 
A.                                                                     B. 
 
C. 
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Figure 22. CNOT1 limits TXNIP mRNA levels in SW480 and HEK293 cell lines.  (A) TXNIP 
mRNA expression levels in RNA samples used for the microarray assay were determined by 
qRT-PCR. (B) TXNIP mRNA levels in HEK293 cells depleted for CNOT1 were determined by 
qRT-PCR. HEK293 cells were transfected with either CNOT1 siRNA or a non-targeting siRNA 
control as described in Figure 17. Total RNA was extracted 48 hours after the second transfection 
and subjected to qRT-PCR to determine TXNIP levels. (C) HEK293 cells were transfected with 
plasmids encoding CNOT1L (NM_016284.4) or a control plasmid encoding green fluorescent 
protein (GFP). 48 hours after transfection RNA samples were isolated and TXNIP mRNA levels 
were determined by qRT-PCR. Values in (A), (B), (C) represent mean ± SD of 3, 2, 4 
independent experiments, respectively. Significance of differences was calculated by a t-test. * = 
p < 0.05. 
Increased TXNIP Levels are Linked to CNOT1-Mediated Apoptosis 
To determine if CNOT1-mediated up-regulation of TXNIP might be responsible 
for decreased cell viability seen in CNOT1-depleted cells, we examined the effect of 
overexpression of TXNIP on cell viability. For these experiments a plasmid encoding 
TXNIP was transiently overexpressed in HEK293 cells.  Control cells were transfected 
with a GFP-encoding plasmid in the same vector. Transfection efficiency was estimated 
to be 60%. TXNIP mRNA expression was increased by 7.5-fold 48 hours after 
transfection (Figure 23A). In a parallel experiment, cells were evaluated for cell viability 
by MTT assay. Viability was decreased to about 50% that of control cells at 72 hours 
(Figure 23B). To test this relationship further, we deterimined whether elevated TXNIP 
levels occurred before apoptosis in CNOT1-depleted cells. Compilation of data shown in 
Figures 18A, 18B and 22A indicates that upregulation of TXNIP mRNA expression is 
detected as early as 2 days (day 5) after the first transfection. However, detectable 
increases in apoptosis do not occur until the first day (day 7) after the second transfection 
(Table 3). This result is consistent with CNOT1 mediating cell viability by regulating 
TXNIP levels. To summarize, depletion of CNOT1 results in increased apoptosis, 
decreased cell viability and increased levels of TXNIP in SW480 and HEK293 cells. 
Increased levels of TXNIP result in decreased cell viability in HEK293 cells. Finally, 
CNOT1 depletion in SW480 cells results in increased TXNIP levels before increased 
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apoptosis and decreased cell viability. Taken together, these results suggest that CNOT1 
protects cell viability at least in part by limiting TXNIP expression. 
A.                                                           B. 
  
Figure 23. Overexpression of TXNIP reduces SW480 cell viability. HEK 293 cells were 
transiently transfected with plasmids encoding either TXNIP or GFP as a control. (A) Total RNA 
was isolated 48 hours after transfection and TXNIP mRNA levels were determined by qRT-PCR. 
(B) Transfected cells were plated at 2 x 104  cells per well in triplicate in 96 well plates. Cell 
viability was measured by MTT assay on 6 hours to 72 hours after transfection. Viability is 
shown as absorbance at 595 nm. Each data point represents mean ± SD of three replicates from 
one representative experiment of two. Significance of differences in cell viability at 72 hours was 
determined by a t-test. * = p < 0.05.   
  d3 d4 d5 d6 d7 d9 
Transfection 1st tfx.     2nd tfx     
CNOT1 fold change   0.11 0.13 0.17   0.1 
TXNIP fold change   0.81 6.04 2.9 4.37 8.8 
Apoptosis fold change       No change Increase   
Table 3. Time course study of a correlation between CNOT1 depletion, upregulated TXNIP 
and cell apoptosis. Compilation of results of CNOT1 depletion in SW480 cells taken from 
Figures 17A, CNOT1 depletion; 17B, cell viability; 18C, apoptosis; and 22A, TXNIP mRNA 
levels. Fold change = level in CNOT1-depleted cells/level in non-targeting control treated cells. 
Results are shown relative to a timeline of the CNOT1 siRNA depletion protocol. 
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Identification of CNOT1 Isoforms and CCR4-NOT Subunits Involved in TXNIP 
Regulation 
We then investigated the mechanism by which CNOT1 regulates TXNIP levels. 
Human cells express three CNOT1 transcript variants with translated protein products 
(See details in Introduction). The two longest forms (CNOT1L, NM_016284.4 and 
CNOT1M, NM_001265612.1) contain a C-terminal NOT domain with binding sites for 
several potentially biologically relevant interactors, such a CNOT2, CNOT3, and CNOT5. 
To determine which of these variants contribute to cell viability in SW480 cells, primers 
were designed to specifically distinguish between the two long forms (CNOT1L and M) 
and the short form (CNOT1S). qRT-PCR analysis of SW480 cells revealed that one or 
both of the long forms are virtually the only form expressed in these cells (98%), while 
the short form makes up no more than 2% of overall CNOT1 mRNA expression (Figure 
24A). In addition, the short form is almost undetectable in CRC liver metastasis and 
normal colon samples, suggesting that one or both of the long forms are the biologically 
relevant form in the colon (Figure 24B). Importantly, expression of the shortest isoform 
(CNOT1S) resulted in increased TXNIP expression (Figure 24C). This result suggests 
that some part of the C-terminal region unique to the CNOT1L and/or CNOT1M 
isoforms contributes to downregulation of TXNIP. As CNOT1 acts as part of a larger 
complex CNOT1S may act as a dominant negative by sequestering essential subunits.  
Because CNOT1 is part of the CCR4-NOT complex and because the full range of 
configurations of this complex is not known (Chen et al., 2011) we determined if 
knockdown of other CCR4-NOT subunits would also decrease cell viability and increase 
TXNIP levels. We focused on CNOT2, which is also a core member of the CCR4-NOT 
and which has also been identified as a candidate CRC gene in SB screens, and on the 
four deadenylase subunits because deadenylation leading to mRNA degradation is the 
best characterized mechanism of CCR4-NOT mediated gene regulation. Analysis of 
SW480 cells depleted for CNOT2, and the deadenylase subunits CNOT6, 6L, 7 and 8 
(Figure 24D) indicated that while cell viability was decreased in cells depleted for each of 
these subunits (CNOT6 not measured), TXNIP levels were elevated only in CNOT8-
depleted cells (7.07 fold) (Figure 24E). These results suggest that CNOT1 works with 
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CNOT8 to regulate TXNIP levels. In addition, they suggest that CNOT1 will be found to 
regulate cell viability by additional pathways involving interactions with other CCR4-
NOT subunits. 
A.                                                               B. 
   
C.                                                               D. 
   
E.                                               
 
Figure 24. Identification of CNOT1 isoforms and CCR4-NOT subunits involved in TXNIP 
regulation. (A) CNOT1 variants expressed in untreated SW480 cells were determined by qRT-
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PCR using primers designed to distinguish between the two long isoforms, CNOT1L and 
CNOT1M (NM_016284.4 and NM 001265612.1) and the short isoform CNOT1S 
(NM_206999.2). Values represent mean ± SD of three independent experiments. Significance of 
differences was calculated by a t-test. ** = p < 0.01. (B) FPKM (fragments per kilobase of exon 
per million fragments mapped) expression levels of CNOT1L and CNOT1S in 20 liver metastasis 
of stage IV human CRCs and 5 normal colonic tissues. Values represent mean ± SD of each 
group of samples. Significance of differences was calculated by one-way ANOVA. *** = p < 
0.001. (C) Expression of TXNIP was determined in cells overexpressing CNOT1S. HEK 293 cells 
were transfected with plasmids encoding either CNOT1S or GFP as a control. Total RNA was 
isolated at 48 hours after transfection and probed for TXNIP levels by qRT-PCR. Values 
represent result of one experiment. (D) SW480 cells were transfected with siRNA oligos targeting 
CNOT2, 6, 6L, 7, 8, or non-targeting siRNA, twice, 48 hours apart, at a final concentration of 50 
nM. Total RNA was extracted 72 hours after the second transfection and depletion of target genes 
was determined by qRT-PCR. Relative mRNA level = level of indicated subunit in subunit-
specific siRNA-treated cells/control siRNA treated. On day 1 after the second transfection 
SW480 cells were plated at 2,500 cells per well in triplicate in 96 well plates. Cell viability was 
measured by MTT assay on day 6 after the second transfection. Relative cell viability represents 
= absorbance at 595 nm of cells treated with indicated siRNA/cells treated with non-targeting 
control. Results represent at least two experiments except for CNOT6 (one experiment, no MTT 
assay). (E) TXNIP expression levels were determined by qRT-PCR in SW480 cells depleted for 
CNOT2, and the deadenylase subunits CNOT6, 6L, 7, and 8. Values represent mean ± SD of at 
least two experiments except for CNOT6 (one experiment). Significance of difference was 
calculated by a t-test. 
CNOT1 Limits TXNIP mRNA Levels Through Decreasing mRNA Stability 
As CCR4-NOT subunits with deadenylase activity, such as CNOT8, can initiate 
mRNA degradation, we pursued the idea that CNOT1 regulates TXNIP mRNA stability.  
CNOT1-depleted and control SW480 cells were treated with Actinomycin D to block 
transcription and TXNIP mRNA levels were determined by qRT-PCR for 2 hours. This 
study showed that TXNIP levels were significantly higher in CNOT1-depleted cells after 
2-hour exposure to Actinomycin D (Figure 25) indicating that TXNIP mRNA stability is 
enhanced in the absence of CNOT1.  
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Figure 25. CNOT1 limits TXNIP mRNA levels through decreasing mRNA stability. SW480 
cells were transfected with either CNOT1 siRNA or control siRNA. Actinomycin D was added at 
a final concentration of 5 µg/ml 72 hours after one siRNA transfection. Total mRNA was isolated 
at indicated intervals from 0 to 120 mininutes after treatment. TXNIP mRNA levels were 
determined by qRT-PCR. The TXNIP mRNA levels at each time point are shown as the 
percentage of TXNIP mRNA levels at 0 minute. Values represent mean ± SD of three 
independent experiments. The best-fit line is shown as a dotted line.  Significance of difference 
was calculated by a t-test at 60 minutes and 120 mininutes. * = p < 0.05.   
3’UTR Binding Proteins ZFP36 (TTP), PUM1, PUM2 and CELF1 (CUGBP1) Are 
Not Involved in CNOT1-Mediated Regulation of TXNIP.  
CNOT1 commonly regulates mRNA stability by acting as an adapter between 
3’UTR binding factors and deadenylase subunits of the CCR4-NOT complex. CNOT1 
has been reported to interact with the 3’UTR binding proteins ZFP36, PUM1 and PUM2 
(Fabian et al., 2013, Van Etten et al., 2012), which mediate deadenylation and 
degradation of targeted mRNAs. In addition Pum1, Pum2 and Celf1, another 3’UTR 
binding protein, were identified as candidate colorectal cancer genes in SB screens (Starr 
et al., 2009, Starr et al., 2011). To determine if these 3’UTR binding proteins were 
involved in CNOT1 regulation of TXNIP, TXNIP levels were determined in SW480 cells 
depleted for each protein. Depletion of each of these proteins results in less than two-fold 
increase in TXNIP (Figure 26A and B) suggesting that these 3’UTR binding proteins are 
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not involved in CNOT1-mediated regulation of TXNIP. 3’UTR binding proteins often 
bind AU rich motifs in the 3’UTR to target mRNAs for deadenylation and decay. 
Examination of the number and locations of conserved ARE motifs in the TXNIP mRNA 
transcript using a bioinformatics tool (AREsite 1.0 http://rna.tbi.univie.ac.at/cgi-
bin/AREsite.cgi) identified only one ARE motif (ATTTA) in the 3’UTR of TXNIP 
mRNA (1934-1938 nt). As mRNAs targeted by RBPs usually contain multiple sites, the 
lack of ARE sites may account for the result that TXNIP mRNA is not regulated by these 
3’UTR binding proteins.   
A.                                                B.                                                                
    
Figure 26. 3’UTR binding proteins ZFP36, PUM1, PUM2 and CELF1 are not involved in 
CNOT1-mediated regulation of TXNIP. SW480 cells were transfected with siRNA oligos 
targeting indicated 3’UTR binding proteins or non-targeting siRNA, twice, 48 hours apart, at a 
final concentration of 50 nM. (A) Relative mRNA levels of targeted genes. Relative mRNA level 
= levels of indicated RBPs in RBP siRNA-treated cells/control siRNA treated. (B) TXNIP mRNA 
levels in SW480 cells depleted for indicated RNA binding proteins. The values represent result of 
one experiment, except for ZNF36, which represents mean ± SD of two experiments. 
Significance of differences was calculated by a t-test.   
miR-17 Downregulates TXNIP mRNA Levels 
CNOT1 also interacts as an adapter between TNRC6A (GW182) of the 
microRNA RISC complex and CCR4-NOT deadenylase subunits, thus facilitating 
microRNA-mediated mRNA degradation. TXNIP has been reported to be degraded by 
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miR-17 suggesting that CNOT1 may facilitate miR-17-mediated degradation of TXNIP. 
However, miR-17 regulates TXNIP expression in a cell specific fashion. For instance, it is 
active in pancreatic beta cells but not in macrophages. The role of microRNAs in TXNIP 
mRNA stability in CRC cells is unknown so we first sought to determine if miR-17 
regulates TXNIP in SW480 cells. In initial studies miR-17 was found to be present in 
SW480 cells (Figure 27A) and overexpression of a miR-17 mimic in SW480 cells 
resulted in a 31% decrease in levels of TXNIP mRNA.  mRNA levels of two other miR-
17 targets, which like TXNIP are upregulated in CNOT1 depleted cells, HBP1 (Li et al., 
2011) and TGFBR2 (Dews et al., 2010), were decreased by 30% and 49%, respectively 
(Figure 27B). In addition, TXNIP levels were reduced by more than 50% in HEK293 
cells transfected with the miR-17 mimic (Figure 27C). Results of these studies suggested 
that miR-17 downregulates TXNIP levels in SW480 and HEK293 cell lines.  
These results support a model in which CNOT1 regulates TXNIP expression post-
transcriptionally by facilitating the deadenylase activity of CNOT8. This CCR4-NOT 
complex may be recruited to the 3’UTR of TXNIP mRNA via interaction with a miRNA 
RISC complex containing miR-17. 
A. 
 
B.                                                                           C. 
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Figure 27.  miR-17 downregulates TXNIP mRNA levels. (A) Amplification curve showing 
amplification of endogenous miR-17 and U6 snRNA from SW480 cells using qRT-PCR. Ct 
(cycle threshold) = the number of cycles required for the fluorescent signal to cross the threshold 
(0.1 in this case). Total RNA including small RNAs was isolated using a miRNeasy Mini Kit 
(Qiagen). RNA was then transcribed to cDNA and ligated with universal adaptors using a 
miScript II RT Kit (Qiagen). Expression levels of mature miR-17 and U6 snRNA (internal control, 
abundant in most type of cells) were measured by qRT-PCR using a miScript SYBR Green PCR 
Kit with a miScript universal primer and specific primer for miR-17 and U6 from the miScript 
Primer Assay Plate (Qiagen). (B and C) SW480 and HEK293 cells were transfected with either 
miR-17 mimic oligos or non-targeting siRNA control at 5nM final concentration. Total RNA was 
extracted 24 hours after transfection and probed for known targets of miR-17 by qRT-PCR. 
Values represent ratio of mRNA expression in miR-17 mimic treated cells relative to non-
targeting control treated cells. (B) Expression levels of three known mirR-17 targets, TXNIP, 
HBP1 and TGBR2, in SW480 cells. Values represent mean ± SD of two independent experiments. 
Significance of difference was calculated by a t-test. *** = p < 0.001, ** = p < 0.01. (C) 
Expression levels of TXNIP in HEK293 cells. Values represent result from one experiment.  
TXNIP and CNOT1 Are Associated with the Unfolded Protein Response (UPR). 
TXNIP and the UPR. TXNIP is activated to promote apoptosis by cellular 
conditions such as oxidative stress and extreme endoplasmic reticulum (ER) stress. 
Accumulation of unfolded proteins in the ER results in ER stress and activation of the 
unfolded protein response (UPR). Moderate ER stress leads to activation of an adaptive 
UPR, which initiates several pathways that decrease general translation and increase 
transcription and translation of factors to increase ER folding capacity. However, under 
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conditions of extreme stress the UPR initiates pathways leading to cell death, a process 
known as terminal UPR. It has recently been reported that activation of TXNIP can 
promote the switch from adaptive to terminal UPR. Further, this activation takes place in 
part by means of relief of miR-17-mediated degradation of TXNIP mRNA. Thus, 
CNOT1-mediated downregulation of TXNIP expression may contribute to protection 
from terminal UPR pathways. 
To test this idea we first determined if the UPR contributed to apoptosis in 
SW480 cells. Cells were treated with different concentrations of tunicamycin, a potent 
pharmacological inducer of ER stress and the UPR, from 0.05 µg/ml to 1.0 µg/ml over a 
time period of 96 hours and cell viability was evaluated by MTT assay at intervals of 24 
hours (Figure 28A). This experiment revealed that treatment with tunicamycin results in a 
dose and time dependent decrease in cell viability in SW480 cells. To confirm that 
treatment with tunicamycin can induce ER stress and activate UPR pathways, we also 
measured mRNA levels of genes involved in UPR signaling. We found that GRP78/Bip, 
sXBP1, ATF6, PERK and XBP1 mRNA levels showed at least two fold upregulation in 
SW480 cells treated with tunicamycin at 0.25 µg/ml for 6 hours (Figure 28B). This result 
suggested that tunicamycin could induce decreased cell viability through activation of 
UPR signaling.  
A.                                                                     B. 
      
Figure 28. Tunicamycin induces decreased cell viability and activation of UPR signaling in 
SW480 cells. (A) SW480 cells were plated at 2 X 104 cells per well in triplicate in 96 well plates. 
Cells were treated with tunicamycin at 0.05 µg/ml to 1.0 µg/ml and cell viability was measured 
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by MTT assay over a time period of 96 hours at intervals of 24 hours. Each data point represents 
mean ± SD of three replicates from an MTT assay. (B) SW480 cells at 70% confluence were 
treated with tunicamycin at 0.25 µg/ml for 6 hours. Total RNA was extracted and measured for 
mRNA expression levels of indicated genes. Values represent mean ± SD of two experiments. 
Significance of differences was determined by a t-test.  *** = p < 0.001, * = p < 0.05.  
To determine if TXNIP is involved in the response to UPR in SW480 cells we 
first examined the effect of tunicamycin treatment on TXNIP expression. Treatment with 
tunicamycin at 0.25 µg/ml for 6 hours resulted in upregulated TXNIP levels (Figure 29A) 
consistent with a role for TXNIP in the UPR in these cells. We then examined cell 
viability in cells treated with a moderate dose (0.1 µg/ml) of tunicamycin. TXNIP-
depleted cells showed increased viability compared to control cells (Figure 29B) 
suggesting that TXNIP promotes the terminal UPR pathway in these cells. 
A.                                                                  B. 
      
Figure 29. TXNIP plays a role in the UPR in SW480 cells. (A) SW480 cells were treated with 
tunicamycin of 0.25 µg/ml for 6 hours. Total RNA was isolated and analyzed by RT-qPCR to 
determine TXNIP expression levels. Values represent mean ± SD of two experiments. 
Significance of differences was calculated by a t-test. (B) SW480 cells were transfected with 
either siRNA targeting TXNIP or control siRNA twice 48 hours apart. Cells were plated at 5000 
cells per well in triplicate in 96 well plates 24 hours after the second transfection. Cells were 
treated with tunicamycin at 0.1 µg/ml and cell viability was measured by MTT assay over a time 
period of 96 hours as indicated. Each data point represents mean ± SD of three replicates from 
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one experiment. Significance of differences in cell viability was determined at 72 hour and 96 
hour by a t-test. ** = p < 0.01.   
CNOT1 and the UPR. To determine if CNOT1 also plays a role in the UPR in 
SW480 cells we examined expression of mRNAs upregulated during the UPR. qRT-PCR 
analysis revealed that mRNA levels of genes involved in all three pathways of the UPR 
are upregulated in CNOT1-depleted SW480 cells (Figure 30A), such as sXBP1 (IRE1α 
pathway), PERK, ATF4 and DDIT3 (CHOP) (PERK pathway), and ATF6, XBP1(ATF6 
pathway). It is important to note that only changes in mRNA levels were examined. To 
gain a full picture of the effect of CNOT1 on these pathways we will need to examine 
translational and post-translational regulation.   
To determine if CNOT1 might be involved in apoptotic pathways initiated by 
TXNIP activation we examined expression of IL8 and NFKB1 and found that their levels 
were increased in CNOT1-depleted cells consistent with a model in which CNOT1 acts 
through TXNIP (Figure 30B). 
A.                                                                               B. 
      
Figure 30. Depletion of CNOT1 results in ER stress and activation of UPR pathways. (A) 
Quantification of mRNA expression levels of genes involved in UPR pathways in SW480 
depleted for CNOT1 by qRT-PCR. (B) mRNA expression levels of NFKB1 and IL8 in SW480 
depleted for CNOT1. Values represent mean ± SD of three independent experiments. Significance 
of differences was calculated by a t-test. *** = p < 0.001, * = p < 0.05. 
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To further characterize the role of CNOT1 in the unfolded protein response we 
performed GSEA to analyze the altered gene expression profile following CNOT1 
depletion. A complete ranked expression dataset was generated in which genes were 
ranked according to ratio of expression in CNOT1-depleted cells to control treated cells. 
Genesets were compiled to represent gene expression in adaptive UPR or terminal UPR. 
GSEA revealed significant overlap with a group of mRNAs associated with response to 
extreme UPR known as Regulated IRE-1 Dependent Decay (RIDD) genes. These 
included RIDD genes degraded in mouse liver (So et al., 2012) and in pancreatic beta 
cells (Han et al., 2009) in response to extreme ER stress. Transcripts down-regulated in 
CNOT1-depleted cells were enriched in genes down-regulated in response to extreme ER 
stress, suggesting that downregulation of CNOT1 promotes RIDD and therefore CNOT1 
expression is protective (Figure 31A, Table 6). In addition, comparison with the 
Molecular Signatures Database geneset collection of cellular components (MsigDB C5 
CC, http://www.broadinstitute.org/gsea/msigdb/collections.jsp#C5) revealed that four of 
the five most enriched genesets consisted of plasma membrane localized components and 
thus transcripts that would be translated and processed in the ER (Figure 31B, Table 7). 
This result suggests that CNOT1 may also protect the cell from the UPR by limiting 
transcript levels. Together these results suggest that CNOT1 may protect against the 
effects of ER stress by mechanisms in addition to TXNIP regulation. 
 
C.  
 
vs. CNOT1-depleted array 
GENESET NES Nom. P Value 
RIDD genes  (So et al) -1.99 <0.001 
Plasma membrane protein genes 2.02 <0.001 
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Figure 31. CNOT1 is involved in ER stress and activation of UPR pathways. Gene set 
enrichment analysis (GSEA) of gene expression profile in SW480 cells depleted for CNOT1. 
Ranked CNOT1 expression data set (see text) was analyzed for enrichment in UPR-related 
genesets. (A) Representative enrichment plot of genesets compiled from gene expression studies 
of adaptive and terminal responses to the UPR.  Shown is RIDD geneset from So et al (So et al., 
2012). (B) Representative enrichment plot analysis of genesets found in MsigDB C5 CC 
collection, consisting of genes expressed in specific cellular components.  Shown is enrichment 
plot for the GO geneset ‘PLASMA_MEMBRANE_PART’. (C) Normalized enrichment score 
(NES) and nominal p value (Nom. p value) are shown for each comparison. 
 
Figure 32. A model for roles of CNOT1 in regulating cell viability. 
To summarize, these studies demonstrate that depletion of CNOT1 in the human 
CRC cell line SW480 results in decreased cell viability, increased apoptosis and 
increased TXNIP levels. Increased TXNIP levels in HEK293 cells resulted in decreased 
cell viability. In addition, in CNOT1-depleted SW480 cells, elevation of TXNIP levels 
occurs before an increase in apoptosis. These results suggest that decreased cell viability 
in CNOT1-depleted cells is due to increased TXNIP levels. To further test this idea we 
will examine the effect of co-expression and co-depletion of CNOT1 and TXNIP. Further, 
our data indicate that CNOT1 destabilizes TXNIP mRNA possibly through miR-17-
mediated degradation involving CNOT8 deadenylase. To test this idea we will examine 
3’UTR reporter activity. 
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In pancreatic beta cells elevation of TXNIP levels occurs in response to extreme 
ER stress and leads to apoptosis. As increased TXNIP levels occur through post-
transcriptional stabilization, CNOT1 expression may protect from and CNOT1 depletion 
may exacerbate the effects of extreme ER stress and the terminal unfolded protein 
response in SW480 cells. In support of this idea, depletion of TXNIP in SW480 cells 
protects against tunicamycin-induced cell death suggesting that CNOT1-mediated 
limitation of TXNIP may be protective. In support of a role for CNOT1, mRNAs from 
each of the major UPR pathways are upregulated in CNOT1-depleted cells. In addition, 
analysis of gene expression in CNOT1-depleted cells suggests that CNOT1 may limit the 
UPR by other mechanisms as well. 
A model based on these results is shown in Figure 32. This model predicts that 
CNOT1 activity protects cell viability by limiting the effects of the terminal UPR.  
Severe cellular conditions, such as protein overprocduction and oxidative stress, cause 
ER stress and activate UPR pathways. Under terminal, non-remediable ER stress, 
hyperactivation of IRE1α results in uregulated TXNIP expression, which in turn, activates 
apoptotic signaling pathways. CNOT1 activity may protect against the effects of severe 
ER stress through directly limiting TXNIP transcript levels.  In addition, CNOT1 activity 
may limit the pool of mRNA to be translated in the ER.   
However, two major gaps need to be filled. (1) Evidence that increased activity of 
CNOT1 can prevent cell apoptosis under severe ER stress, such as treatment with 
tunicamycin, needs to be provided. (2) We also need to show increased TXNIP activity is 
the cause of increased apoptosis in CNOT1-depleted cells and that limiting TXNIP 
activity can improve cell viability in these cells. As cancer cells are often subject to 
extreme stresses due to harsh growth conditions or enhanced protein production, 
increased activity of CNOT1 may protect cancer cells from apoptosis through this 
mechanism and confer growth advantage to cancer cells.  
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Supplemental Information: 
Table 4. List of 266 genes showing significant upregulated (A) and downregulated (B) 
expression levels in SW480 cells depleted for CNOT1.  
(A) Upregulated Genes: 
Gene Symbol log fold change n fold change 
TXNIP 2.896508483 7.44622 
DKK1 2.35158454 5.10385 
DUSP5 2.150944437 4.44118 
EMP1 2.096157218 4.27569 
NA 1.973349402 3.92679 
NRP1 1.96182098 3.89553 
TNFRSF6B 1.923383113 3.79312 
IL1RAPL1 1.918700003 3.78082 
LYPD6B 1.915699299 3.77297 
SGK1 1.88472168 3.69282 
S100P 1.863698467 3.63939 
STEAP1 1.812791333 3.51321 
BTG1 1.771000055 3.41290 
PLAUR 1.762770283 3.39349 
ZNF365 1.7489493 3.36114 
MUC13 1.714169268 3.28108 
PLIN2 1.6600699 3.16032 
PROCR 1.654243386 3.14758 
SERPINE1 1.648272383 3.13458 
GPRC5A 1.643272601 3.12374 
IGFBP3 1.637889705 3.11210 
HAVCR2 1.629860019 3.09483 
EFNB2 1.624880988 3.08417 
LYPD6B 1.6078959 3.04807 
IGFBP3 1.574230479 2.97777 
ADAM19 1.567745266 2.96441 
TM4SF1 1.565727169 2.96027 
TNFRSF6B 1.563680091 2.95607 
TGM2 1.56321117 2.95511 
LPAR5 1.547263062 2.92262 
ZBED2 1.522691159 2.87327 
AKAP12 1.52109659 2.87009 
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POLR1C 1.50002564 2.82848 
PLAUR 1.498237703 2.82497 
FZD9 1.48279479 2.79490 
TMEM22 1.482594424 2.79451 
SGK1 1.476720245 2.78315 
C2orf49 1.471895329 2.77386 
CD58 1.453009577 2.73779 
NA 1.448875551 2.72995 
NRP1 1.43272506 2.69956 
COL7A1 1.419252403 2.67447 
MMD 1.411019172 2.65925 
SERPINB5 1.410881657 2.65900 
SGK1 1.405235672 2.64861 
POLR1C 1.404352218 2.64699 
F2RL1 1.386263215 2.61401 
UCN2 1.368591711 2.58218 
BCAR3 1.368519302 2.58205 
PRDM1 1.367655949 2.58051 
KLF9 1.359572662 2.56609 
CD58 1.354648683 2.55735 
NA 1.349074792 2.54749 
F2RL1 1.341613134 2.53435 
KLF2 1.328770538 2.51189 
CDKN2B 1.327136363 2.50904 
MYC 1.322388951 2.50080 
EDAR 1.322030806 2.50018 
ZNF296 1.316873858 2.49126 
PELO 1.313247411 2.48500 
PTRH2 1.312743744 2.48414 
DNAJB9 1.309275207 2.47817 
DHRS2 1.300894478 2.46382 
MYC 1.300779098 2.46362 
DEPDC7 1.299956801 2.46222 
IFRD1 1.292732494 2.44992 
UBE2H 1.276342691 2.42224 
TRIB1 1.266021197 2.40497 
IFRD1 1.263630497 2.40099 
PLIN2 1.261534137 2.39751 
HIST1H2BD 1.261314556 2.39714 
LMO2 1.257296455 2.39047 
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ICAM2 1.254362976 2.38562 
SERPINE2 1.253807761 2.38470 
DKK4 1.244804631 2.36986 
NOP2 1.244625355 2.36957 
TNFRSF6B 1.243115008 2.36709 
DEPDC7 1.23948181 2.36114 
HEY2 1.235810152 2.35514 
KRT81 1.231054712 2.34739 
FRAT2 1.225722218 2.33872 
SLC40A1 1.219612857 2.32884 
TNFRSF11B 1.21452103 2.32064 
TANC1 1.213628042 2.31920 
AKIRIN2 1.212223406 2.31694 
KANSL2 1.211242518 2.31537 
VASN 1.211055295 2.31507 
RGL1 1.210689082 2.31448 
GZMB 1.202988495 2.30216 
GNL3 1.198410379 2.29487 
FAM216A 1.197542091 2.29349 
HES7 1.195248472 2.28984 
HS3ST3A1 1.192675668 2.28576 
YRDC 1.191016461 2.28314 
CST1 1.18858886 2.27930 
KIAA0895 1.185541336 2.27449 
KCTD14 1.184888387 2.27346 
ARHGEF3 1.184740405 2.27322 
PHLDA1 1.177206928 2.26139 
TMEM177 1.175174863 2.25820 
TM4SF19 1.174174787 2.25664 
KRT6A 1.167536766 2.24628 
RNF149 1.165157634 2.24258 
RNASE1 1.164472224 2.24151 
ANXA1 1.160708624 2.23567 
ITGA2 1.15583959 2.22814 
NDRG1 1.155667332 2.22787 
TSPAN5 1.155568505 2.22772 
NOP16 1.152421033 2.22287 
SLC30A1 1.151151774 2.22091 
ATG16L1 1.144311522 2.21041 
NOP16 1.139920452 2.20369 
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ITGA5 1.137479692 2.19996 
IRF1 1.135474794 2.19691 
GTF2B 1.132604331 2.19254 
RN28S1 1.132534635 2.19244 
GJB3 1.132510918 2.19240 
S100A3 1.12691402 2.18391 
GJB4 1.126536321 2.18334 
ARHGEF2 1.123660666 2.17899 
LGR6 1.123615779 2.17892 
ADCK3 1.121741223 2.17609 
GPRC5C 1.117589583 2.16984 
TNFRSF21 1.110188935 2.15874 
SRPK2 1.110075426 2.15857 
LRRN4 1.109654821 2.15794 
RCL1 1.107295885 2.15441 
ECE2 1.107189669 2.15426 
WFDC3 1.105573451 2.15184 
PDE8B 1.104913843 2.15086 
BRIX1 1.103104365 2.14816 
MRPS30 1.102410059 2.14713 
NGDN 1.098735412 2.14167 
GTPBP4 1.097972613 2.14054 
CXorf38 1.093019097 2.13320 
IRF9 1.092852582 2.13295 
ELF1 1.088877751 2.12709 
EFNB1 1.085619757 2.12229 
NA 1.080680745 2.11503 
HBEGF 1.077663741 2.11062 
NA 1.0726737 2.10333 
BRIX1 1.072631123 2.10327 
BMP4 1.066868563 2.09488 
GNE 1.064478369 2.09141 
TNFRSF1B 1.062264226 2.08821 
PHLDB2 1.062150174 2.08804 
C15orf39 1.061062307 2.08647 
SLC52A3 1.058176403 2.08230 
TPST2 1.053237269 2.07518 
BIK 1.052793952 2.07454 
PCGF1 1.050910242 2.07184 
ERRFI1 1.049601191 2.06996 
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NA 1.047888796 2.06750 
GEMIN4 1.046831838 2.06599 
KRT80 1.043820483 2.06168 
GRWD1 1.043588185 2.06135 
TIPARP 1.041089411 2.05778 
PHLDB2 1.040286765 2.05664 
DYRK2 1.038949974 2.05473 
SLC30A1 1.038818451 2.05454 
LARP6 1.036906679 2.05182 
ESM1 1.032017112 2.04488 
NGDN 1.031984235 2.04483 
CLPX 1.031922469 2.04475 
MAOA 1.031648332 2.04436 
NA 1.031440349 2.04406 
GNL3 1.030186706 2.04229 
ATG16L1 1.027767688 2.03887 
KCNK6 1.026330093 2.03684 
SERPINH1 1.025405705 2.03553 
NAA30 1.023109618 2.03229 
SLC16A6 1.020905652 2.02919 
NOLC1 1.019195294 2.02679 
ITPRIPL2 1.017698402 2.02469 
IFFO1 1.015243453 2.02124 
SMAGP 1.01417318 2.01975 
FAT1 1.014064792 2.01959 
NA 1.013732904 2.01913 
PLCXD1 1.012174234 2.01695 
TGFBR2 1.006768665 2.00941 
RIOK2 1.005436348 2.00755 
TGFBR2 1.005031254 2.00699 
TNFRSF10A 1.002916451 2.00405 
(B) Downregulated Genes: 
Gene Symbol log fold change n fold change 
NOTUM -1.000398452 0.49986 
CAPNS1 -1.001472128 0.49949 
DPM3 -1.00613552 0.49788 
MYO1D -1.007438581 0.49743 
PNPLA7 -1.008982297 0.49690 
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NA -1.009959309 0.49656 
ACAT2 -1.011950446 0.49588 
FRG1B -1.016104068 0.49445 
PRDX5 -1.018125981 0.49376 
ACTA2 -1.019750865 0.49320 
LRRC26 -1.022477331 0.49227 
GUSB -1.024492829 0.49158 
NBPF10 -1.026236051 0.49099 
C9orf86 -1.02854056 0.49021 
LARP1 -1.028968038 0.49006 
PRDX2 -1.029784963 0.48978 
NA -1.034871243 0.48806 
ATP5G2 -1.039293116 0.48657 
STMN1 -1.039295822 0.48656 
MT2A -1.039511988 0.48649 
ZNF358 -1.041108951 0.48595 
CCDC3 -1.042282209 0.48556 
BLOC1S1 -1.044234985 0.48490 
TMEM139 -1.046606621 0.48411 
PHPT1 -1.049034528 0.48329 
SWI5 -1.054176634 0.48157 
RRM2 -1.055679283 0.48107 
NA -1.056466049 0.48081 
DUT -1.062637917 0.47876 
DGCR6L -1.06420164 0.47824 
PRDX5 -1.065571077 0.47778 
ID2 -1.084708887 0.47149 
EEF1A1 -1.085389656 0.47126 
HES6 -1.086841283 0.47079 
COL18A1 -1.088102123 0.47038 
NA -1.089487748 0.46993 
NA -1.09305909 0.46877 
CHMP3 -1.095295069 0.46804 
NOTUM -1.095386954 0.46801 
ESPN -1.097498842 0.46733 
LYPD5 -1.100455961 0.46637 
NEBL -1.1127466 0.46241 
ANAPC11 -1.113088303 0.46230 
NA -1.126632316 0.45798 
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TNNC1 -1.127174225 0.45781 
SLC48A1 -1.129260008 0.45715 
CHMP3 -1.135397638 0.45521 
BCL7C -1.14512003 0.45215 
DGCR6 -1.147594581 0.45138 
ASPSCR1 -1.151948655 0.45002 
LAMA5 -1.153491384 0.44954 
TMSB15B -1.156822818 0.44850 
NA -1.172094204 0.44378 
ITGAE -1.177191077 0.44221 
DUT -1.17874924 0.44173 
LSM4 -1.180022421 0.44134 
RARRES2 -1.18033437 0.44125 
TMSB15B -1.181507537 0.44089 
TSTD1 -1.183928672 0.44015 
NA -1.187084934 0.43919 
SPC24 -1.187984996 0.43892 
SLC25A23 -1.197016162 0.43618 
C1orf86 -1.205394913 0.43365 
C11orf51 -1.215371146 0.43066 
C9orf142 -1.221651257 0.42879 
NA -1.225679708 0.42760 
HMGB3 -1.230032617 0.42631 
DGCR6 -1.259765955 0.41761 
ANAPC11 -1.262579478 0.41680 
RPS23 -1.279880514 0.41183 
PDXK -1.287642434 0.40962 
GCHFR -1.298126329 0.40665 
NA -1.305968633 0.40445 
MAL2 -1.323249611 0.39963 
AGRN -1.341449303 0.39462 
SKA2 -1.349357812 0.39247 
C18orf56 -1.368946242 0.38717 
NUDT14 -1.378213468 0.38469 
GAS6 -1.503109748 0.35279 
GAS6 -1.508886578 0.35138 
TCEA3 -1.57567094 0.33549 
PXMP2 -1.636131507 0.32172 
CNOT1 -2.549125461 0.17086 
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Figure 33. Molecules in top three gene networks in IPA shown in Figure 20. Names in bold 
represent genes that change expression in CNOT1-depleted cells. Unbold represent interacting 
genes.  Arrows show direction of change. 
Table 5. Core genes enriched in CNOT1-HI/CNOT1-LO.  
(A) Genes differentially expressed in proliferating intestinal crypts (Merlos-Suarez et al., 
2011). 
NAME PROBE 
RANK IN 
GENE LIST 
RANK 
METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
row_0 ZNRF3 58 1.5959 0.0111 Yes 
row_1 POLR1E 188 1.2693 0.0145 Yes 
row_2 BCKDHB 239 1.2092 0.0226 Yes 
row_3 ZC3H7B 256 1.1874 0.0326 Yes 
row_4 CYP39A1 267 1.1748 0.0430 Yes 
row_5 POLA1 430 1.0580 0.0423 Yes 
row_6 BARD1 448 1.0437 0.0509 Yes 
row_7 FADS1 536 0.9853 0.0544 Yes 
row_8 HAUS6 577 0.9663 0.0608 Yes 
row_9 MYB 587 0.9618 0.0693 Yes 
row_10 MDN1 636 0.9364 0.0749 Yes 
row_11 TSPAN12 642 0.9346 0.0833 Yes 
row_12 GEN1 751 0.8938 0.0846 Yes 
row_13 NCAPD2 777 0.8853 0.0912 Yes 
row_14 TUBB 797 0.8779 0.0982 Yes 
row_15 NDE1 833 0.8654 0.1040 Yes 
row_16 GTSE1 834 0.8652 0.1121 Yes 
row_17 CEP192 851 0.8588 0.1191 Yes 
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row_18 KIF24 1073 0.7982 0.1120 Yes 
row_19 TXNDC16 1118 0.7851 0.1165 Yes 
row_20 SGOL2 1176 0.7697 0.1200 Yes 
row_21 PUS7 1181 0.7683 0.1269 Yes 
row_22 GLS2 1219 0.7601 0.1316 Yes 
row_23 CKAP2L 1239 0.7536 0.1374 Yes 
row_24 TBC1D4 1250 0.7518 0.1438 Yes 
row_25 DACH1 1289 0.7422 0.1482 Yes 
row_26 DNA2 1309 0.7364 0.1539 Yes 
row_27 GEMIN4 1312 0.7354 0.1606 Yes 
row_28 CELSR2 1317 0.7346 0.1672 Yes 
row_29 FTSJD1 1329 0.7314 0.1734 Yes 
row_30 MCM5 1332 0.7304 0.1801 Yes 
row_31 TTPA 1369 0.7198 0.1844 Yes 
row_32 CASC5 1420 0.7098 0.1878 Yes 
row_33 LIG1 1633 0.6709 0.1802 Yes 
row_34 SCML2 1649 0.6692 0.1854 Yes 
row_35 CEP76 1654 0.6672 0.1914 Yes 
row_36 CENPI 1728 0.6526 0.1927 Yes 
row_37 PCK2 1768 0.6454 0.1962 Yes 
row_38 ALMS1 1808 0.6355 0.1996 Yes 
row_39 MCM8 1851 0.6288 0.2027 Yes 
row_40 RRM2 1875 0.6239 0.2071 Yes 
row_41 PIP4K2B 1904 0.6188 0.2110 Yes 
row_42 CP110 1955 0.6120 0.2135 Yes 
row_43 RPUSD2 2032 0.6002 0.2141 Yes 
row_44 MYC 2034 0.6002 0.2196 Yes 
row_45 MCM7 2082 0.5933 0.2221 Yes 
row_46 DUS4L 2180 0.5806 0.2212 Yes 
row_47 CCNF 2274 0.5656 0.2204 Yes 
row_48 DSN1 2339 0.5547 0.2214 Yes 
row_49 CDCA2 2344 0.5537 0.2263 Yes 
row_50 MPHOSPH9 2356 0.5514 0.2307 Yes 
row_51 ZBTB16 2381 0.5480 0.2343 Yes 
row_52 BRCA1 2467 0.5356 0.2337 Yes 
row_53 MELK 2485 0.5320 0.2376 Yes 
row_54 DCK 2548 0.5229 0.2384 Yes 
row_55 KIF18B 2557 0.5214 0.2428 Yes 
row_56 KLHL23 2596 0.5176 0.2451 Yes 
row_57 KBTBD6 2612 0.5153 0.2489 Yes 
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row_58 TUBE1 2723 0.4975 0.2464 Yes 
row_59 RPP40 2736 0.4959 0.2502 Yes 
row_60 ZNF367 2747 0.4943 0.2542 Yes 
row_61 TPX2 2771 0.4912 0.2573 Yes 
row_62 INCENP 2829 0.4828 0.2581 Yes 
row_63 KIF20B 2874 0.4770 0.2596 Yes 
row_64 PFAS 2961 0.4659 0.2584 Yes 
row_65 XRCC2 3117 0.4461 0.2524 Yes 
row_66 SMC2 3130 0.4442 0.2557 Yes 
row_67 ZNF275 3132 0.4438 0.2598 Yes 
row_68 WDR35 3136 0.4428 0.2638 Yes 
row_69 TSGA14 3145 0.4418 0.2674 Yes 
row_70 SGOL1 3160 0.4397 0.2706 Yes 
row_71 PRR11 3181 0.4373 0.2734 Yes 
row_72 WDR76 3184 0.4368 0.2773 Yes 
row_73 KIFC1 3220 0.4319 0.2791 Yes 
row_74 DIAPH3 3228 0.4303 0.2826 Yes 
row_75 KIF11 3293 0.4220 0.2824 Yes 
row_76 KIAA0649 3301 0.4211 0.2859 Yes 
row_77 NFATC2 3319 0.4188 0.2887 Yes 
row_78 RFC3 3322 0.4187 0.2925 Yes 
row_79 SHCBP1 3327 0.4184 0.2961 Yes 
row_80 ASPM 3335 0.4170 0.2996 Yes 
row_81 SLC7A2 3386 0.4117 0.3001 Yes 
row_82 CLSPN 3433 0.4043 0.3009 Yes 
row_83 HMMR 3462 0.4005 0.3028 Yes 
row_84 TOPBP1 3492 0.3967 0.3046 Yes 
row_85 CHEK1 3604 0.3841 0.3009 Yes 
row_86 GSTCD 3622 0.3809 0.3034 Yes 
row_87 POLE2 3733 0.3679 0.2996 Yes 
row_88 TRIM37 3745 0.3661 0.3023 Yes 
row_89 NRM 3779 0.3621 0.3035 Yes 
row_90 FIGNL1 3820 0.3570 0.3042 Yes 
row_91 RAD18 3826 0.3562 0.3072 Yes 
row_92 NCAPH 3831 0.3550 0.3103 Yes 
row_93 BLM 3866 0.3523 0.3114 Yes 
row_94 KIF4A 4061 0.3300 0.3017 Yes 
row_95 LMNB1 4075 0.3290 0.3039 Yes 
row_96 HAUS5 4102 0.3263 0.3053 Yes 
row_97 TAF4B 4154 0.3209 0.3049 Yes 
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row_98 MYBL2 4161 0.3203 0.3075 Yes 
row_99 PLK4 4168 0.3191 0.3101 Yes 
row_100 ESPL1 4199 0.3153 0.3111 Yes 
row_101 ZNF473 4210 0.3141 0.3134 Yes 
row_102 ESCO2 4265 0.3083 0.3127 Yes 
row_103 ATAD5 4349 0.2978 0.3101 Yes 
row_104 TCF19 4371 0.2956 0.3115 Yes 
row_105 BCL7A 4383 0.2944 0.3135 Yes 
row_106 MCM4 4458 0.2851 0.3113 Yes 
row_107 NEIL3 4518 0.2788 0.3101 Yes 
row_108 NCAPG2 4525 0.2782 0.3123 Yes 
row_109 ATAD2 4556 0.2745 0.3129 Yes 
row_110 TMEM107 4560 0.2743 0.3152 Yes 
row_111 AURKA 4580 0.2720 0.3165 Yes 
row_112 FAM54A 4603 0.2687 0.3176 Yes 
row_113 BUB1 4677 0.2613 0.3153 Yes 
row_114 KIF18A 4682 0.2607 0.3174 Yes 
row_115 PALB2 4720 0.2571 0.3174 Yes 
row_116 ANLN 4777 0.2505 0.3161 Yes 
row_117 DKC1 4796 0.2484 0.3172 Yes 
row_118 PSIP1 4809 0.2468 0.3187 Yes 
row_119 NUSAP1 4832 0.2433 0.3196 Yes 
row_120 POLD1 4833 0.2433 0.3219 Yes 
 
(B) CIS-associated genes identified in SB screens by Starr et al. (Starr et al., 2009, Starr et al., 
2011, Starr T.K., unpublished data). 
NAME PROBE 
RANK IN 
GENE LIST 
RANK METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICH-
MENT 
row_0 CNOT1 31 1.8093 0.0220 Yes 
row_1 MKLN1 230 1.2179 0.0253 Yes 
row_2 ATF2 232 1.2174 0.0414 Yes 
row_3 INO80D 237 1.2098 0.0572 Yes 
row_4 LMO7 244 1.2050 0.0729 Yes 
row_5 CDK12 252 1.1907 0.0882 Yes 
row_6 SMG1 271 1.1719 0.1026 Yes 
row_7 ELF1 281 1.1665 0.1175 Yes 
row_8 RREB1 314 1.1414 0.1306 Yes 
row_9 PUM2 330 1.1241 0.1446 Yes 
row_10 RAD50 350 1.1132 0.1581 Yes 
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row_11 SND1 452 1.0393 0.1654 Yes 
row_12 PUM1 454 1.0387 0.1791 Yes 
row_13 EXOC2 499 1.0067 0.1896 Yes 
row_14 PPP4R2 526 0.9901 0.2011 Yes 
row_15 UGGT1 550 0.9791 0.2126 Yes 
row_16 PBRM1 569 0.9711 0.2243 Yes 
row_17 GMDS 580 0.9652 0.2365 Yes 
row_18 INPP5D 616 0.9466 0.2468 Yes 
row_19 ATP8B1 649 0.9321 0.2571 Yes 
row_20 STAG1 696 0.9174 0.2663 Yes 
row_21 ROCK2 698 0.9170 0.2784 Yes 
row_22 CNOT4 725 0.9033 0.2887 Yes 
row_23 MKL2 791 0.8793 0.2962 Yes 
row_24 UBAP2 876 0.8506 0.3020 Yes 
row_25 UBN2 1049 0.8030 0.3015 Yes 
row_26 TM9SF2 1130 0.7812 0.3067 Yes 
row_27 ANKRD11 1197 0.7652 0.3125 Yes 
row_28 MLL3 1222 0.7590 0.3211 Yes 
row_29 KCTD20 1283 0.7440 0.3270 Yes 
row_30 PDZD8 1285 0.7434 0.3369 Yes 
row_31 DACH1 1289 0.7422 0.3465 Yes 
row_32 SETD5 1337 0.7293 0.3532 Yes 
row_33 RSF1 1346 0.7278 0.3623 Yes 
row_34 STXBP5 1497 0.6961 0.3618 Yes 
row_35 CDK8 1519 0.6913 0.3696 Yes 
row_36 NSD1 1522 0.6907 0.3787 Yes 
row_37 RASGRF1 1546 0.6868 0.3863 Yes 
row_38 XPO7 1591 0.6768 0.3924 Yes 
row_39 ZNRF2 1699 0.6589 0.3942 Yes 
row_40 MYO5B 1726 0.6528 0.4012 Yes 
row_41 ZNF48 1795 0.6386 0.4052 Yes 
row_42 TPP2 1892 0.6202 0.4072 Yes 
row_43 PDCD6IP 1930 0.6150 0.4130 Yes 
row_44 MAPK8 1954 0.6121 0.4196 Yes 
row_45 ARID2 1973 0.6097 0.4266 Yes 
row_46 CASP8 2004 0.6042 0.4326 Yes 
row_47 GSK3B 2008 0.6039 0.4405 Yes 
row_48 ZCCHC7 2052 0.5985 0.4456 Yes 
row_49 ESCO1 2120 0.5883 0.4491 Yes 
row_50 PAN3 2221 0.5740 0.4502 Yes 
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row_51 UHRF2 2349 0.5527 0.4493 Yes 
row_52 PTPRK 2355 0.5515 0.4563 Yes 
row_53 SNX4 2376 0.5487 0.4623 Yes 
row_54 RASEF 2415 0.5425 0.4670 Yes 
row_55 MOBKL2B 2416 0.5424 0.4742 Yes 
row_56 FUBP1 2544 0.5233 0.4729 Yes 
row_57 PIK3R1 2655 0.5081 0.4725 Yes 
row_58 ANKRD17 2684 0.5044 0.4774 Yes 
row_59 NOTCH1 2739 0.4953 0.4804 Yes 
row_60 MAN1A2 2794 0.4879 0.4834 Yes 
row_61 SORT1 2922 0.4721 0.4814 Yes 
row_62 TNPO3 2964 0.4653 0.4849 Yes 
row_63 APC 2968 0.4648 0.4909 Yes 
row_64 FNBP1L 2971 0.4645 0.4969 Yes 
row_65 ARHGAP5 3009 0.4595 0.5006 Yes 
row_66 KCNQ1 3018 0.4588 0.5062 Yes 
row_67 ERBB2IP 3118 0.4459 0.5057 Yes 
row_68 AP1AR 3168 0.4389 0.5083 Yes 
row_69 TDRKH 3178 0.4377 0.5136 Yes 
row_70 CLTC 3300 0.4212 0.5113 Yes 
row_71 TNKS 3412 0.4086 0.5095 Yes 
row_72 DMXL1 3420 0.4068 0.5144 Yes 
row_73 SIPA1L1 3458 0.4016 0.5174 Yes 
row_74 RNF111 3557 0.3888 0.5162 Yes 
row_75 CSNK2A1 3573 0.3871 0.5203 Yes 
row_76 CFTR 3645 0.3780 0.5207 Yes 
row_77 TRIM33 3669 0.3764 0.5242 Yes 
 
(C) CIS-associated genes identified in a SB screen by March et al (March et al., 2011).  
NAME PROBE 
RANK IN 
GENE LIST 
RANK METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICH-
MENT 
row_0 LRP5 22 1.9433 0.0295 Yes 
row_1 CNOT1 31 1.8093 0.0577 Yes 
row_2 BIRC6 116 1.4012 0.0745 Yes 
row_3 NEDD4 132 1.3770 0.0954 Yes 
row_4 LRIG1 148 1.3435 0.1158 Yes 
row_5 PRKCA 202 1.2556 0.1324 Yes 
row_6 PCF11 311 1.1427 0.1435 Yes 
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row_7 RREB1 314 1.1414 0.1615 Yes 
row_8 ITGA6 339 1.1207 0.1778 Yes 
row_9 NIPBL 395 1.0834 0.1914 Yes 
row_10 PUM1 454 1.0387 0.2042 Yes 
row_11 GMDS 580 0.9652 0.2114 Yes 
row_12 MLL5 614 0.9470 0.2243 Yes 
row_13 ATP8B1 649 0.9321 0.2369 Yes 
row_14 ROCK2 698 0.9170 0.2484 Yes 
row_15 NRIP1 894 0.8449 0.2491 Yes 
row_16 ATAD2B 936 0.8326 0.2597 Yes 
row_17 LGR4 944 0.8304 0.2724 Yes 
row_18 PIP5K1B 946 0.8303 0.2856 Yes 
row_19 DENND4C 973 0.8245 0.2970 Yes 
row_20 ARID1B 1147 0.7759 0.2981 Yes 
row_21 EML4 1245 0.7525 0.3037 Yes 
row_22 ITFG3 1262 0.7494 0.3146 Yes 
row_23 GTF2IRD1 1288 0.7430 0.3248 Yes 
row_24 BAZ2B 1302 0.7381 0.3357 Yes 
row_25 TLK1 1381 0.7167 0.3420 Yes 
row_26 USP6NL 1477 0.7000 0.3470 Yes 
row_27 NSD1 1522 0.6907 0.3551 Yes 
row_28 NUP98 1571 0.6818 0.3628 Yes 
row_29 ASXL1 1735 0.6515 0.3626 Yes 
row_30 SLC25A20 1790 0.6403 0.3692 Yes 
row_31 CTNND1 1829 0.6317 0.3768 Yes 
row_32 SETD2 1918 0.6162 0.3809 Yes 
row_33 ARID2 1973 0.6097 0.3871 Yes 
row_34 GSK3B 2008 0.6039 0.3945 Yes 
row_35 WAPAL 2204 0.5766 0.3910 Yes 
row_36 PAN3 2221 0.5740 0.3990 Yes 
row_37 WDR33 2236 0.5715 0.4072 Yes 
row_38 PDXDC1 2251 0.5689 0.4154 Yes 
row_39 RRBP1 2314 0.5584 0.4202 Yes 
row_40 DDX6 2342 0.5540 0.4273 Yes 
row_41 PTPRK 2355 0.5515 0.4352 Yes 
row_42 ATRX 2476 0.5342 0.4359 Yes 
row_43 PIK3R1 2655 0.5081 0.4324 Yes 
row_44 ANKRD17 2684 0.5044 0.4386 Yes 
row_45 MPP5 2785 0.4889 0.4399 Yes 
row_46 MAN1A2 2794 0.4879 0.4472 Yes 
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row_47 ATP2A2 2841 0.4813 0.4518 Yes 
row_48 VPS24 2916 0.4727 0.4545 Yes 
row_49 ZFHX3 2948 0.4674 0.4599 Yes 
row_50 SDC1 2967 0.4652 0.4662 Yes 
row_51 APC 2968 0.4648 0.4736 Yes 
row_52 FNBP1L 2971 0.4645 0.4808 Yes 
row_53 CAPRIN1 3004 0.4601 0.4860 Yes 
row_54 ARHGAP5 3009 0.4595 0.4931 Yes 
row_55 KCNQ1 3018 0.4588 0.4999 Yes 
row_56 FAM116A 3043 0.4550 0.5055 Yes 
row_57 ERBB2IP 3118 0.4459 0.5078 Yes 
row_58 GAB1 3194 0.4355 0.5099 Yes 
row_59 NFIB 3211 0.4331 0.5157 Yes 
row_60 ACVR1B 3347 0.4161 0.5136 Yes 
row_61 MYOM1 3383 0.4121 0.5178 Yes 
row_62 SYNCRIP 3427 0.4059 0.5215 Yes 
 
Table 6. Core RIDD genes enriched in CNOT1-depleted SW480 cells (So et al., 2012).  
NAME PROBE RANK IN GENE LIST 
RANK METRIC 
SCORE RUNNING ES 
CORE 
ENRICHMENT 
row_19 COL18A1 5581 -0.082292341 -0.4058358 Yes 
row_20 BTBD1 5619 -0.083633006 -0.38739416 Yes 
row_21 DERA 5641 -0.084373057 -0.36650765 Yes 
row_22 PAPOLA 5705 -0.087333411 -0.35065457 Yes 
row_23 FDPS 5961 -0.09705963 -0.3588861 Yes 
row_24 SLC27A5 6177 -0.108391821 -0.3583285 Yes 
row_25 ABCA2 6183 -0.108704239 -0.3283367 Yes 
row_26 FADS1 6184 -0.108723998 -0.29764056 Yes 
row_27 PTPRF 6232 -0.11189945 -0.27261585 Yes 
row_28 BOLA3 6366 -0.120483741 -0.2571854 Yes 
row_29 IDI1 6518 -0.130967647 -0.2413104 Yes 
row_30 RNF130 6563 -0.13481155 -0.20939767 Yes 
row_31 TM7SF2 6566 -0.135234132 -0.17149644 Yes 
row_32 PMVK 6816 -0.162154734 -0.16051117 Yes 
row_33 TPP1 7127 -0.245197475 -0.13460472 Yes 
row_34 BLOC1S1 7129 -0.246350572 -0.06519217 Yes 
row_35 PXMP2 7145 -0.261100173 0.006428248 Yes 
Table 7. Plasma membrane localized components (PLASMA_MEMBRANE_PART) 
enriched in CNOT1-depleted SW480 cells.  
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 PROBE 
RANK IN 
GENE LIST 
RANK 
METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
1 GPRC5A 11 0.466 0.0112 Yes 
2 PROCR 12 0.463 0.024 Yes 
3 EFNB2 13 0.46 0.0367 Yes 
4 STEAP1 16 0.434 0.0484 Yes 
5 SLC40A1 28 0.378 0.0572 Yes 
6 F2RL1 29 0.377 0.0676 Yes 
7 GZMB 43 0.354 0.0755 Yes 
8 ITGA2 53 0.331 0.0833 Yes 
9 TM4SF1 55 0.328 0.0922 Yes 
10 ITGA5 56 0.327 0.1013 Yes 
11 MMD 62 0.322 0.1094 Yes 
12 ICAM2 70 0.311 0.117 Yes 
13 HBEGF 79 0.306 0.1243 Yes 
14 KCNK6 80 0.306 0.1327 Yes 
15 SLC16A6 103 0.285 0.1374 Yes 
16 TNFSF10 139 0.266 0.1396 Yes 
17 EFNB1 162 0.258 0.1435 Yes 
18 ITGA1 180 0.252 0.148 Yes 
19 SLC20A2 251 0.229 0.1441 Yes 
20 ZAP70 252 0.229 0.1504 Yes 
21 EPHA4 258 0.227 0.156 Yes 
22 EGFR 262 0.226 0.1618 Yes 
23 SLC31A2 274 0.222 0.1663 Yes 
24 GPRC5C 299 0.217 0.1688 Yes 
25 CD24 305 0.215 0.174 Yes 
26 KCNN4 307 0.215 0.1798 Yes 
27 GPER 308 0.215 0.1857 Yes 
28 LAT 322 0.212 0.1896 Yes 
29 CCR7 323 0.212 0.1955 Yes 
30 PRRG1 354 0.207 0.1968 Yes 
31 IFNGR1 358 0.206 0.2021 Yes 
32 CD55 410 0.196 0.2001 Yes 
33 ACVR1 414 0.195 0.205 Yes 
34 GJB2 447 0.191 0.2056 Yes 
35 RCE1 452 0.19 0.2103 Yes 
36 RGMB 459 0.189 0.2146 Yes 
37 CD33 469 0.188 0.2185 Yes 
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38 TLR4 494 0.185 0.2201 Yes 
39 MALL 521 0.181 0.2213 Yes 
40 ZYX 526 0.181 0.2257 Yes 
41 TRIP6 530 0.18 0.2303 Yes 
42 TNFRSF1A 535 0.18 0.2346 Yes 
43 CCR3 538 0.18 0.2393 Yes 
44 SLC25A13 539 0.18 0.2443 Yes 
45 BCAR1 546 0.179 0.2483 Yes 
46 EFNA4 600 0.172 0.2454 Yes 
47 TRIM27 603 0.172 0.2498 Yes 
48 TACSTD2 617 0.17 0.2526 Yes 
49 IL27RA 634 0.169 0.255 Yes 
50 ACVR1B 644 0.168 0.2583 Yes 
51 CD97 675 0.164 0.2584 Yes 
52 EPHA2 698 0.162 0.2597 Yes 
53 PRNP 718 0.16 0.2613 Yes 
54 SLC7A2 721 0.16 0.2655 Yes 
55 ATP6V0A4 745 0.158 0.2665 Yes 
56 TRPM2 769 0.156 0.2674 Yes 
57 CXCR4 793 0.153 0.2683 Yes 
58 ADORA2B 819 0.151 0.2688 Yes 
59 VIPR1 864 0.148 0.2665 Yes 
60 GPR35 886 0.146 0.2675 Yes 
61 SLC19A1 912 0.144 0.2678 Yes 
62 NTSR1 913 0.144 0.2718 Yes 
63 PDZD2 916 0.144 0.2755 Yes 
64 SLC2A8 930 0.143 0.2775 Yes 
65 IFNGR2 931 0.143 0.2815 Yes 
66 P2RY2 937 0.143 0.2847 Yes 
67 IL28RA 940 0.143 0.2884 Yes 
68 LAT2 949 0.142 0.2911 Yes 
69 ORAI1 953 0.142 0.2946 Yes 
70 CTLA4 958 0.141 0.2979 Yes 
71 DCBLD2 959 0.141 0.3018 Yes 
72 EFNA1 985 0.139 0.302 Yes 
73 ROR2 987 0.139 0.3057 Yes 
74 CCRL2 993 0.138 0.3087 Yes 
75 ABCA1 1027 0.136 0.3077 Yes 
76 SLC7A7 1040 0.135 0.3097 Yes 
77 BST2 1047 0.134 0.3125 Yes 
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78 CD83 1053 0.134 0.3155 Yes 
79 IL2RB 1061 0.133 0.3181 Yes 
80 MC1R 1068 0.133 0.3209 Yes 
81 GZMA 1069 0.133 0.3246 Yes 
82 CAV1 1076 0.133 0.3274 Yes 
83 STOM 1105 0.131 0.3269 Yes 
84 SYTL2 1116 0.13 0.3291 Yes 
85 SLMAP 1118 0.13 0.3325 Yes 
86 AXIN1 1126 0.13 0.3351 Yes 
87 IL4R 1132 0.13 0.3379 Yes 
88 VCL 1161 0.128 0.3374 Yes 
89 TM4SF5 1193 0.126 0.3363 Yes 
90 PAG1 1199 0.125 0.3391 Yes 
91 LCK 1272 0.12 0.3319 Yes 
92 CLDN3 1273 0.12 0.3352 Yes 
93 ITGB7 1285 0.119 0.3369 Yes 
94 CLDN23 1350 0.116 0.3308 Yes 
95 KCNK1 1362 0.115 0.3324 Yes 
96 SORBS1 1364 0.115 0.3354 Yes 
97 LDLR 1376 0.115 0.337 Yes 
98 SLC46A1 1378 0.114 0.34 Yes 
99 BTN2A1 1388 0.114 0.3418 Yes 
100 PSMG1 1395 0.114 0.3441 Yes 
101 LYN 1399 0.114 0.3468 Yes 
102 SLC4A11 1466 0.11 0.3402 Yes 
103 CXADR 1489 0.109 0.34 Yes 
104 LAPTM5 1496 0.109 0.3421 Yes 
105 LYPD3 1505 0.108 0.3439 Yes 
106 ABCB4 1519 0.107 0.345 Yes 
107 ARRB1 1608 0.103 0.335 Yes 
108 CD52 1609 0.103 0.3378 Yes 
109 CAPRIN1 1617 0.102 0.3397 Yes 
110 STX4 1620 0.102 0.3422 Yes 
111 CLDN11 1638 0.101 0.3425 Yes 
112 ERBB3 1671 0.1 0.3406 Yes 
113 NCSTN 1677 0.1 0.3426 Yes 
114 MAEA 1681 0.1 0.3449 Yes 
115 LAMB1 1691 0.099 0.3464 Yes 
116 OXTR 1697 0.099 0.3484 Yes 
117 PTPRJ 1708 0.098 0.3496 Yes 
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118 KL 1732 0.098 0.349 Yes 
119 TMEM11 1750 0.097 0.3492 Yes 
120 PODXL2 1754 0.097 0.3514 Yes 
121 SLC16A3 1764 0.097 0.3527 Yes 
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Chapter 3  
Discussion 
Cnot1 was identified as a candidate CRC cancer gene in multiple Sleeping 
Beauty-based screens. In addition, a high incidence of CNOT1 somatic mutations in CRC 
has been documented by several projects including the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), TCGA (Cancer Genome 
Atlas Network, 2012) and, Seshagiri et al., 2012, providing evidence for a correlation 
between genetic alterations in CNOT1 and CRC. To determine the contribution of genetic 
alterations in CNOT1 to CRC we evaluated cell viability in CNOT1-depleted SW480 
CRC cell line and the non-cancerous HEK293 cell line.  Depletion of CNOT1 resulted in 
a dramatic decrease in cell viability in both cell lines (Figure 17), and increased cell 
apoptosis in SW480 cells (Figure 18), suggesting that CNOT1 might act as an oncogene.  
In support of this role, CNOT1 limits expression of TXNIP which has been 
identified as a tumor suppressor in several cancers, including colorectal cancer. The 
enforced expression of TXNIP inhibits proliferation of cancer cells and suppresses tumor 
growth and metastasis in transplantation models (Han et al., 2003，Wang et al., 2002，
Goldberg et al., 2003). In addition, activation of TXNIP initiates apoptotic pathways 
under some cell stress conditions, including extreme ER stress through multiple 
mechanisms including activation of ASK1-induced apoptotic pathways and maturation of 
IL-1β (Tobiume et al., 2001, Zhou, et al., 2010). Two results suggest that CNOT1 may 
protect cell viability by means of limiting TXNIP levels.  First, in HEK293 cells depletion 
of CNOT1 leads to increased TXNIP levels, while overexpression of TXNIP leads to 
decreased cell viability. Second, in CNOT1-depleted SW480 cells, upregulation of 
TXNIP precedes increased apoptosis and decreased cell viability (Table 3). 
Our data argue that CNOT1 limits TXNIP expression by facilitating post-
transcriptional degradation as we found that TXNIP mRNA transcripts were significantly 
stabilized after CNOT1 knockdown. CNOT1-mediated destabilization likely involves 
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CNOT8-mediated deadenylation as depletion of CNOT8 caused decreased cell viability 
and increased expression of TXNIP (Figure 24E). TXNIP mRNA levels are limited by 
miR-17 in pancreatic beta cells. We have found that miR-17 regulates TXNIP levels in 
SW480 and HEK293 cells as well. Given that CNOT1 binds GW182 and acts as an 
adapter between the miRNA RISC complex and CCR4-NOT deadenylase subunits, this 
result suggests that CNOT1 may limit TXNIP expression by facilitating miR-17-mediated 
TXNIP mRNA degradation. 
TXNIP mRNA levels are upregulated in response to extreme ER stress.  Increased 
TXNIP activity can, in turn, initiate pro-apoptotic signaling pathways. Upregulation of 
TXNIP following depletion of CNOT1 suggests that CNOT1 may be involved in the 
unfolded protein response to ER stress as well. In support of this idea depletion of 
CNOT1 in SW480 cells results in upregulated transcripts of genes involved in all three 
UPR pathways such as sXBP1 (IRE1α pathway), PERK, ATF4 and DDIT3 (PERK 
pathway), and ATF6, XBP1 (ATF6 pathway) (Figure 30A) (see Figure 16 in introduction 
describing the three UPR pathways).  It is important to note that only changes in mRNA 
transcripts levels of these genes were examined. To gain a full picture of the effect of 
CNOT1 depletion on these pathways we will need to examine translational and post-
translational regulation. 
Moreover, the disrupted deadenylation function of the CNOT complex can cause 
upregulated mRNA levels of a large group of genes (Aslam et al., 2009). When these 
mRNAs are translated in the ER, it may cause overproduction of proteins in the ER, 
inducing ER stress and activation of UPR pathways. This is supported by an Ito et al 
study showing that depletion of CNOT1 in Hela cells can cause ER stress and activation 
of UPR pathways (Ito et al., 2011). We examined global gene expression in CNOT1-
depleted SW480 cells using a microarray assay. 266 genes showed a significant alteration 
in mRNA expression levels and 2/3 of them were upregulated, consistent with the idea 
that CNOT1-mediated degradation plays a major role in these cells and that CNOT1 
depletion could result in an enlarged mRNA pool. In support of this idea, GSEA 
comparison of microarray data with the Molecular Signatures Database geneset collection 
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of cellular components (MsigDB C5 CC, http://www.broadinstitute.org/gsea/msigdb/ 
collections.jsp#C5) revealed that four of the five most enriched genesets consisted of 
plasma membrane localized components and thus transcripts that would be translated and 
processed in the ER (Figure 31B, Table 7), suggesting that CNOT1 may help in limiting 
protein production in the ER. 
Under moderate ER stress the only known target of IRE1 alpha RNase activity is 
the XBP1 transcript.  However, under extreme ER stress IRE1 alpha RNase becomes less 
specific.  This is thought to lead to degradation of miR-17 and thus upregulation of 
TXNIP (see introduction for details).  In addition, under extreme stress IRE1 alpha RNase 
activity degrades a pool of RNAs in a process known as Regulated IRE1 alpha 
Dependent Decay (RIDD).  Decay of these mRNAs is a well-characterized part of the 
terminal UPR. GSEA of global gene expression changes revealed that transcripts 
downregulated in CNOT1-depleted SW480 cells were enriched in genes downregulated 
in response to extreme ER stress (RIDD genes), suggesting that downregulation of 
CNOT1 promotes RIDD and therefore CNOT1 expression is protective against terminal 
UPR (Figure 31A, Table 6).  
Based on these studies we will determine if CNOT1 is required for miR-17-
mediated degradation by determining if depletion of CNOT1 can ablate the effect of 
overexpression of miR-17. 
In sum, these results suggest a model in which CNOT1 protects cell viability by 
protecting cells against ER stress by raising the bar for activation of the apoptotic UPR 
pathways both by limiting TXNIP expression and possibly by regulating expression of 
other pools of mRNAs. Cancer cells are commonly subject to increased levels of ER 
stress. Thus increased CNOT1 activity may provide a selective advantage to cancer cells 
by making it more difficult to activate the UPR apoptotic pathway under high stress 
conditions, such as severe ER stress. Thus, this model suggests a mechanism by which 
CNOT1 may act as an oncogene. 
Although our data are supportive of this model, several key experiments remain to 
be done to fill the gaps. (1) To determine if increased TXNIP activity contributes to 
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increased apoptosis in CNOT1-depleted cells we will need to examine the effect of co-
depletion of CNOT1 and TXNIP on cell viability and apoptosis. If CNOT1-depletion 
promotes apoptosis by increasing TXNIP activity, then apoptosis will be reduced when 
TXNIP is depleted together with CNOT1 depletion. (2) Several experiments will be 
conducted to further investigate the mechanism of CNOT1-mediated destabilization of 
TXNIP mRNA transcripts. mRNA stability is commonly regulated through interactions of 
complexes containing 3’UTR binding factors, adapters and deadenylases with the 3’UTR 
region of the target mRNA transcript. To determine if CNOT1 regulates TXNIP mRNA 
stability through the TXNIP 3’UTR we will examine the effect of CNOT1 depletion on 
expression of a luciferase reporter construct containing the 3’UTR of TXNIP.  To 
determine if miR-17-mediated regulation of TXNIP involves CNOT1 we will co-transfect 
SW480 cells with both miR-17 mimics and CNOT1 siRNA to investigate whether 
depletion of CNOT1 reduces the effect of overexpression of miR-17 on TXNIP mRNA 
levels. (3) Finally to determine if CNOT1 is protective against severe ER stress we will 
look at the response to induction of ER stress on cells depleted for or overexpressing 
CNOT1 to determine if CNOT1 depletion results in increased cell death and 
overexpression is protective and improving cell viability under severe ER stress. 
Although these in vitro studies point to a role for CNOT1 as an oncogene in CRC, 
the actual role in in vivo cancers is likely to be more complex. As the scaffold for the 
CCR4-NOT complex CNOT1 is likely involved in most or all functions of the complex 
in addition to deadenylation, such as transcriptional regulation, chromatin modification 
and ubiquitin-mediated proteolysis (Bartlam et al., 2010). In addition, as an adapter 
mediating mRNA degradation by several 3’UTR binding factors, including miRNAs and 
RNA binding proteins, CNOT1 can potentially influence expression of a large group of 
genes, which is supported by the microarray data. Therefore, the roles of CNOT1 in CRC 
are likely to depend on the context of a specific tumor, including other genetic alterations, 
stage of tumor development and interactions between the cancer and its 
microenvironment.  
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Our data suggest that CNOT1 interaction with additional CNOT subunits also 
plays a role in regulating TXNIP levels. The shortest isoform of CNOT1, CNOT1S, lacks 
a NOT domain that is important for interaction with CNOT 2, CNOT3 and CNOT5 
(Boland et al., 2013). Unlike the long isoform of CNOT1 (CNOT1L) overexpression of 
CNOT1S results in increased expression of TXNIP mRNA levels, suggesting that one or 
more of these subunits may also be important to TXNIP regulation by CNOT1. 
In addition, depletion of CNOT 6L and 7 results in decreased cell viability but 
little or no increase in TXNIP levels, indicating that the CNOT complex can support cell 
viability by mechanisms other than TXNIP regulation.  
Finally, in SB screens insertions into CNOT1 are found in both orientations 
(Figure 11). This pattern is often associated with inactivation of a tumor suppressor gene. 
However, it could indicate that either activation or inactivation of a specific gene could 
contribute to development of CRC depending on site of insertion and the context of other 
genetic alterations. Two pieces of data from our work suggest that this might be the case. 
First, overexpression of CNOT1S has the opposite effect as overexpression of CNOT1L 
(Figure 24C), suggesting that the specific domains affected by a genetic alteration will 
influence the effect of CNOT1 on gene regulation. Second, analysis of human CRC liver 
metastases reveals both CNOT1 high expressers and CNOT1 low expressers, with 
different gene expression profiles (Figure 21), suggesting that genetic context will 
influence which alterations in CNOT1 provide selective advantage to cancer cells. 
Together, although our in vitro studies suggest a role for CNOT1 as an oncogene 
in CRC through protecting cells from severe ER stress-induced cell apoptosis via limiting 
TXNIP levels and limiting mRNA transcripts to be translated in the ER, we should note 
that CNOT1 might contribute to CRC through additional mechanisms. The following 
experiments are designed to further investigate the role of genetic alteration in CNOT1 in 
CRC. (1) Perform in vivo studies in a mouse model carrying a conditional knockout allele 
of CNOT1 in wildtype or ApcMin backgrounds to investigate the effect of CNOT1 
deficiency on intestinal tumor phenotypes. (2) Evaluate the effect of somatic mutations in 
CNOT1 on oncogenic phenotypes, assembly of the CNOT complex and deadenylation of 
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target mRNA transcripts in in vitro studies. Furthermore, we may carry out in vivo studies 
by producing transgenic mice bearing the CNOT1 mutations which show strong 
phenotypes in cell line based studies. (3) Evaluate the role of CNOT1 in maintenance of 
colonic epithelial stem cells. The CNOT complex has been reported to influence other 
aspects of cancer development. For example, Cnot1, Cnot2 and Cnot3 were reported to 
play critical roles in maintaining mouse and human embryonic stem cell (ESC) identity 
and inhibiting ESC differentiation into the extraembryonic lineages via repressing the 
expression of early trophectoderm transcription factors such as Cdx2 (Zheng et al., 2012). 
CRC is thought to arise from stem cells that lie in the base of colonic crypts. Factors that 
affect normal stem cell activity also affect development of cancer stem cells so that the 
role of CNOT1 and other members of the CCR4-NOT complex in ES cells may also 
reflect a role in CRC. In particular, the unfolded protein response is required for 
differentiation of progenitor cells from stem cells in the normal colon epithelium 
(Heijmans et al., 2013), suggesting that factors that limit the unfolded protein response 
may support stem cell activity. Organoid culture can be used to model stem cell activity 
and study differentiation of colonic crypts.  Therefore we will investigate the role of 
CNOT1 and the CNOT complex in stem cell activity using this system. 
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Chapter 4  
Material and Methods 
Reagents 
Tunicamycin and Actinomycin D were obtained from Sigma Aldrich (St. Louis, 
MO, USA).  Stocks were prepared in DMSO at 1mg/ml and stored at -20˚C. Dimethyl 
sulfoxide (DMSO), Dithiothreitol (DTT) and β-Mercaptoethanol (β-ME) were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). RNasin was obtained from Promega 
(Madison, WI, USA). 
Cell Culture 
SW480 and HEK 293 cells were purchased from American Type Culture 
Collection (ATCC). Cells were maintained in DMEM supplemented with 10% FBS, 2 
mmol/L glutamine, and incubated in a humidified atmosphere of 95% air and 5% CO2 at 
37℃.  
RNA Isolation 
RNA isolation from cell culture. Total RNA was extracted from cell cultures 
using an RNeasy kit (Qiagen) according to manufacturer’s directions for isolation of 
cytoplasmic RNA with an added DNA digestion step. Cells growing in a monolayer on 
culture dishes were harvested using Trypsin-EDTA 0.25% at 37℃ and centrifuged at 300 
x g for 3 minutes. The plasma membrane was lysed by addition of 175 µl ice cold RLN 
buffer (50 mM Tris-HCl pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, 0.5% (v/v) NP-40, 
DEPC H2O) supplemented with 1000 U/ml RNasin and 1 mM DTT on ice for 5 minutes. 
Lysate was centrifuged at 300 x g for 2 minutes at 4˚C to remove nuclei and debris, 
followed by addition of RLT (guanidine thiocyanate) buffer supplemented with 10 U/ml 
β-mercaptoethanol and 100% ethanol. Sample was applied to column and washed with 
RW1 buffer.  DNase digestion was carried by incubation with 240 unit of RNase free 
  93 
DNase (Qiagen) for 15 minutes at room temperature.  After washes with RPE buffer, 
RNA was eluted with 30 µl elution buffer.  RNA was stored at -80℃. 
RNA isolation from human fresh frozen tissue. Samples obtained during 
resection of human CRC liver metastases or CRC were flash frozen in liquid nitrogen and 
processed by the University of Minnesota Biological Procurement Network (BioNet).  
Total RNA was isolated from 20 fresh frozen CRC liver metastasis samples and 5 fresh 
frozen normal colon tissues. Tissues were transferred from liquid nitrogen to precooled 
RNAlater-ICE (Ambion, Foster City, CA, USA) at -80℃ for 30 minutes followed by 
transfer to -20℃ for at least 48 hours to inactivate endogenous RNase activities. 
Immediately before RNA isolation, tissue in RNAlaterICE was placed in 3 ml of RLT 
buffer supplemented with β-mercaptoethanol at 10 µl/ml. The tissue was then 
homogenized using an IKA ultra-Turrax T25 digital homogenizer (Fisher Scientific, 
Waltham, MA, USA). Tissue lysates were centrifuged at 300 x g for 5 minutes and 
supernatants were transferred to new 1.5 ml tubes. RNA isolation was then conducted 
using an RNeasy Mini Kit (Qiagen) following the manufacturer’s directions with an 
added DNase digestion step starting after the RLT addition step. RNA was stored at         
-80℃. 
Plasmid Construction 
Plasmids encoding various open reading frames were obtained from Open 
Biosystems (Thermo Scientific).  
To construct a plasmid expressing the short form of CNOT1 (encoded by 
NM_206999.2) Open Biosystems clone #5266600 encoding CNOT1S ORF (BC040523) 
in a pBluescriptR vector was digested with Not1 and Apa1 and inserted between the 
corresponding restriction sites on a pcDNA3 vector (Life Technologies) to generate 
pcDNA3-CNOT1S. To construct a plasmid expressing the longest form of CNOT1 
(CNOT1L) (encoded by NM_016284.4) pcDNA3-CNOT1S was combined with a 
fragment obtained from OpenBiosystems clone #3913601 encoding a partial CNOT1L 
ORF (BC0234317) in a pCMV-SPORT6 vector.  To add the 3’ region of CNOT1L to 
CNOT1S to generate a full length CNOT1L plasmid both plasmids were digested with 
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Cla1 and Apa1 and the Cla1-Apa1 fragment from the partial CNOT1L plasmid was 
inserted into the pcDNA3-CNOT1S plasmid. To construct a plasmid expressing TXNIP 
(NM_006472.4) Open Biosystems clone #7939547 encoding the TXNIP ORF 
(BC093702) in a pCR4-TOPO vector was digested with EcoR1 and inserted in the EcoR1 
restriction sites of pcDNA3 vector to generate pcDNA3-TXNIP. Orientation was 
determined by Sanger sequencing. Plasmids were prepared using a QIAprep Spin 
Miniprep Kit (Qiagen) following the manufacturer’s protocol.  
DNA and RNA Quantification and Integrity Analysis 
DNA and RNA quantity and purity was analyzed using a Nanodrop 2000 
spectrophotometer  (NanoDrop, ThermoScientific) to measure absorbance (A) at a range 
of concentrations. DNA concentration = A260 x 50 µg/µl. RNA concentration = A260 x 40 
µg/µl. The ratio of the A260 nm/A280 nm values allows the assessment of nucleic acid 
purity. Pure preparations of DNA will have a 260/280 ratio > 1.8. RNA samples are 
considered to be pure if the absorbance ratio is close to 2.0.  For Illumina gene expression 
array analysis and Illumina RNA sequence analysis, RNA integrity was assessed by 
capillary electrophoresis using an Agilent BioAnalyzer 2100 (Agilent Technologies). An 
RNA integrity number (RIN) was generated for each sample representing 28S/18S 
ribosomal RNA detection as well as other parameters.  All the samples met the standard 
of quality with a RIN > 8. 
qRT-PCR 
cDNA synthesis. For each experimental sample 1.5 µg RNA was converted to 
cDNA with random nonomer primers (IDT) and recombinant Omniscript Reverse 
Transcriptase using the Omniscript RT kit (Qiagen) according to manufacturer’s 
instructions. Each reaction consisted of 2 µl of 10 X RT buffer, 2 µl of 50 mM dNTPs, 4 
µl of random nonomer primers, 0.25 µl of RNasin RNase inhibitor (Promega) and 1 µl of 
Omniscript Reverse Transcriptase, 1.5 µg RNA and H2O sufficient for final volume of 
20 µl. Reactions were incubated at 65°C for 60 minutes, 72°C for 10 minutes, 85°C for 5 
minutes. cDNA was stored at -20°C until needed.  
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qPCR. Target cDNAs and 18S ribosomal DNA were amplified from cDNA by 
PCR. Real-time PCR reactions were carried out in 10 µl using 2 µl cDNA from a 10 X 
dilution of the 20 µl RT reaction (equivalent to 15 ng reverse transcribed RNA) for target 
genes and a 100 X dilution for 18S rRNA, 500 nM each primer, 5 µl LightCycler480 
SYBR Green 1 Master Mix (Roche Applied Science). PCRs were performed on a 
LightCycler® 480 System (Roche Diagnostics) in 96 well plates using the amplification 
protocol: 1 cycle of preincubation, 5 minutes at 95°C; 45 cycles of amplification each 
consisting of denaturation at 95°C for 5 seconds, annealing at 60°C for 5 seconds and 
elongation at 72°C for 10 seconds; 1 cycle melting at 95°C for 5 seconds, 65°C for 1 
minutes, heating to 97°C; 1 cycle cooling at 40°C for 30 seconds.  Water was used as a 
template for negative control amplifications for each PCR run. All reactions were 
performed in duplicate. Standards were generated by reverse transcription of total RNA 
from untreated cells followed by PCR amplification to generate template DNA of the 
same sequence as target genes or 18S gene PCR product.  Serial dilutions of template 
DNA were amplified in parallel with experimental samples and used to generate a 
standard curve for each gene.  Data were analyzed using Roche LightCycler® 480 
software and CP’s calculated using the Absolute Quantification-Second Derivative 
Maximum method. The standard curve was used to determine efficiency of PCR 
amplification (E) for each gene.  “Relative mRNA levels” represent the relative 
expression of a target gene in corresponding siRNA-treated cells to expression in control 
siRNA-treated cells. Target gene expression was normalized to 18S rRNA levels and 
relative mRNA levels were calcµlated as described by Pfaffl (Pfaffl M.W., 2001): 
relative mRNA levels = ([Etarget] 
ΔCPtarget(control-treated)
)/([Eref] ΔCPref(control-treated)). Primers used 
in RT-PCR are shown below (Table 8).  
Table 8. Primers used in qRT-PCR. 
Gene Forward primer Reverse primer 
18s CGCCGCTAGAGGTGAAATTCTT CAGTCGGCATCGTTTATGGTC 
AFT6 ATGTCTCCCCTTTCCTTATATGGT AAGGCTTGGGCTGAATTGAA 
ATF4 CCACCATGGCGTATTAGGGG TGCTGAATGCCGTGAGAAGC 
BTG1 TCTCCAAGTTTCTCCGCACC GGTAACCCGATCCCTTGCAT 
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CDX2 ACTACAGTCGCTACATCACCA GAAGACACCGGACTCAAGGG 
CHOP GGTGGCAGCGACAGAGCCAAA ACTCAGCTGCCATCTCTGCAGTT 
CNOT1 CTTTCA ACCCCCAATCAGACC AGGTTTCATCTTACTCTGCTGGA 
CNOT1 long GAGGCCTACCAAAGCTCCTG TGTGCATACATAGGCCACCC 
CNOT1 total TCCCTGCAGTGAATAACGACC CCACACCTGAGACAAGTCCG 
CNOT2 CTTAACGAACATTCACATTAGGGATA CTTCACCATATCGGCCAAGT 
CNOT6 GTGGCCTGATGCCTTACACGAA CCAGAGGGCCCAGGATGCCTA 
CNOT6L AGCAGAGGAGGTAGCCAATGGGA AGGTGCAGCGCTGTCAAGTGT 
CNOT7 CCCTCACTATGCCAGCGGCAA ACCACACCTGGAAACTCGGTGTC 
CNOT8 GGGCCTGCGCTTACCGGAAA TCCACAAGTGCTGCAGGCATCC 
CELF1 GCGCAGCATCTGTGTGGGGA GGGTGGAGGCTGCTCAGGGT 
DKK1 GGCGGGAATAAGTACCAGACC CGAGACAGATTTGCACGCC 
EMP1 ACCATGGAGAAGGGAAACCG ATAGCCGTGGTGATACTGCG 
GRP78/Bip AAGCTGTAGCGTATGGTGCT GTTTGGTCATGACACCTCCCA 
HBP1 CGACCAGTCCACAAAGTCCA GAGGGCGTGCATAGGAATGT 
IGFBP3 TAAAGACAGCCAGCGCTACA ATTTCTCTACGGCAGGGACC 
IL8 TTTTGCCAAGGAGTGCTAAAGA AACCCTCTGCACCCAGTTTTC 
p27kip TAGCGGAGCAATGCGCAGGAA ACCGGCATTTGGGGAACCGTC 
PERK ATGAGACAGAGTTGCGACCG TGGATGACACCAAGGAACCG 
PUM1 ACGGATTCGAGGCCACGTCC TGGCCATCTAGTTCCCGAACCAT 
PUM2 AGCTCTTGCATTAGAATCTCGGGGA TGGTGAGAAGCTCCCCATGCAGT 
sXBP1 CTGAGTCCGCAGCAGGTGC TTGTCCAGAATGCCCAACAGG 
TGFBR2 CCCCTGTGTCGAAAGCATGA TCACACACCATCTGGATGCC 
ZFP36 TCCCACTCTCGGCCGACACC GATGGCACGGGCACGTCAGG 
TXNIP TCCCACTCTCGGCCGACACC GATGGCACGGGCACGTCAGG 
XBP1 GGGGAATGAAGTGAGGCCAG TTGTCCAGAATGCCCAACAGG 
Transfection Protocols 
DNA plasmid transfection. HEK 293 cells were plated at 7.5 x 105 cells/dish into 
6 cm dishes or 2 x 104 cells/well in 96 well plates. 24 hours later, cells were transfected 
with pcDNA3-CNOT1S, pcDNA3-CNOT1L, pcDNA3-TXNIP or a pcDNA3-GFP 
plasmid using Lipofectamine LTX with Plus reagent (Invitrogen) according to the 
manufacturer’s protocol. For a 6 cm dish, 4 µg of plasmid was added to 4 µl PLUS 
reagent in 200 µl of OptiMEM. The plasmid solution was mixed with 12 µl 
Lipofectamine LTX reagent in 200 µl OptiMEM. The 400 µl reaction was then added to 
the cells. 
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siRNA transfection. SW480 cells and HEK 293 cells at 70% confluence were 
transfected twice, unless otherwise noted, 48 hours apart, with short interfering RNA 
oligonucleotides (siRNA oligos) targeting a specific gene or with a non-targeting control 
siRNA, at a final concentration of 50 nmol/L, using Lipofectamine 2000 transfection 
reagent (Life Technologies). Oligo targeting CNOT1 was obtained from Dharmacon: 
CNOT1 On-TARGETplus SMARTPool. Control siRNA oligo was also obtained from 
Dharmacon: OnTARGETplus Non-targeting siRNA # 3. siRNA oligos targeting other 
genes were obtained from Qiagen: Hs_CDX2_6_HP siRNA, Hs_CNOT2_10_HP siRNA, 
Hs_CNOT6_3_HP siRNA, Hs_CNOT6L_4_HP siRNA, Hs_CNOT7_4_HP siRNA, 
Hs_CNOT8_5_HP siRNA, Hs_CELF1_1_HP siRNA ， Hs_PUM1_6_HP siRNA, 
Hs_PUM2_4_HP siRNA, Hs_ZFP36_6_HP siRNA, Hs_TXNIP_6_HP siRNA. 
Transfection of miR-17 mimic. SW480 cells and HEK 293 cells at 70% 
confluence were transfected once with an miR-17 mimic (Qiagen, Syn-hsa-miR-17-5p 
miScript miRNA Mimic) or with a non-targeting control siRNA (Dharmacon, 
OnTARGETplus Non-targeting siRNA # 3) at a final concentration of 5 nmol/L, using 
Lipofectamine 2000 transfection reagent (Life Technologies). 
Illumina Beadchip Microarray 
SW480 cells were transfected twice, 48 hours apart, with CNOT1 siRNA or with 
a non-targeting control siRNA. Three experiments were done to achieve three biological 
replicates for each treatment. Total RNA was extracted from cells as described. Six 
samples of total RNA, 2 µg per sample, were submitted to the University of Minnesota 
BioMedical Genomics Center for microarray analysis. All samples had RIN > 8.  1 ug of 
total RNA was converted to biotinylated, antisense cRNA using the Illumina TotalPrep-
96 RNA Amplification Kit (Life Technologies), and 1500 ng of biotin-labeled cRNA was 
hybridized onto an Illumina HumanHT-12 v4 Expression BeadChip (Illumina). 
Hybridized Beadchips were scanned with an Illumina iScan scanner. Raw intensity data 
was extracted from iScan scan image files using GenomeStudio software (Illumina), log2 
transformed, and normalized. Microarray raw data was analyzed by Dr. Ying Zhang at 
the University of Minnesota Supercomputing Institute using the R package: lumi and 
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limma according to the manufacturer’s protocol. Differential gene expression between 
CNOT1 siRNA and control siRNA transfected cells was assessed by a statistical linear 
model analysis using the bioconductor package limma, in which an empirical Bayes 
method was used to moderate the standard errors of the estimated log-fold changes of 
gene expression. The moderated t-statistic p values derived from the limma analysis were 
further adjusted for multiple testing by Benjamini and Hochberg’s method to control false 
discovery rate (FDR).  
Illumina RNA Sequencing 
Total RNA isolated from fresh frozen human CRC liver metastasis and normal 
colon samples was sequenced by the University of Minnesota BioMedical Genomics 
Center (BMGC) using an Illumina Highseq 2000 sequencer (Illumina). 3 µg of each total 
RNA sample was sent to BMGC in a 96 well plate on dry ice. Samples were quantified 
using fluorimetry (RiboGreen assay) and RIN determined. For the library creation, total 
RNA was enriched for polyadenylated RNA using oligo-dT purification, and the enriched 
polyA(+) RNA was converted to cDNA through reverse transcription. The cDNA was 
then fragmented, blunt-ended, and ligated to indexed (barcoded) adaptors. The 
fragmented cDNA library was size selected for 190-210 base-pair fractions, and size 
distribution was validated using capillary electrophoresis. The cDNA fragments were 
quantified using a fluorimetry (PicoGreen). The indexed libraries were then normalized, 
pooled, clustered on a flow cell, and loaded onto the Illumina Highseq 2000 instrument 
for paired-end sequencing. The resulting reads were then subjected to further analysis. 
Gene expression levels were calculated as fragments per kilobase of exon per million 
fragments mapped (FPKM).  
Global Gene Expression Analysis 
Differential gene expression heatmap.  Differentially expressed genes showing 
fold change ≥ 2 and p value < 0.05 were used to generate a heat map by unsupervised 
hierarchical clustering. Extent of differential expression is shown as Z-value.   
Ingenuity Pathways Analysis (IPA). To identify the gene networks and cellular 
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pathways associated with CNOT1 knockdown, the dataset consisting of 266 differentially 
expressed genes (fold change ≥ 2, p < 0.05, Table 4) identified by Illumina HumanHT-12 
v4 Expression Beadchips analysis were used as input for network analysis using 
Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood CA). For this type of 
analysis, differentially expressed genes, which interact with other molecules in the 
Ingenuity Knowledge Base are designated “Network Eligible” molecules. “Network 
eligible” molecules are combined into networks that maximize connections based on 
known biological attributes. Functional categories are assigned based on overlap with 
known function categories in Ingenuity Database. Networks are then scored based on the 
percent of dataset molecules they contain. The score is calculated using the Fishers Exact 
Test to determine the likelihood of the network containing a given number of Network 
Eligible molecules by chance.  The score = -log (Fisher's Exact test result). 
Gene Set Enrichment Analysis (GSEA). GSEA was performed using GSEA 
v.2.0, (Broad Institute, MIT http://www.broad.mit.edu/gsea/). To identify pathways 
altered in human liver CRC metastasis samples expressing high levels of CNOT1 a 
complete ranked dataset was generated in which genes were ranked according to ratio of 
expression in CNOT1 high expressing (CNOT1-Hi) to CNOT1 low expressing (CNOT1-
Lo) samples. The ranked dataset was compared to genesets derived from Merlos-Suárez 
et al. characterizing gene expression in sub-popµlations of the intestinal crypt epithelium 
(Merlos-Suárez et al., 2011). The complete group of genesets tested consisted of: ISC 
Signature (EphB2), Proliferation Signature, Late TA Signature and Lgr5-defined 
Signature. This dataset was also compared to genesets of candidate CRC cancer genes 
identified by SB screens. These genesets were derived from reports in Starr et al. papers 
(Starr et al., 2009, Starr et al., 2011, Starr T.K., unpublished reports of a p53 mutant 
screen) as well as a report from March et al. (March et al., 2011). To identify pathways 
altered in CNOT1-depleted SW480 cells a complete ranked dataset was generated in 
which genes were ranked according to ratio of expression in CNOT1-depleted to control 
treated cells. This dataset was compared to genesets characterizing gene expression in 
adaptive vs. terminal UPR.  The complete group consisted of Han et al. paper 
supplemental table 1 (representing both adaptive and terminal responses) and 
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supplemental table 2 (representing the terminal response) (Han et al., 2009), and So et al. 
paper supplementary table 1 (So et al., 2012). This table was split into two genesets, one 
consisting of adaptive response genes activated by sXBP1 and a separate geneset 
consisting of RIDD genes. This dataset was also compared to the MSigDB C5 CC 
collection. In all the comparisons, normalized gene expression data was ranked using the 
Signal2Noise metric, which represents a Z value. An enrichment score (ES) was 
calculated that reflects the degree to which a geneset is overrepresented at the extremes 
(top or bottom) of the entire ranked differentially expressed geneset using a running-sum 
statistic. The statistical significance (nominal p value) of the ES was estimated by using 
an empirical phenotype-based permutation test procedure. GSEA was performed against 
1000 random gene set permutations. The ES for each gene set was then normalized to 
account for the size of the set, yielding a normalized enrichment score (NES). The false 
positives were controlled by calculating the false discovery rate (FDR) corresponding to 
each NES, which is the estimated probability that a set with a given NES represents a 
false positive finding. The proportion of false positives was controlled for by calculating 
the false discovery rate (FDR) corresponding to each NES.  
Assessment of Cell Function 
Cell viability assay. Cell viability was determined using a 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay (Cell Viability Kit 
1, Roche Applied Sciences) in which absorbance at 595 nm is proportional to viable cell 
number. Cells were plated into 96 well plates at indicated cell densities in triplicate in 
DMEM medium. At each time point 100 µl fresh media was added with 10 µl MTT 
reagent.  After 4 hour incubation, 100 µl of lysis buffer was added. After overnight 
incubation, absorbance at 595 nm was read using a plate reader. Cell viability was 
determined on days 2-6 after the second siRNA transfection or 1-4 days after plasmids 
transfection unless otherwise indicated. 
Apoptosis assay. Apoptosis was determined using an Annexin V fluorescein 
isothiocyanate (AV-FITC) and propidium iodide (PI) double staining flow cytometry 
assay. AV-FITC binds to phosphatidylserine which translocates to the outer layer of the 
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plasma membrane lipid bilayer during the early stages of apoptosis.  PI is a vital stain, 
which can only enter the cell when the membrane loses integrity during late apoptosis 
and cell death. Thus AV-FITC- PI- staining identifies live healthy cells; AV-FITC+ PI- 
identifies early apoptotic cells; and AV-FITC+ PI+ identifies late apoptotic and dying 
cells. For this assay 1 X 106 cells were washed twice with cold PBS and resuspended in 
400 µl of 1 X Annexin V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 
mM CaCl2).  Suspension was divided into 4 x 100 µl aliquots to be stained with: no dye, 
5 µl of Annexin V–FITC, 5 µl of PI, and 5 µl of Annexin V–FITC plus 5 µl of PI, 
respectively. Cells were stained for 15 minutes at room temperature in the dark. Then, 
flow cytometric analysis was conducted using a Becton-Dickinson FACScan 
cytofluorometry (Becton-Dickinson) and data analysis were performed with FlowJo 
software (Tree Star, Inc.). 
mRNA stability assay. SW480 cells were plated at 7.5 X 105/dish in 6 cm dishes 
and transfected once with CNOT1 siRNA or with a non-targeting control siRNA. 48 
hours after transfection, cells were treated with actinomycin D at 5 µg/ml final 
concentration and total RNA was extracted at indicated intervals from 0 to 120 minutes. 
TXNIP and CNOT1 mRNA levels were then measured by qRT-PCR. Values represent 
mean ± SD of three independent experiments. The best-fit lines, determined by least-
squares methods, are shown as dotted lines.  
Analysis of unfolded protein response (UPR). Tunicamycin is a 
pharmacological agent which blocks the first step in the synthesis of N-linked 
glycoproteins and thus causes accumulation of unprocessed proteins in the ER and 
induction of the UPR.  In order to study factors affecting the UPR, SW480 cells were 
treated with tunicamycin under conditions described in results. 
Statistics   
All data were analyzed by comparing means with Student’s t-test or One-Way 
ANOVA method as indicated using SPSS (Version 19.0). Data is shown as mean ± SD 
and p < 0.05 is considered as statistically significant difference.  
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Abstract 
It is proposed that a progressive series of mutations and epigenetic events leads to 
human colorectal cancer (CRC) and metastasis. Furthermore, data from resequencing of 
the coding regions of human CRC suggests that a relatively large number of mutations 
occur in individual human CRC, most at low frequency. The functional role of these low-
frequency mutations in CRC, and specifically how they may cooperate with high-
frequency mutations, is not well understood. One of the most common rate-limiting 
mutations in human CRC occurs in the adenomatouspolyposis coli (APC) gene. To 
identify mutations that cooperate with mutant APC, we performed a forward genetic 
screen in mice carrying a mutant allele of Apc (ApcMin) using Sleeping Beauty (SB) 
transposon-mediated mutagenesis. ApcMin SB-mutagenized mice developed three times as 
many polyps as mice with the ApcMin allele alone. Analysis of transposon common 
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insertion sites (CIS) identified the Apc locus as a major target of SB-induced 
mutagenesis, suggesting that SB insertions provide an efficient route to biallelic Apc 
inactivation. We also identified an additional 32 CIS genes/loci that may represent 
modifiers of the ApcMin phenotype. Five CIS genes tested for their role in proliferation 
caused a significant change in cell viability when message levels were reduced in human 
CRC cells. These findings demonstrate the utility of using transposon mutagenesis to 
identify low-frequency and cooperating cancer genes; this approach will aid in the 
development of combinatorial therapies targeting this deadly disease.  
Human colorectal cancers (CRC) generally can be divided into two classes based 
on whether they display chromosomal instability (CIN) or microsatellite instability 
(MSI). The majority of CRC (∼80–90%) have a CIN phenotype; the remaining cases are 
characterized by MSI (Grady and Markowitz 2002). CRC displaying CIN frequently 
harbor allelic losses or mutations in adenomatous polyposis coli (APC), v-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS), SMAD family member 4 (SMAD4), and 
tumor protein p53 (TP53), whereas MSI-type CRC usually have a mutation in one of six 
DNA mismatch repair genes (Takayama et al. 2007). In both CIN and MSI CRC 
complete functional loss of a gatekeeper tumor suppressor gene typically is the rate-
limiting event in intestinal cell transformation. For CIN CRC, APC plays the key gate-
keeping role, and its loss underlies the great majority of CIN CRC and >80% of all CRC. 
Although both classes of CRC are characterized by high-frequency mutations, such as 
those in APC, it is evident that many more low-frequency mutations are required for CRC 
development, and the majority of these low-frequency mutations are unknown (Wood et 
al., 2007). 
To identify these low-frequency mutations, we performed a forward genetic 
screen in mice using the Sleeping Beauty (SB) DNA transposon as a mutagen in intestinal 
epithelial cells. To focus on mutations that contribute to the CIN phenotype, we 
conducted the screen in mice carrying the ApcMin allele. ApcMin mice harbor a T→A 
nonsense mutation in the Apc gene (Moser et al., 1990, Su et al., 1992) that results in a 
truncated protein product that is unable to bind β-catenin and promote its degradation, 
  127 
thus leading to abnormal levels of β-catenin protein and up-regulation of β-catenin target 
genes such as cyclin D1 (Ccnd1) and myelocytomatosis oncogene (C-Myc). The Min 
mutation corresponds to a mutational hotspot in the human APC ortholog, and these 
mutations similarly result in dysregulation of the WNT/β-catenin signaling pathway. 
There is strong evidence that β-catenin dysregulation is a common transformative event 
in tumorigenesis in the ApcMin mouse and in both the inherited form of APC-deficient 
CRC (familial adenomatous polyposis, FAP) and in sporadic CRC (Fodde R 2002). Thus, 
the ApcMin mouse is an informative genetic model for APC-deficient intestinal cancer. 
ApcMin mice on the C57BL/6J background strain rarely survive beyond 120 d and can 
develop >100 tumors throughout the small and large intestine, with the phenotype 
dependent on diet, mouse strain, and other environmental factors (Dietrich et al., 1993, 
Cormier et al., 1997). 
As in human CRC patients, loss of heterozygosity (LOH) leading to inactivation 
of both alleles of Apc is necessary for tumorigenesis to commence in ApcMin mice (Levy 
et al., 1994, Luongo et al., 1994). However, in contrast to LOH events in many human 
CRC, LOH in ApcMin tumors occurs predominantly by homologous somatic 
recombination (Haigis and Dove 2003). In this study we screened for mutations that 
cooperate with the ApcMin mutation by randomly mutating genes through selective 
activation of SB transposition in intestinal cells of ApcMin mice. The results of our screen 
support the importance of the loss of the second allele of Apc, because the great majority 
of tumors analyzed contained a transposon insertion in Apc, in particular in tumors in 
which there was maintenance of heterozygosity (MOH) for the Min allele. In addition to 
Apc, we identified 32 other genes and loci that probably facilitate the development of 
intestinal cancer in an ApcMin model. The function of these additional mutations could be 
to remove the requirement for Apc LOH, or they may function in some other manner. The 
majority of these genes have not been associated with CRC previously. To confirm that 
these genes play a causal role in tumor development, we used siRNA to knock down 
message levels of nine of the candidate genes in human colon cancer cell lines and 
demonstrated that five of these genes affected the growth rate of these cells. 
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Results 
Design of a Forward Genetic Screen for CRC Genes. In a previous study we 
demonstrated that SB transposon-mediated mutagenesis in the intestinal tract of 
C57BL/6J Apc+/+ mice resulted in polyp formation (Starr et al., 2009). By mapping 
transposon insertions in DNA extracted from these tumors, we were able to identify 77 
genetic loci which probably harbored genes that, when mutated, contributed to tumor 
development. Because APC loss is rate limiting in the development of most human CRC 
(Powell et al., 1992), we reasoned that SB mutagenesis in a mouse already harboring a 
mutation in Apc might generate more tumors with a shorter latency and reveal mutations 
that cooperate with Apc during tumor development. 
To identify these genes, we performed a forward genetic screen using SB 
transposon-mediated mutagenesis in ApcMin mice. The screen consisted of a cohort of 
ApcMin SB transgenic test mice along with three groups of ApcMin control mice. The 
ApcMin SB test mice harbored three transgenes required for targeting SB mutagenesis to 
the gastrointestinal tract (Figure 35). The first transgene was a concatamer of oncogenic 
transposons (T2/Onc) that were resident on chromosome 1 (Collier et al., 2005). To 
enhance the mutagenic potential of the transposon, T2/Onc contains a strong viral 
promoter, splice acceptors in both orientations, and a bidirectional polyA signal. The 
second transgene was a conditionally expressed knockin SB11 transposase allele 
downstream of the Rosa26 promoter (Rosa26-LsL-SB11) (Zambrowics et al., 1997, 
Dupuy et al., 2009). Because of the presence of a floxed stop cassette, the transposase 
allele is not expressed unless Cre recombinase protein is present. The third transgene was 
Cre recombinase driven by the gastrointestinal tract-specific Villin promoter (Vil-Cre) (el 
Marjou et al., 2004). We have shown previously that these three transgenes effectively 
limit SB mutagenesis to the intestinal tract (Starr et al., 2009). All mice were 
heterozygous for the ApcMin allele, and all the transgenes were fully congenic on the 
C57BL/6J genetic background. The first control group contained Rosa26-LsL-SB11 and 
either Vil-Cre or T2/Onc; the second control group contained T2/Onc and/or Vil-Cre but 
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not Rosa26-LsL-SB11; and the third control group harbored only the ApcMin allele. Mice 
were killed when moribund or at 120 d. 
Intestinal Tumorigenesis Is Enhanced Significantly in ApcMin SB Test Mice. ApcMin 
mice that harbored all three transgenes (Rosa26-LsL-SB11, T2/Onc, and Vil-Cre) 
developed an average of 360 polyps (test mice, Table 9). In contrast, mice carrying the 
ApcMin allele alone developed an average of 112 polyps (control group 3, Table 9), a 
result that is consistent with the phenotype of ApcMin mice in our colony (McAlpine et al., 
2006). Surprisingly, we also observed an enhanced rate of polyp development in control 
group 1 that carried the Rosa-26-LsL-SB11 allele but not the complete combination of 
alleles required for transposition. This control group developed an average of 182 polyps 
(control group 1, Table 9), a result that was unexpected based on previous screens. It is 
possible that the increased polyp number in these animals is caused by one or more 
modifiers linked to the Rosa26-LsL-SB11 transgene, because strain-specific modifiers 
are known to exist (Fodde and Smits 2001). Control animals carrying the ApcMin allele, 
T2/Onc, and/or Vil-Cre, but not Rosa26-LsL-SB11 (control group 2, Table 9) developed 
the same number of polyps as the control mice carrying the ApcMin allele alone. Although 
the Rosa26-LsL-SB11 allele alone contributes to polyp formation, the effect of active SB 
transposition was much greater, resulting in twice as many polyps in the test mice. In 
addition, the tumor burden was so extensive that ApcMin SB test mice became moribund 
earlier than any of the three control groups (Table 9). Indeed, in a subset of ApcMin SB 
test mice the tumor load was very severe, with some animals developing as many as 700 
tumors.  
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Table 9. Polyp number and age of death for transgenic mice. 
 
Although polyp number was greatly increased by SB mutagenesis, there was no 
evidence of local or systemic metastasis in experimental or control mice. We performed 
histopathologic analysis of tumors collected from 10 animals. These analyses identified 
numerous microadenomas and adenomas in the small intestine and a much smaller 
number of these lesions in the large intestines. No adenocarcinomas were identified, 
perhaps because of the short lifespan of ApcMin SB test mice. Immunohistochemistry for 
β-catenin was performed on 24 adenomas from seven animals. There was increased 
expression of β-catenin in all tumors compared with the adjacent normal mucosa 
epithelium (Figure. 34).  
      
Figure 34. A pedunculated adenoma stained with H&E (A) or immunostained for β-catenin 
(B and C). (B) There is increased staining for β-catenin (arrow) in the adenoma. (C) Higher-
power magnification of a different section showing increased cytoplasmic and nuclear (arrows) 
staining for β-catenin in tumor cells compared with adjacent normal tissue seen in lower right and 
bottom of picture. (Scale bars: A and B, 500 µm; C, 50 µm.) 
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Analysis of Common Insertion Sites Identifies 30 Candidate Cancer Genes. To 
identify genes that contribute to tumor initiation and development in ApcMin mice, we 
analyzed transposon insertions in 96 polyps, representing all regions of the intestines, 
from 12 mice to find common insertion sites (CIS). A CIS is defined by analyzing 
transposon insertions in many tumors and identifying genomic loci that contain 
transposon insertions at a higher rate than would be expected by chance (SI Materials and 
Methods). The presence of a CIS indicates that a transposon-mediated mutation in that 
locus probably has contributed to tumor development. By analyzing the genes within the 
CIS, one can identify candidate cancer genes. To map transposon insertions, we isolated 
DNA from the 96 tumors, digested the DNA with restriction enzymes, and performed 
ligation-mediated PCR (LM-PCR) to amplify transposon-genomic fragments specifically 
(Mueller and Wold 1989). Barcodes and fusion sequences were attached to the LM-PCR 
primers to enable pooling of the amplicons, which then were sequenced using the Roche 
GS FLX pyrosequencing machine. Six separate sequencing runs produced 347,993 
sequence reads, 93% of which contained a barcode, the transposon sequence, and 
sufficient genomic sequence (>16 bp) for BLAST analysis. We were able to map more 
than half of these sequences (53%) unambiguously to the mouse genome. Of the 173,101 
mapped sequences, 100,171 (67%) were redundant, leaving 72,930 nonredundant 
mapped insertions. Roughly half of the nonredundant insertions mapped to the same 
chromosome as the donor transposon concatamer (Chr 1), as expected because of the 
phenomenon of local hopping seen in other SB screens (Starr et al. 2009, Collier et al. 
2005, Keng et al. 2009). To eliminate statistical bias in the dataset, these sequences were 
eliminated along with a smaller number of insertions that probably represent PCR 
artifacts (SI Materials and Methods). The remaining 30,088 insertions (Table 15) 
weranalyzed to determine CIS. We used Monte Carlo simulations to find insertion rates 
in a given genomic window size that would not be expected to occur by chance (Starr et 
al., 2009). For example, based on a random assignment of 30,088 insertions to the mouse 
genome, one would not expect to find five or more insertions within a 12-kb window. 
Using these Monte Carlodefined parameters, we identified 37 CIS. Two of these CIS 
were removed from further analysis because all the tumors contributing to these two CIS 
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originated from a single mouse, indicating the tumors may be clonally related. Two more 
CIS were removed because they also were identified in a control dataset of tail-snip DNA 
from mice harboring unselected SB insertions and may represent hotspots for SB 
insertions (Starr et al., 2009) Because this control dataset was generated from tail snips, it 
is possible that other hotspots exist in other types of cells. After removal of these possible 
artifacts, 33 CIS remained (Table 10).  
We assigned a candidate gene to each CIS if the majority of the insertions were in 
or near a single gene (Table 10). Four of the 33 CIS did not have an annotated gene 
within 40 kb and were not assigned a candidate gene. Another CIS contained two 
overlapping genes, SET domain-containing 5 (Setd5) and lipoma HMGIC fusion partner-
like 4 (Lhfpl4), and all insertions in this CIS were in both genes. Notably, this CIS is 
located adjacent to the Rosa26 locus where the conditional SB11 knockin is located, and 
eight of nine insertions in this CIS are oriented with the internal promoter in the direction 
that would cause overexpression of the transgene. Rather than tagging an endogenous 
cancer gene, this CIS could represent selective pressure for increased mutagenesis via 
overexpression of SB11 transposase. Whether the transposon insertion caused a gain- or 
loss-of-function mutation sometimes can be predicted by analyzing the location and 
orientation of the insertions in all the tumors that comprise a single CIS. If all the tumors 
in a single CIS have transposon insertions in the same intron, and all the transposons are 
oriented in the direction of transcription, we predict the insertion causes a gain-of-
function mutation. If the distribution of transposon insertions in all the tumors of a CIS is 
apparently random, and there is no bias in orientation, we predict a loss-of-function 
effect. Table 10 lists the predictions for the CIS. In total we identified 30 genes and four 
genomic loci with no annotated genes that probably contribute to intestinal tract cancer 
when mutated.  
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Table 10. List of 33 CIS. 
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Transposon Insertions Implicated in LOH of the Wild-Type Allele of Apc. The most 
commonly mutated gene in this study was Apc (in 72 of 96 tumors), reflecting the strong 
selective pressure for loss of the wild-type allele in ApcMin mice. Previous studies have 
demonstrated that loss of the Apc+ allele is an early event that occurs in almost every 
adenoma in ApcMin mice (Levy et al., 1994, Luongo et al., 1994). In addition, inactivation 
of the wild-type Apc allele is caused predominantly by homologous somatic 
recombination events, leading to the replacement of the Apc wild-type allele with a 
second ApcMin allele. We reasoned that in our transgenic model LOH could be 
accomplished by an inactivating transposon insertion, as opposed to duplication of the 
Min allele. To test this hypothesis, we performed PCR on DNA from tumors to amplify 
the region surrounding the Min mutation (T2860A). By sequencing the PCR amplicon, 
LOH can be ascertained in ApcMin mice by measuring the ratio of the T:A trace peak 
heights at the location of the Min mutation. In heterozygous tissue the T:A ratio is 
between 0.8 and 1.2, which is considered MOH, but in tissue that has lost the wildtype 
allele the ratio drops below 0.5 (Figure 36). Ratios between 0.5-0.8 and >1.2 are 
considered uninformative, most likely caused by contamination from nontumor tissue. Of 
the 96 tumors tested, 47 gave informative results (Table 11). Of these 47 tumors, 32 had 
an identified transposon insertion in the Apc locus, and 15 did not. The majority (73%) of 
tumors lacking a transposon insertion in Apc had T:A ratios < 0.5, indicating LOH 
probably caused by loss of the entire allele. In support of our hypothesis, 53% of the 
tumors that had a transposon insertion in the Apc locus had T:A ratios between 0.8 and 
1.2, indicating maintenance of the wild-type Apc locus at the site of the Min mutation. 
This result suggests that in these tumors the wild-type Apc allele is inactivated by the 
transposon more frequently than by duplication of the Min allele. 
Set of CIS Identified in ApcMin Mice Differs Significantly from Those Found in Apc 
Wild-Type Mice. We compared the list of genes identified in this study with the 77 
genes identified in the screen we performed on an Apc wild-type background (Starr et al., 
2009). Surprisingly, only four genes were identified in both studies: Apc, nuclear receptor 
binding SET domain protein 1 (Nsd1), Sfi1 homolog, spindle assembly associated (Sfi1), 
and WW domain containing adaptor with coiled-coil (Wac). There are several reasons 
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that could explain why the overlap between the two studies was low. First, the total 
number of genes that could contribute to tumor formation may be large enough that the 
size of these two studies is not sufficient to saturate the candidate genes. Second, because 
we use a statistical method to identify cancer genes, it is likely that transposon insertions 
contributed to carcinogenesis in some of the tumors, but the insertions did not occur at a 
rate high enough to qualify as a CIS. In support of this hypothesis, 70% of the loci 
identified as CIS in this study (23 of 33) also had one or more insertions in the same 
locus in the previous study. Third, the overlap may be small because selection pressure 
for specific genetic mutations in cells that already have an Apc mutation is biased toward 
a different set of cancer genes than in cells with a different initial mutation. Fourth, 
because of technical limitations, our method of amplifying and sequencing transposon 
insertions does not identify all transposon insertions, so a portion of driver mutations will 
not be identified. For example, analysis of replicate sequencing runs indicates that 20–
40% of the PCR amplicons in a given library are not sequenced in a given GS FLX 
sequencing run (SI Materials and Methods and Table 12). 
Relevance to Human Disease. To determine the relevance of these findings to human 
cancers, we analyzed the regions of human orthology to the CIS loci and the orthologous 
human genes. Of the 30 candidate mouse genes associated with a CIS, 28 had human 
orthologs. We queried the literature for mutations and recurrent copy number changes in 
these genes in human CRC. Three of the genes, APC, NSD1, and phosphodiesterase 4D 
interacting protein (PDE4DIP), are considered bona fide cancer genes based on the 
cancer gene census maintained by the Wellcome Trust Sanger Institute (Futreal et al. 
2004). Eight genes, APC, activating transcription factor-2 (ATF2), atlastin GTPase 2 
(ATL2), casein kinase 1, alpha 1 (CSNK1A1), integrin, alpha M (ITGAM), programmed 
cell death 6-interacting protein (PDCD6IP), and WAC, have documented mutations in 
human cancers cataloged in the COSMIC database (Forbes et al., 2006).  
We found strong concordance between the CIS mouse loci and orthologous 
regions in the human genome showing recurrent chromosomal losses and gains in human 
CRC (Vogelstein et al., 1989, Reid et al., 1996, Nakao et al., 2004, Habermann et al., 
2007, Lassmann et al., 2007, Shih et al., 2001, Derks et al., 2008, Kurashina et al., 2008). 
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Of the 33 identified CIS, 31 can be mapped to an orthologous human locus. Of these 31 
candidate cancer loci, 24 are found in regions that commonly are lost or gained in human 
CRC (Table 13), including several of the CIS that are orthologous to human 
chromosomal arms 18q, 17p, 5q, and 4q. Interestingly, one CIS that has no annotated 
genes nearby (CIS No gene 16) is in an orthologous region (3q21–24) that is associated 
with CRC based on genome-wide linkage analyses (Kemp et al., 2006, Neklason et al., 
2008). To determine the significance of this overlap, we performed the analysis using 
randomly generated CIS lists and a single dataset of regions that are lost recurrently in 
human CRC (Nakao et al., 2004). Roughly 250 genomic regions in this dataset were lost 
in > 5% of the human samples tested, and 22 of the 31 CIS were located within these 
regions. In 10,000 simulations using equivalent-sized randomly generated CIS lists, we 
find an overlap of this magnitude < 0.3% of the time. These results suggest that our SB 
screen may be capable of pinpointing the affected genes in these regions. 
Candidate Genes Regulate Proliferation of Human CRC Cell Lines. We tested nine 
genes [CCR4-NOT transcription complex, subunit 1 (CNOT1), PDE4DIP, PDCD6IP, 
ATF2, SFI1, formin-binding protein 1-like (FNBP1L), myosin VB (MYO5B), sorting 
nexin 24 (SNX24), and stromal antigen 1 (STAG1)] for their effect on proliferation of the 
human CRC cell line SW480 by knocking down message levels using siRNA. We used 
the SW480 line because it has an APC gene-truncation mutation similar to the ApcMin 
mutation (Nishisho et al., 1991). Cells were transfected two times at 48-h intervals with 
siRNA targeting the human genes. Knockdown efficiency was at least 50% for all nine 
genes as measured by quantitative real-time PCR. Cell proliferation was measured using 
a tetrazolium-based colorimetric assay on days two and six after the second transfection. 
Depletion of five (CNOT1, PDE4DIP, PDCD6IP, ATF2, and SFI1) of the nine genes 
tested resulted in a significant decrease in cell viability compared with a control siRNA 
of at least 33% at day six after transfection (Table 14). 
Discussion 
Using a transposon-based forward genetic screen in mice, we identified 33 
genomic loci that probably cooperate with a germline mutation in the Apc gene to cause 
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intestinal tumorigenesis. The most frequently mutated locus was the Apc locus, a result 
that supports the hypothesis that there is strong selective pressure to lose the wild-type 
copy during tumor formation. SB insertions in Apc were found in 72 of 96 tumors (75%), 
suggesting that 75% of the tumors in ApcMin SB test mice undergo LOH at the Apc locus 
via SB insertional mutagenesis. This hypothesis is supported by sequencing of the region 
spanning the 1-bp Min mutation, which indicated that the majority of tumors containing 
SB insertions at the Apc locus maintained heterozygosity at the location of the T:A Min 
mutation. In contrast, the majority of tumors lacking a transposon insertion in Apc 
showed loss of the wild-type sequence at the Min mutation site. These results suggest that 
the majority of tumors underwent biallelic loss of Apc activity through transposon 
insertion or somatic recombination. However, it also is possible that in some cases 
activity was lost through other mechanisms of Apc inactivation or through transposon 
insertion substituting for loss of the wildtype allele.  
Although LOH at the Apc locus is the rate-limiting event in tumor initiation in the 
ApcMin mouse and in familial and sporadic APC-deficient CRC, loss of APC probably is 
insufficient for the survival and growth of transformed cells into adenomas and, 
eventually, adenocarcinomas. SB-mutagenized animals showed increased polyp number 
but no evidence of adenocarcinoma or metastasis. Thus, it is likely that the CIS candidate 
genes identified in this SB screen contribute in a diverse fashion to initiation, 
establishment, and survival of adenomas. Moreover, depending on the complexity of the 
mechanism or pathway, the CIS candidates discovered in our screen, like the relatively 
large number of genes reported to be mutant in individual human CRC (Wood et al., 
2007), might be expected to occur at a low frequency if mutations at any one of multiple 
genes in a complex pathway can contribute equally to tumorigenesis.  
Aside from Apc, only a few of the remaining 28 known genes that we identified as 
CIS in our screen have been implicated directly in CRC development, although > 90% 
are located in genomic regions that are lost or gained in human CRC. To eliminate false 
positives, we removed CIS that also were identified in a control dataset of unselected 
transposon insertions mapped in tail snips. However, it is possible that other 
tissuespecific hotspots could result in false positives. Nevertheless, the known functions 
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of several of the CIS candidate genes make them plausible candidates for drivers of 
human CRC. For example, CNOT1 is a member of the Ccr4-Not complex, which is 
implicated in mRNA decay and transcriptional repression. In human cells, CNOT1 has 
been reported to be a repressor of nuclear receptor-mediated transcription (Winkler et al., 
2006). One target of CNOT1 repression appears to be estrogen receptor alpha (ERα), via 
interactions between CNOT1 and the ligand-binding domain of ERα. Inhibition of 
CNOT1 caused an increase in the expression of ERα target genes in breast cancer cells, 
and ERα has been shown to be a tumor suppressor gene in the intestinal tract (Cho et al., 
2007); in particular, knockout of ERα in ApcMin mice caused a significant increase in 
intestinal tumorigenesis (Cleveland et al., 2009).  
Another gene identified in this study, Pdcd6ip (also known as ALG-2 interacting 
protein X, Alix) is involved in membrane trafficking and apoptosis (Odorizzi G 2006). 
Pdcd6ip produces a protein that binds to the protein product of Pdcd6, a proapoptotic 
gene involved in T-cell receptor–, Fas-, and glucocorticoid-induced cell death (Vito et al., 
1996). Pdcd6ip also can block down-regulation of the EGF receptor (EGFR), thereby 
having a positive effect on growth factor signaling (Schmidt et al., 2004). These 
contradictory roles could explain why loss of Pdcd6ip in the mouse tumors promoted 
growth (via the loss of the proapoptotic function) but the loss of Pdcd6ip in SW480 cells 
caused decreased proliferation (via increased down-regulation of EGFR). Further 
functional studies are required to elucidate the role of this adaptor protein. 
In summary, our approach identified 30 genes that probably modify tumorigenesis 
in the ApcMin model of human CRC. Further functional analysis of these CIS candidate 
genes may provide insights into the etiology and treatment of human CRC, especially 
those cancers arising downstream of APC deficiency. 
 
Materials and Methods (Detailed protocols are given in SI Materials and Methods.) 
Mice. Mice containing ApcMin, Rosa26-LsL-SB11, Villin-Cre, and T2/Onc were reared 
using Institutional Animal Care and Use Committee-approved protocols. All mice were 
  139 
on an isogenic C57BL/6J background. Mice were monitored daily and killed and 
necropsied when moribund or after 120 d. 
Histopathology and Immunohistochemistry. Formalin-fixed tissues were embedded in 
paraffin, and standard techniques were used to stain tissue sections with H&E. Standard 
immunohistochemistry techniques were used to detect β-catenin. 
Linker-Mediated PCR. Linkers [described previously (Wu et al. 2003)] were ligated to 
NlaIII- (right-side) or BfaI- (left side) digested genomic DNA using T4 DNA ligase. A 
secondary digest (XhoI, right side; BamHI, left side) was performed to destroy 
concatamer-generated products. Primary and secondary PCR was performed using 
primers specific for linker and SB transposon sequences along with Fusion and barcode 
sequences. PCR amplicons were sequenced using the GS FLX (Roche). 
Sequence Analysis. Sequences were analyzed for the presence of the barcode, inverted 
repeat/direct repeat (IR/DR) sequences required for transposition, and linker sequences. 
Genomic sequence was blasted against the mouse genome using BLASTN at 95% 
stringency and requiring a single match. Of the 324,898 sequences analyzed, 53% could 
be uniquely mapped to the mouse genome. Sequences were removed if they were 
redundant, on the donor concatamer resident chromosome (Chr 1), in the En2 gene 
(because the En2 sequence is present in the transposon), and when a single TA 
dinucleotide contained multiple insertions from several tumors from multiple mice 
(because of the possibility of a PCR artifact). The remaining 30,088 nonredundant 
sequences were used to identify CIS. A CIS was defined by Monte Carlo simulations 
using a random dataset of 30,088 insertions.  
Apc LOH Analysis. To measure LOH for the ApcMin mutation, DNA was isolated from 
individual polyps, and PCR was performed using primers that flank the mutation (sense 
primer: CGGAGTAAGCAGAGACACAA; antisense primer: 
GGGAGGTATGAATGGCTGAT). The PCR product was purified using Qiagen 96 
MinElute vacuum purification plates per the manufacturer’s protocol and was sequenced 
using the sense primer as the sequencing primer. Trace peak heights at the location of the 
mutation were measured for each tumor, and the ratio of the T peak to the A peak was 
calculated.  
  140 
Comparisons with Human Data. Eight publicly available studies measuring DNA copy 
number in CRC compared with normal tissue were analyzed. Mutations in human tumors 
were examined using the Catalog of Somatic Mutations in Cancer database (Forbes et al. 
2006), and cancer gene status was based on the Census of Human Cancer Genes 
maintained by the Wellcome Trust Sanger Institute (Futreal et al. 2004). 
Knockdown of CIS Candidate Genes using siRNA in SW480 Cells. SW480 cells were 
obtained from ATCC (catalog no. CCL-228) and were cultured under recommended 
conditions. Transient siRNA transfection was used to deplete expression of Min CIS 
genes. 
Cell Viability Assay. Viability of siRNA-treated SW480 cells was determined using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Cell Viability 
Kit 1; Roche Applied Sciences). 
 
Supporting Information 
SI Materials and Methods 
Mice. ApcMin mice (C57BL/6J-ApcMin /J), which harbor a T→A nonsense mutation in 
the Apc gene that results in a truncated protein product, were obtained from a breeding 
colony at the University of Minnesota Medical School Animal Services facility. Rosa26-
LsL-SB11 mice (backcrossed to C57BL/6J) were a generous gift from Adam Dupuy 
(University of Iowa, Iowa City, IA). Villin-Cre mice [B6.D2-Tg(Vil-Cre)20Syr], strain 
01XE7, were purchased from the National Cancer Institute Mouse Repository. T2/Onc 
mice (mixture of C57BL/6J and FVB) were described previously (Collier et al. 2005). 
Mice were necropsied, and both normal and tumor tissues were collected by snap-
freezing in liquid nitrogen or overnight fixation in 10% buffered formalin followed by 
70% ethanol. PCR primer sequences were as follows: T2/Onc forward: 
CGCTTCTCGCTTCTGTTCGC, T2/Onc reverse: CCACCCCCAGCATTCTAGTT; 
Villin-Cre forward: CAAGCCTGGCTCGACGGCC, Villin-Cre reverse: 
CGCGAACATCTTCAGGTTCT; Rosa26-lox-stop-lox-SB11 and Rosa26-SB11 knock-
in3- primer: wild-type forward: CTGTTTTGGAGGCAGGAA, wildtype reverse: 
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CCCCAGATGACTACCTATCCTCCC, knock-in reverse: 
CTAAAAGGCCTATCACAAAC. ApcMin mice were genotyped as described previously 
(Dietrich et al. 1993). 
Histopathology and Immunohistochemistry. Histopathological analysis of tumors and 
adjoining normal tissue was performed on tissues that were fixed in 10% neutral buffered 
formalin, routinely processed into paraffin, sectioned at a thickness of 4µm, and stained 
with H&E. Multiple H&E sections were obtained from tumors from the colon and 
duodenum. All tissues were analyzed by an American College of Veterinary Pathologists-
certified veterinary pathologist (M.G.O.) from the University of Minnesota Masonic 
Cancer Comparative Pathology Shared Resources facility and using the standardized 
nomenclature of the 2003 Consensus Report and Recommendations for pathology of 
mouse models of intestinal cancer (Boivin et al. 2003). Immunohistochemistry was 
performed on 4-µm formalin-fixed, paraffin-embedded sections of small intestine which 
were deparaffinized and rehydrated, followed by antigen retrieval using 10 mM citrate 
buffer, pH 6.0, in a steamer. Staining for β-catenin was performed on a Dako Autostainer 
using a goat anti-human β-catenin polyclonal antibody (catalog no. sc-1496; Santa Cruz) 
as primary antibody (after blocking endogenous peroxidase and application of a protein 
block), with detection by a biotinylated donkey anti-goat antibody (Jackson 
ImmunoResearch Laboratories) and streptavidin-linked horseradish peroxidase (Dako) 
using diaminobenzidine (Dako) as the chromogen. Mayer’s hematoxylin (Dako) was 
used as the counterstain. Small intestinal adenomas from ApcMin/+ mice were used as a 
positive control tissue, and for negative control slides the primary antibody was 
substituted with Super Sensitive Goat Negative Serum (Biogenex).  
Linker-Mediated PCR. Linkers used to sequence insertions weredescribed previously 
(Wu et al. 2003). Genomic DNA was digested with NlaIII (for sequencing from the right 
side of T2/Onc) or BfaI (for sequencing from the left side of T2/Onc) and ligated to the 
linker using T4 DNA ligase. A secondary digestion was performed to destroy 
concatamer-generated products (XhoI for right-side cloning and BamHI for left-side 
cloning). These two enzymes do not cut the transposon distal to the NlaIII or BfaI sites 
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but do cut the plasmid backbone present in the transgene concatamer, effectively 
destroying concatamer linker amplicons. Primary PCR was performed using primers that 
flank the inverted repeat/di direct repeat (IR/DR) sequences and the linker. Primer 
sequences are listed below. Primary PCR products were diluted 1:75 and used in a 
secondary PCR with nested primers. Secondary PCR was performed using 
FusA+BC+Left2°Primer or FusA+BC+ Right2°Primer and FusB+linker2°Primer primers 
(see below). FusA and FusB are sequences required for pyrosequencing using the 454 
GSFlex machine (BC, barcode). PCR products were quantified using QuantIT picogreen 
assay (Invitrogen) and diluted to a concentration of 200,000 molecules/µL. All tumor 
samples were combined and diluted by the number of samples added, for a final 
concentration of 200,000 molecules/µL. Samples were sequenced using the Roche 
Genome Sequencer FLX using 454 pyrosequencing technology (Roche Applied Science) 
by the University of Minnesota Biomedical Genomics Center. Sequences (all sequences 
are listed in the 5′ → 3′ direction) used were 
Left linker+: GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC 
Left linker−: TAGTCCCTTAAGCGGAG 
Right linker+: GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG 
Right linker−: GTCCCTTAAGCGGAGCC 
Linker 1°Primer: GTAATACGACTCACTATAGGGC 
Linker 2°Primer: AGGGCTCCGCTTAAGGGAC 
(Note, linker primers work for both the Left linker and the Right linker) 
Left 1°Primer: CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAAC 
Left 2°Primer: GGACATCTACTTTGTGCATGACACAAGTC 
Right 1°Primer: GCTTGTGGAAGGCTACTCGAAATGTTTGACCC 
Right 2°Primer: CCACTGGGAATGTGATGAAAGAAATAAAAGC 
FusA+BC+Left2°Primer: 
GCCTCCCTCGCGCCATCAGAATGCCGCATTTAAGTGTATGTAAACTTC 
Fusion A: GCCTCCCTCGCGCCATCAG 
Example barcode (each tumor is different): AATGCCGCAT. 
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FusA+BC+Right2°Primer: 
GCCTCCCTCGCGCCATCAGAATGCCGCATTAAGGTGTATGTAAACTTC 
FusB+linker2°Primer: GCCTTGCCAGCCCGCTCAGAGGGCTCCGCTTAAGGGAC 
Fusion B: GCCTTGCCAGCCCGCTCAG 
A full list of barcodes is available upon request. 
Processing of Sequence Files. PCR amplicons were generated so that the 10-bp library-
identifying barcode always appeared in the beginning of the sequence in the sense 
orientation. Sequence quality was outstanding even up to the first base. Using a custom 
Perl script, we scanned positions 1–12 of all reads for the presence of the library barcode, 
allowing 0 or 1 mismatch. We typically found perfect matches to a single barcode at 
positions 1–11, with matches at 2–12 occurring rarely. We did not find barcode 
sequences (0–1 mismatch) anywhere else in the read sequences. We successfully 
assigned 98% of all sequence reads to a library barcode. All barcodes differed by at least 
2 bp, and no sequence read matched two or more barcodes in a given region. This process 
was carried out separately for each of the six 454 pyrosequencing regions used in these 
analyses. Following barcode identification, the data for each of the six runs were merged 
to allow uniform handling of the entire dataset. Note that we did not attempt to assemble 
reads into contigs for several reasons: (i) The read quality was outstanding, matching the 
consensus with >99.9% accuracy when assembly was performed; (ii) the contigs tended 
not to tile at all, because the reads all were primed at the same location and are of similar 
length, conferring little advantage to using contigs; and (iii) assembly might introduce 
chimeric artifacts, particularly when two relatively closely spaced insertion sequences 
appeared on opposite strands. 
To identify and remove IR/DR and linker sequences from each read, we applied 
EMBOSS Vectorstrip (Rice et al. 2000) with custom-designed modifications for pipeline 
application and assessed the best mismatch parameters to use. We sequentially attempted 
to match both construct elements (IR/DR and linker) in sense and antisense orientations 
with four successively less stringent parameter sets: 
i) 10% mismatch allowed, long-construct elements (17–32 bp) 
ii) 10% mismatch allowed, short-construct elements (<26 bp) 
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iii) 15% mismatch allowed, short-construct elements (<26 bp) 
iv) 20% mismatch allowed, short-construct elements (<26 bp) 
Note that the short-construct elements affect only the IR/ DR sequence, because the 
linker element already is shorter than 26 bp. As we reduced the stringency, more 
construct elements could be detected, but the risk of finding spurious chance matches 
increased. To guard against the introduction of spurious matches, we used generic scripts 
to assign a label to each recognized construct that was encountered from the 5′end to the 
3′ end. We assigned the following labels: Ideal: a construct with both IR/DR and linker 
elements in the same orientation 
No-linker: a construct with an IR/DR but missing a linker 
No-IR/DR: a construct missing the IR/DR 
Bad: a construct with no recognizable elements or multiple IR/DRs 
Unknown: anything else 
For example, an ideal construct might look like 11-[+IR/DR]- 42-[+linker]-4, where, in 
this case, the 42-bp insertion is in the sense orientation (as indicated by the + signs for 
IR/DR and linker). The numbers between elements in this representation indicate the 
number of base pairs between elements. Insertions < 16 bp were considered empty or 
unmappable. Ideal and nearly ideal construct configuration counts were monitored as the 
stringency parameters were relaxed. We expected the number of ideal configurations 
detected to increase and the unknown count to remain steady until we hit a parameter set 
that was too lax. We started with the strictest set of parameters (stringency level 0) and 
collected all ideal configurations. Then we took all sequences with nonideal 
configurations through stringency levels 1–3 to see if we could move them into the ideal 
category. In our final merged summary sequence table, the best status (ideal > no-linker > 
no-IR/DR > bad) was reported for each sequence along with the data for the most 
stringent run level (0–3) where it achieved this label. 
Mapping Insertion Sequences. To map sequences to the mouse genome [National 
Center for Biotechnology Information (NCBI) Build 37], we used BLASTN (DeCypher’s 
TeraBLASTN, Active Motif, http://timelogic.com), requiring query sequences to align 
within 1 bp of the start of right-IR/DR sequences or within 1 bp of the end of left-IR/DR 
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sequences (i.e., within 1 bp of the transposon insertion site with both types of reads). 
Additionally, the query was required to match with at least 95% identity. Lower 
thresholds of 90% and 85% identity were tested but failed to yield sufficiently higher 
percentages of newly mappable insertions to warrant lowering the matching stringency. 
Because we were most interested in the IR/DR position, we were careful to ensure that 
the query matched within 1 bp of the IR/DR insertion site, but we did not require the 3′ 
end of the query to match, in case cloning artifacts had altered that end of the sequence. If 
secondary genome hits were found that were at least 95% as long as the first match, their 
count was recorded, and the insertion location was considered ambiguous. However, if all 
secondary hits appeared within 5,000 bp of the primary hit on the same chromosome, we 
considered the insertion to be uniquely mappable to that locus. Of the 324,898 sequences 
analyzed by BLASTN, 173,101 (53%) could be uniquely mapped to the mouse genome. 
We removed redundant sequences that arose from the same tumor and mapped to the 
same TA dinucleotide insertion site in the genome. Of the 173,101 mapped sequences, 
100,171 (67%) were redundant, leaving 72,930 nonredundant mapped insertions. Three 
more filtering steps were performed: 
i) To avoid the bias of “local hopping,” all nonredundant insertions mapping to the 
chromosome containing the transposon donor concatamer (Chr 1) were removed. 
ii) The T2/Onc transposon contains sequence from an intron and splice acceptor of the 
murine En2 gene. Any insertions mapping to this sequence were removed because they 
might represent a transposition event back into the concatamer and not an insertion into 
the genomic En2 locus. 
iii) Three-primer PCR was used to validate a sampling of nonredundant mapped 
insertions. We were successful in validating mapped insertions except in one 
circumstance. When a single TA dinucleotide contained multiple insertions from several 
tumors from multiple mice, we could not validate the insertions with three-primer PCR in 
some cases. We hypothesize that some of these TA dinucleotides are neasequences that 
cause PCR artifacts and do not represent true transposon insertions. We chose to adopt a 
conservative approach to avoid these artifacts, so we eliminated all insertions in TA 
dinucleotides containing insertions from two or more tumors from two or more different 
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mice. These three filtering steps removed 42,842 (59%) insertions, leaving a total of 
30,088 nonredundant mapped insertions. This set was used to determine CIS.  
Statistics Used to Identify CIS. To identify CIS, nonredundant insertions were assigned 
to clusters if the local density of insertions in a given window size exceeded that which 
would be expected by chance. Window sizes were determined by exact Monte Carlo 
simulation (see below). Based on a dataset of 30,088 insertions, the significance 
thresholds obtained are: 
Five or more insertions within 12,000 bp  
Six or more insertions within 22,000 bp 
Seven or more insertions within 34,000 bp 
Eight or more insertions within 50,000 bp, 
Nine or more insertions within 65,000 bp 
Ten or more insertions within 82,000 bp 
Eleven or more insertions within 105,000 bp 
Twelve or more insertions within 124,000 bp 
Thirteen or more insertions within 150,000 bp 
Fourteen or more insertions within 175,000 bp 
Fifteen or more insertions within 200,000 bp 
The assumption of standard Poisson statistics that potential insertion sites are randomly 
distributed throughout the genome is not strictly correct, because (i) TA dinucleotides are 
naturally clustered in genomes, and (ii) numerous unfinished regions in the mouse 
genome are “off-limits” because they are long tracts of Ns. For example, the initial 
telomeric region of every chromosome except Y is padded with 3 million consecutive Ns. 
Both these factors lead standard analytical approaches to underestimate\ the size and 
number of clusters that actually would be encountered by simply picking randomly 
chosen real TA sites. In other words, by ignoring the natural clustering of TA sites in the 
genome, the number of false-positive CIS that will be predicted is increased 
systematically. The magnitude of deviation gets larger as more and more insertion sites 
are scattered about the genome, as one would expect intuitively. Hence, we wrote a 
program to compute exactly the expected number of CIS of a given size in a specified 
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window across all the chromosomes that one would encounter by chance via Monte Carlo 
simulation. The observed number of unambiguous mappable nonredundant insertions was 
used for each chromosome separately as input. For example if chromosomes 1 and 2 had 
2,100 and 1,420 insertions, respectively, then we randomly distributed 2,100 insertions 
among the real TA dinucleotide sites on mouse chromosome 1 and another 1,420 among 
the TA sites of chromosome 2. Once the total count of insertions was distributed 
randomly among the real TA sites across the whole genome, a tally of the number of CIS 
of size ≥3, ≥4, . . ., ≥15 was recorded within windows of 10,000 bp, 20,000 bp, . . . 
150,000 bp. This process was repeated 100 times, and the average counts over those 100 
iterations were computed. Four independent simulations of 100 iterations each were 
performed, yielding SE bars between simulations of < 1%, indicating sufficient 
convergence. The values obtained can be interpreted as expected values (E-values), 
because they indicate the expected number of CIS of a given number of insertions that 
would be observed within a given window size merely by chance. We chose a threshold 
with an E-value < 1. Thus, finding 11 CIS of ≥ 15 insertions within 200,000 bp, when not 
even a single CIS was expected, is highly significant. We compared the thresholds 
obtained by this method with the thresholds obtained using standard Poisson statistics 
with the assumption of random insertion in the genome. We found our method was 
uniformly more stringent and yielded fewer false positives than the standard Poisson 
statistics. A modified Poisson model that takes into account the local density of TA sites 
in the genome yielded excellent agreement with the Monte Carlo calculations. 
Annotation and Sequence Information Management.We created two primary 
annotation files: one outlining details of each unique insertion, and one describing each 
CIS. These files provide information on the chromosomal mapping position of each 
insertion or CIS, redundancy information on each insertion, and characteristics of the 
nearest EnsEMBL gene that flanks the insertion. EnsEMBL mappings were identified by 
a custom Perl script that uses the published Application Programmer Interface (Stabenau 
et al. 2004). To facilitate the management of all sequence information, an MySQL 
relational database was constructed to store (i) genotypic and phenotypic information on 
all mice and tumors from which the insertion sequences were derived; (ii) 
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metainformation on the sequencing runs themselves; (iii) raw read sequences; (iv) 
construct element matching characteristics; (v) final processed insertion sequences; (vi) 
mapping information for each processed insert sequence to the mouse genome; (vii) 
clustering assignments of inserts into CIS; and (viii) annotation information on all 
mapped inserts and CIS. SQL queries were performed to facilitate the merging of distinct 
gastrointestinal tract tumor datasets and the annotation process. 
Analysis of Replicate Sequencing Runs to Determine Percentage of Library 
Capture. To estimate the extent of undersampling of transposon insertions in our study, 
we analyzed the GS FLX sequencing replicates separately. Using a four-region plate, one 
sequencing run of the GS FLX machine can sequence four separate samples. In one of the 
sequencing runs we ran two aliquots of the left-side ligation-mediated (LM)-PCR pool in 
separate regions (1 and 4) and two aliquots of the right-side LMPCR in separate regions 
(2 and 3). We analyzed the sequence reads by custom Perl script to determine the extent 
of overlap (Table 12). For example, region 1 returned 68,371 total reads, of which 56,435 
contained a perfect match to a barcode, the transposon-specific sequence, and a genomic 
TA dinucleotide along with at least 16 bases of genomic DNA. When duplicate 
sequences were combined, 20,654 unique transposon insertion reads remained. Region 4, 
which was a replicate, had 18,863 unique reads. The overlap between these two regions 
was 10,448 reads, a little more than 50%. Because this process is similar to a mark-
recapture experiment, one can use the Lincoln–Peterson method (Seber GAF 2002) to 
estimate the number of amplicons in the total population (see below). Based on the 
overlap between the replicates sampled in regions 1 and 4, we estimate that there were 
37,289 unique amplicons in the original pool. As a rough approximation, our protocol 
sampled about 78% of the amplicons present in the original left-side LM-PCR pool. If we 
apply the same analysis to the right-side LM-PCR pool, where the overlap was lower 
(∼35%), we estimate that we sampled only 58% of the amplicons in the original right-
side LM-PCR pool. In either case, it is apparent that by increasing the number of 
sequencing runs, or perhaps by using a different sequencing platform, we could find more 
transposon insertions and perhaps more candidate cancer genes.  
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Lincoln–Peterson Method to Estimate Total Population in a Mark-and- Recapture 
Experiment. A mark-and-recapture experiment can be used to estimate population size 
in an ecological setting where the researcher marks all animals captured during a first 
visit. The researcher then returns and makes a second capture, noting how many of the 
animals in the second capture were marked in the first capture. To use the Lincoln–
Peterson method (Seber GAF 2002) in our study, we assume that the duplicate pools of 
amplicons contain equal numbers of the same amplicons. This assumption could be 
invalid, because the concentration in the amplicon pool is very small (∼200,000 
molecules/µL). Randomly removing a small volume could result in the two volumes 
containing different amplicons. Another caveat to using the Lincoln–Peterson method is 
that our use of unique reads instead of actual reads is not directly analogous to a mark-
and-recapture experiment. Nevertheless, if we assume the aliquots are similar, then the 
number of reads in the first region (M) is analogous to the number of animals caught and 
marked in the first capture of a mark-andrecapture experiment. The number of reads in 
the second region (C) is analogous to the number of animals caught in the second capture, 
and the number that overlaps (R) is analogous to the number of animals marked in the 
first capture that are caught in the second capture. To estimate the total population (N), 
the Lincoln–Peterson method states that the proportion of marked individuals in the 
second capture to the number in the first capture (R/M) should equal the proportion of the 
number of animals in the second capture to the total population (C/N). Rearrangement of 
this equation gives n = (M × C)/R. Using the number of unique reads in regions 1 and 4 
(Table 12) equates to (20,654 × 18,863)/10,448 = 37,289. The total number of unique 
reads we captured in both sequencing regions (20,654 + 18,863 − 10,448 = 29,069) 
represents 78% of the estimated total population of 37,289. Using the same analysis of 
the unique reads in region 2 and 3 (Table 12) equates to an estimated total populationof 
(25,753 × 25,804)/9,079 = 73,194. In this case, we have sampled only (25,753 + 25,804 − 
9,079 = 42,478) 58% of the total population. 
Apc Loss of Heterozygosity Analysis. To measure loss of heterozygosity (LOH) for the 
ApcMin mutation, DNA was isolated from individual polyps, and PCR was performed 
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using primers that flank the mutation (sense primer: CGGAGTAAGCAGAGACACAA; 
antisense primer: GGGAGGTATGAATGGCTGAT). The PCR product was purified 
using Qiagen 96 MinElute vacuum purification plates according to the manufacturer’s 
protocol and was sequenced using the sense primer as the sequencing primer. Trace peak 
heights at the location of the mutation were measured for each tumor. Wild-type DNA 
will only have a single peak, representing thymidine, whereas ApcMin nontumor DNA 
will have two peaks of equal height representing the wild-type thymidine base and the 
mutant adenine base. If significant LOH has occurred, the ratio of the height of the 
thymidine peak to the adenine peak will be < 0.5, whereas a ratio > 0.8 indicates 
maintenance of heterozygosity. Ratios between 0.5 and 0.8 and ratios > 1.2 are 
considered to be contaminated with nontumor tissue. 
Chromosomal Copy Number Analysis. Eight studies measuring DNA copy number in 
CRC compared with normal tissue were analyzed (Vogelstein et al. 1989, Ried et al. 
1996, Nakao et al. 2004, Habermann et al. 2007, Lassmann et al. 2007, Shih et al. 2001, 
Derks et al. 2008, Kurashina et al. 2008). Of the 33 CIS loci, 31 were mapped to the 
homologous human region using the Batch Coordinate Conversion (Lift- Over) utility 
from the University of California, Santa Cruz (UCSC) genome browser (Kent et al. 
2002). The genome build appropriate to each study was analyzed. A CIS locus was 
determined to be lost or gained recurrently based on the individual study methodology. 
To determine the chances of this overlap occurring randomly, we ran 10,000 simulations 
using randomly generatedCIS listscompared with the recurrently lost regions in Nakao et 
al. (Nakao et al. 2004). In this study they hybridized genomic DNA from 135 human 
CRC along with normal lymphocytic DNA to a BAC array (HumArray1.14, University 
of California San Francisco; UCSF) and used Spot/Sproc analysis software (UCSF) to 
determine log2 ratios. They published an Excel file with the log2 ratios for each BAC 
clone for each human sample. Chromosomal losses were based on a log2 ratio lower than 
−0.225. The genomic coordinates of the BAC clones were downloaded from the UCSF 
website(http://cancer.ucsf.edu/_docs/cores/array/analysis/HA1.14_clonepos_May04.2006
0811.txt) and were mapped to the Human genome build HG19 using the Batch 
Coordinate Conversion utility from the UCSC genome browser 
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(http://genome.ucsc.edu/cgi-bin/hgLiftOver). After BAC clones that did not have at least 
65% of samples giving a reading and positions that did not map to the HG19 build were 
removed, log2 ratios for 2,075 BAC clones remained. We selected the subset of these 
clones that had log2 ratios lower than −0.225 in at least 5% of the samples. Genomic 
regions recurrently lost were defined based on the genome coordinates of consecutive 
BAC clones that had log2ratios lower than −0.225. For example, if three adjacent clones 
all showed a loss, we assigned the region based on the start coordinate of the first clone 
and the end coordinate of the last clone. If the neighboring clones on both sides of a BAC 
were not decreased, the region was defined as the coordinates of the single BAC. Next, 
we wrote a Perl script that created 10,000 random sets of 31 CIS using the UCSC Golden 
Path coordinates. Each set of 31 CIS contained 31 randomly generated genomic regions 
that were the same length as the actual ApcMin dataset CIS. The Perl script then counted 
the overlap between the random CIS list and the Nakao recurrently lost regions, and the 
process was repeated 10,000 times. In 10,000 simulations, only three random CIS lists 
had an overlap of 22 regions or more. 
Knockdown of CIS Genes Using siRNA in SW480 Cells. SW480 cells were purchased 
from American Type Culture Collection. Cells were maintained in DMEM supplemented 
with 10% FBS, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin 
and were incubated in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. Cells 
were switched to antibiotic-free medium before siRNA transfection. Cells at 70% 
confluence were transfected twice, 48 h apart, with siRNA oligonucleotides (siRNA 
oligos) targeting the human ortholog of the CIS candidate gene (CIS siRNA) or with a 
nontargeting control (control siRNA), at a final concentration of 50 nmol/L, using 
Lipofectamine 2000 transfection reagent. Oligos targeting CIS genes were obtained from 
Qiagen (Hs_ATF2_3, Hs_PDCD6IP_5 Hs_SFI1_7, and Hs_ PDE4DIP_15) and from 
Dharmacon (CNOT1 On-TARGETplus SMARTPool). The control siRNA oligo 
(OnTARGETplus Nontargeting siRNA#3) was obtained from Dharmacon. Total RNA 
was harvested fromCIS siRNA- and control siRNA-treated cells 2 or 3 d after the second 
siRNA transfection using the RNeasy kit (Qiagen). For each experimental sample, 1.5 µg 
RNA was converted to cDNA with random nonomer primers (Integrated DNA 
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Technologies) and recombinant Omniscript Reverse Transcriptase using the Omniscript 
RT kit (Qiagen) according to manufacturer’s instructions. CIS cDNA and 18S ribosomal 
cDNA (used as internal control) were amplified from total cDNA by PCR. PCR was 
carried out in 10 µL using 2 µL cDNA from a 10× dilution of the 20 µL RT reaction 
(equivalent to 15 ng reversetranscribed RNA) for CIS genes and a 100× dilution for 18S 
rRNA, 500 nM of each primer, and 5 µL LightCycler 480 SYBR Green 1 Master Mix 
(Roche Applied Science). PCR was performed on a LightCycler 480 System (Roche 
Diagnostics) in96-well plates using the amplification protocol: one cycle of 
preincubation, 5 m at 95 °C; 45 cycles of amplification each consisting of denaturation at 
95 °C for 5 s, annealing at 60 °C for 5 s, and elongation at 72 °C for 10 s; one cycle 
melting at 95 °C for 5 s, 65 °C for 1 m, heating to 97 °C; one cycle cooling at 40 °C for 
30 s. Water was used as a template for negative control amplifications for each PCR run. 
All reactions were performed in duplicate. Standards were generated by reverse 
transcription of total RNA from untreated cells followed by PCR amplification to 
generate template DNA of the same sequence as the predicted CIS gene or 18S gene PCR 
product. Serial dilutions of template DNA were amplified in parallel with experimental 
samples and used to generate a standard curve for each gene. Data were analyzed using 
Roche LightCycler 480 software, and crossing points (CPs) were calculated using the 
absolute quantification-second derivative maximum method. The standard curve was 
used to determine efficiency of PCR amplification (E) for each gene. Relative mRNA 
levels represent the expression of the CIS gene in CIS siRNA-treated cells relative to 
expression in control siRNAtreated cells. CIS gene expression was normalized to 18S 
rRNA levels, and relative mRNA levels were calculated as described by Pfaffl (Pfaffl 
MW 2001): relative mRNA levels = ([Etarget] ΔCPtarget(control-treated))/[Eref] 
ΔCPref(control-treated)) × 100, where E is real-time PCR efficiency and CP is defined as 
the point at which fluorescence rises appreciably above background. 
Primer sequences are as follows: activating transcription factor-2 (ATF2), 5′-
TGACCGAAAGGATCATGAACTA-3′ and 5′-GCAGTCCTTTCTCAAGTTTCCA-3′; 
CCR4-NOT transcription complex, subunit 1 (CNOT1), 5′ 
CTTTCAACCCCCAATCAGACC-3′ and 5′-AGGTTTCATCTTACTCTGCTGGA-3′; 
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programmed cell death 6-interacting protein (PDCD6IP), 5′ 
AGGTGTTCCCTGTCTTGGCTGC-3′ and 5′ 
TTCATCATAGCGAGATGCCACTGTTT-3′; phosphodiesterase 4D-interacting protein 
(PDE4DIP), 5′-GAGAACTCCAGGACAAGAAACAGCAT-3′ and 5′-
GGATTCCTCCTGCAGAAGCTGG-3′; Sfi1 homolog, spindle assembly associated 
(SFI1), 5′-AGCAGCAGGAGATGAGGAACAAG-3′ and 5′-
CGAACAACCACGTAGATCAACCAG-3′. 
Cell Viability Assay. Viability of siRNA-treated SW480 cells was determined using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Cell Viability 
Kit 1; Roche Applied Sciences) in which absorbance at 595 nm is proportional to viable 
cell number. One day after the second siRNA transfection, cells were replated into 96-
well plates at 1,250 cells per well (ATF2, PDCD6IP, and PDE4IP) or 5,000 cells per well 
(CNOT1) in triplicate in regular growth medium. Cell viability was determined on days 
2–6 after the second transfection. Day 6 A595 values for each treatment were normalized 
to day 2 values for the same treatment to correct for differences in plating. Relative cell 
viability represents the ratio of normalized absorbance at 595 nm of cells treated with CIS 
siRNA to absorbance of cells treated with control siRNA on day 6. Results shown for 
mRNA and cell viability are the mean ± SD of at least two experiments. 
 
Figure 35. Three alleles used to target SB mutagenesis to the intestinal tract. (A) T2/Onc 
transposon. IR/DR, inverted repeat/direct repeat sequences required for transposition; MSCV 5′ 
LTR, murine stem cell virus 5′ long terminal repeat; SA pA, splice acceptor with a polyA signal. 
(B) Conditional SB allele. Rosa26 locus, endogenous Rosa26 locus [Gt(Rosa)26Sor]; LoxP-
GFP/Stop-LoxP, GFP cDNA flanked by LoxP sites; SB11 transposase pA, SB11 transposase 
cDNA with polyA signal. (C) Cre recombinase cDNA driven by the Villin promoter. 
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Figure 36. PCR technique for detecting Apc LOH. Trace peak heights of the T→A Min 
mutation in (A) wild-type mice, (B) heterozygous ApcMin mice, and (C) an adenoma with LOH. 
Arrows indicate Min mutation. Red peaks = T; green peaks = A. 
Table 11. LOH and MOH in ApcMin tumors based on the ratio of T:A trace peaks. 
 
 
Table 12. Sequence read overlap between duplicate regions of a single GS FLX sequencing 
run. 
  155 
 
Table 13. Human orthologous regions to the mouse CIS with recurrent chromosomal copy 
number changes based on published data. 
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*Based on mouse July 2007 Assembly (mm9) UCSC genome browser. 
†Based on human GRCh37 Assembly (hg19) UCSC genome browser. 
‡Region was identified in one of the following studies: Nakao et al., 2004; Derks et al., 2008; Lassmann et 
al., 2007; Habermann et al., 2007; Ried et al., 1996; Vogelstein et al., 1989; Shih et al., 2001. 
Table 14. Knockdown of ApcMin CIS candidate genes affects viability of human colon cancer 
cells. 
 
 
Table 15. Mapped transposon insertions in 96 tumors. Please see the weblink: 
http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1018012108/-/DCSupplemental/sd01.xls 
 
 
Personal Contribution. Lei Zhao performed MTT experiments analyzed data to 
determine the knockdown effect of the following genes on proliferation of human 
(SW480) CRC cells: CNOT1, PDCD6IP, PDE4DIP and SFI1.  
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Abstract. Kcnq1, which encodes for the pore-forming a-subunit of a voltage-gated 
potassium channel, was identified as a gastrointestinal (GI) tract cancer susceptibility 
gene in multiple Sleeping Beauty DNA transposon-based forward genetic screens in 
mice. To confirm that Kcnq1 has a functional role in GI tract cancer, we created ApcMin 
mice that carried a targeted deletion mutation in Kcnq1. Results demonstrated that Kcnq1 
is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal 
tumors, especially in the proximal small intestine and colon, and some of these tumors 
progressed to become aggressive adenocarcinomas. Gross tissue abnormalities were also 
observed in the rectum, pancreas and stomach. Colon organoid formation was 
  158 
significantly increased in organoids created from Kcnq1 mutant mice compared with 
wild-type littermate controls, suggesting a role for Kcnq1 in the regulation of the 
intestinal crypt stem cell compartment. To identify gene expression changes due to loss 
of Kcnq1, we carried out microarray studies in the colon and proximal small intestine. 
We identified altered genes involved in innate immune responses, goblet and Paneth cell 
function, ion channels, intestinal stem cells, epidermal growth factor receptor and other 
growth regulatory signaling pathways. We also found genes implicated in inflammation 
and in cellular detoxification. Pathway analysis using Ingenuity Pathway Analysis and 
Gene Set Enrichment Analysis confirmed the importance of these gene clusters and 
further identified significant overlap with genes regulated by MUC2 and CFTR, two 
important regulators of intestinal homeostasis. To investigate the role of KCNQ1 in 
human colorectal cancer (CRC), we measured protein levels of KCNQ1 by 
immunohistochemistry in tissue microarrays containing samples from CRC patients with 
liver metastases who had undergone hepatic resection. Results showed that low 
expression of KCNQ1 expression was significantly associated with poor overall survival. 
INTRODUCTION 
The KCNQ1 gene encodes for the pore-forming a-subunit of a voltage-gated 
potassium channel that enables a K+ current after electrical depolarization of the cell 
membrane. KCNQ1 is predominantly expressed in the myocardium, inner ear, stomach, 
intestine and pancreas, tissues in which KCNQ1 expression is critical for ion homeostasis 
(Peroz et al., 2008). Inherited mutations in KCNQ1 underlie several human disease 
syndromes. For example, mutations in KCNQ1 are associated with congenital long QT 
syndrome, a disorder caused by abnormal ventricular repolarization that increases the risk 
of sudden death from cardiac arrhythmias. Jervell and Lange–Nielson syndrome is a rare 
autosomal disorder characterized by deafness in addition to long QT syndrome. Recent 
reports indicate that Jervell and Lange–Nielson syndrome patients can also be susceptible 
to GI defects, including iron-deficiency anemia, gastric and duodenal hyperplasia, 
elevated gastrin levels and, more rarely, gastric adenocarcinoma (Winbo et al., 2012, 
Grahammer et al., 2001, Rice et al., 2011, Nikou et al., 2011). Variants in KCNQ1 are 
  159 
also associated withenhanced risk for type 2 diabetes (Unoki et al., 2008, Yasuda et al., 
2008). 
Relatively little is known about the role of KCNQ1 in cancer, but a potential role 
in GI tract cancers was indicated by its identification as a high-frequency common 
insertion site locus in Sleeping Beauty DNA transposon-based forward mutagenesis 
genetic screens for intestinal (Starr et al., 2009, March et al., 2011) and pancreatic cancer 
(Mann et al., 2011, Perez-Mancera et al., 2012). In our forward genetic screen in Apc 
wild-type mice, we found Kcnq1 mutations in 18 intestinal tumors (13%) (Starr et al., 
2009) ranking it among the top 10 common insertion site genes. In this study, while 
transposon insertions in Kcnq1 were found in tumors from all regions of the intestine, 
approximately two-thirds (64%) were located in the duodenum and jejunum, with 26% in 
the ileum and 10% in the colon. Furthermore, transposon insertions in Kcnq1 were 
observed equally in both the forward and reverse strand orientation, consistent with a 
model whereby the transposon is acting to disrupt gene function. We performed a second 
forward genetic screen in ApcMin mice and found Kcnq1 transposon insertions in 13 
intestinal tumors (14%) (Starr et al., 2011). Another screen in ApcMin mice found Kcnq1 
transposon mutations in 120 intestinal tumors (27%), ranking it no. 15 out of 641 
common insertion site genes (120 kb window) (March et al., 2011). We have also 
conducted a screen using p53R270H mutant mice and identified insertions in Kcnq1 in 15 
intestinal tumors (23%) (TK Starr, personal communication). Six mutant mouse alleles of 
Kcnq1 have been created that partially model human disorders arising from inherited 
mutations in KCNQ1, especially Jervell and Lange–Nielson syndrome (Lee et al., 2000, 
Casimiro et al., 2001, Casimiro et al., 2004, Takagi et al., 2007, Elso et al., 2004). These 
mutant alleles share similar but not identical phenotypes, including bilateral deafness 
from birth, gastric hyperplasia, gastric achlorhydria, elevated serum gastrin, headbobbing, 
bidirectional circling, ataxia, body tremor and hyperactivity with a consequent significant 
decrease in body weight. Conflicting results were reported regarding a cardiac phenotype 
in these models. In mouse small intestine, Kcnq1 expression is strongest in the duodenum 
and proximal jejunum and decreases towards the ileum (Demolombe et al., 2001, Dedek 
et al., 2001). In the large intestine, Kcnq1 expression is strongest in the distal colon 
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(Vallon et al., 2005, Warth et al., 2002). To further investigate the role of Kcnq1 in GI 
tract cancers, we measured GI cancer phenotypes following introgression of a targeted 
knockout (KO) allele of Kcnq1 (Casimiro et al., 2001) into the ApcMin model of intestinal 
tumorigenesis. We then investigated the role of KCNQ1 in progression of human 
colorectal cancer (CRC) by measuring KCNQ1 protein levels in tissue microarrays 
containing samples from more than 500 CRC patients with liver metastases. Results from 
both of these studies indicate that Kcnq1 is a tumor suppressor. 
RESULTS 
Loss of Kcnq1 enhances tumor multiplicity in ApcMin mice. 
Haploinsufficiency for Kcnq1 significantly enhanced ApcMin intestinal tumor 
multiplicity overall, in both males and females, by ~40% (Table 16), with the phenotype 
strongest in the proximal small intestine and colon, where tumors increased 2-fold. 
Kcnq1-/- mice in our study manifested a range of previously reported phenotypes: rapid 
bidirectional circling, ataxia, tremor, head bobbing and they were smaller (~ 25%, body 
weight) and leaner than littermate Kcnq1 wild-type and heterozygous mice. Less than 
half of the expected number of ApcMin Kcnq1-/- mice survived until weaning (23 vs ~60). 
Survivor ApcMin Kcnq1-/- mice demonstrated a very strong increase in tumors in the 
proximal half of the small intestine (B3-fold), especially in the proximal quarter of the 
small intestine containing the duodenum and proximal jejunum (Table 17), the region 
exhibiting strongest expression of Kcnq1 in the intestine. ApcMin Kcnq1-/- mice developed 
B2-fold increase in colon tumors but no increase in the distal small intestine of males, 
and a decrease in females. No significant differences between Kcnq1 genotypes in tumor 
sizes were observed. 
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Table 16.  Loss of Kcnq1 enhances tumor multiplicity in Apc Min mice. 
 
 
Table 17. Apc Min Kcnq1 −/− tumor phenotype is strongest in the proximal quarter of the 
small intestine. 
Loss of Kcnq1 promotes tumor progression 
Tumors in ApcMin mice are invariably benign adenomas that usually vary in size 
between 0.3 and ~5 mm. Adenocarcinomas are extremely rare. In ApcMin mice carrying 
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either heterozygous or homozygous mutations in Kcnq1 development of 
adenocarcinomas occurred at a frequency of ~10–15%. These adenocarcinomas appeared 
as large lesions (some >20 mm), located in the proximal small intestine in a region 
approximate with the duodenal–jejunal flexure at the head of the pancreas. In almost all 
cases, there was buckling of the intestinal tube, in two cases there was a pronounced 
intussusception of the tissue and in two cases the tumors extended across the entire inner 
surface of the intestinal lumen. Six of these large tumors were analyzed by 
histopathology and all were found to be invasive adenocarcinomas (Figure 37). Figure 
37a depicts a lesion of > 2 cm in length from the duodenum of an ApcMin Kcnq1+/- mouse, 
which when sectioned regionally revealed adenocarcinoma tissue in each section. No 
adenocarcinomas were detected in the remainder of the small intestine or in the large 
intestine, and no putative adenocarcinomas were detected in ApcMin Kcnq1+/+ mice.  
 
 
Figure 37. Loss of Kcnq1 promotes tumor progression. (a) Duodenum from ApcMin Kcnq1+/- 
mouse with stomach at right. Bar = 5 mm. Broad area of hyperplastic tissue with embedded 
tumors extends from pylorus–dudoenum juncture past the ampulla to a region approximate with 
the duodenal jejunal flexure. Asterisk indicates area of normal duodenum–proximal jejunum. Box 
encloses a region of adenocarcinoma tissue of > 2 cm. Sections from this lesion were taken from 
various regions and all showed evidence of invasion. Two of these adenocarcinoma sections are 
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depicted in (b–f). Smaller arrow depicts normal large adenoma of ~5mm that is embedded in 
hyperplastic tissue. (b and c) Bars = 500 µm; invasion into muscularis mucosa, (d and e) bar = 
250 µm; prominent scirrhous response to invading tubules that exhibit differentiated goblet cells 
(long arrow) and signet ring cells (short arrows) (f), bar = 50 µm. 
Loss of Kcnq1 is associated with other pathologies in the GI tract.  
Rectal prolapse was evident in ~10% of ApcMin Kcnq1+/- and ApcMin Kcnq1-/- mice 
and in several cases the rectal prolapses were associated with enlarged rectums 
characterized by diffused severe crypt hyperplasia (Figure 44). In addition, Kcnq1-/- mice 
developed severe gastric hyperplasia that was characterized by mucosal hyperplasia, with 
parietal cells increased in size and crypt dilation with extensive cellular debris (Figure 
45). Hyperplastic adenomas in the pylorus were also present in ApcMin Kcnq1 mutant 
mice. Although ApcMin Kcnq1+/- mice showed an incidence of pyloric tumors of ~30%, 
the phenotype was much stronger in ApcMin Kcnq1-/- mice where the incidence of pyloric 
tumors was ~90% (21/23). Furthermore, in ApcMin Kcnq1-/- mice pyloric tumor 
multiplicity was much larger, with some mice developing as many as a dozen tumors. No 
pyloric tumors were observed in ApcMin Kcnq1+/+ mice. Finally, roughly one-third of 
ApcMin Kcnq1-/- mice developed grossly and severely enlarged (~2- to 3-fold) pancreases, 
characterized by extra lobes. Histopathology of a matched pair of samples indicated that 
zymogen granules were less eosinophilic and less prominent, and that both exocrine cells 
and islets were smaller (Figure 46). 
Loss of Kcnq1 has a strong effect on gene expression 
We conducted cDNA microarray expression studies using tissue from distal colon 
and the proximal quarter of the small intestine of Apc+/+ Kcnq1+/+ and Apc+/+ Kcnq1-/- 
mice. Overall, more than 400 genes showed a > 1.5-fold change in expression, and > 200 
of these genes also had a P-value of < 0.05 (Tables 18 and 19). Expression of 20 genes 
was confirmed by reverse transcription–polymerase chain reaction (RT–PCR) (Figures 
38 and 39).  
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Figure 38. qRT–PCR gene expression analysis of mouse colon. Samples were analyzed in 
triplicate and normalized to 18S ribosomal RNA. Data are presented as the mean fold change ± 
s.d. Each bar represents the mean and s.d. of multiple experiments that measured fold differences 
in the mRNA expression of whole colon tissue isolated from adult (~100 days), littermate and 
gendermatched pairs of Apc+/+ Kcnq1+/+ and Kcnq1-/- mice. RNA was isolated from 1 cm sections 
from the same region of distal colon. At least two matched pairs of mRNAs were tested for each 
gene with most genes tested in at least three matched pairs of mRNAs. To be included in this 
figure, genes showed a mean fold difference of at least 1.5. In all cases, the direction in changes 
in gene expression confirmed microarray data. *P<0.05. 
 
  165 
 
Figure 39. qRT–PCR gene expression analysis of mouse proximal small intestine. 
Each gene sample was run in triplicate and gene expression was normalized to the expression of 18S. Data 
are presented as the mean fold change ± s.d. Each bar represents the mean and s.d. of multiple experiments 
that measured fold differences in the mRNA expression in proximal small intestine tissue isolated from 
adult (~100 days), littermate and gendermatched pairs of Apc+/+ Kcnq1+/+ and Kcnq1-/- mice. mRNAs were 
isolated from 1 cm sections of proximal small intestine from the same region for all mice. At least two 
matched pairs of mRNAs were tested for each gene with most genes tested in at least three matched pairs of 
mRNAs. To be included in this figure, genes showed a mean fold difference of at least 1.5. In all cases, the 
direction of changes in gene expression confirmed microarray data. *P<0.05. 
Target genes were clustered into several functional groups: innate immune 
response/goblet and Paneth cell function (Ang4, Retnlb, Clps, Pnliprp2, Clca3, Muc2, 
Reg3a, Reg3b, Reg3g, Car1), ion channels (Trpv6, Slc12a8, Slc30a10, Aqp7, Aqp1, 
Aqp8, Aqp4, Clca3, Clca6), mucins (Muc2, Muc13, Muc4, Muc3), growth regulatory 
signaling pathways (Areg, Egr1, Fos, Ccdn1), cancer cell migration (Mmp9, Mmp15, 
S100a14, Mt1), apoptosis (Casp14, Casp2, Bcl6) inflammation, mediated by mechanisms 
such as detoxification and stress responses (Cyp2c55, Gstk1, Sirt1, Sirt3, Aldh1a1, 
Aldh1b1, Aldh2, Mt1, Gstm2), the adaptive immune response and intestinal stem cell-
  166 
related genes (Clca4, Aqp4, Aldh1a1, Olfm4), consistent with a role for Kcnq1 in the 
intestinal stem cell compartment (Munoz et al. 2012). Interestingly, while loss of Kcnq1 
showed a strong effect on colon secretory cell genes, there was no change in colon tissues 
in the secretory cell populations or cell proliferation (Figure 47).  
Kcnq1, Cftr and Muc2 share common genetic pathways in the GI tract  
Ingenuity Pathway Analysis (IPA) identified significant networks and functional 
groups altered in Kcnq1 KO mice (see Figures 48A and B, and Table 20 (colon); and 
Figure 49 and Table 21 (proximal small intestine). In particular, IPA analysis identified 
Cftr as a top upstream regulator of Kcnq1 KO dysregulated genes, indicating that genes 
differentially expressed in the Kcnq1 KO mice overlap with targets of Cftr (overlap P-
value of 5.81E-13, activation Z-score -2.722). Furthermore, the Cftr network is predicted 
to be downregulated in Kcnq1 KO small intestine, suggesting that Kcnq1 may be 
necessary for some aspects of Cftr function. 
To identify common pathways and genes disrupted by Kcnq1 and Cftr 
deficiencies, we used Gene Set Enrichment Analysis (GSEA). The entire ranked 
expression data set from the Kcnq1 KO proximal small intestine array was compared 
with gene sets compiled from a microarray analysis of gene expression in the small 
intestine of Cftr KO mice (Norkina et al. 2004). Cftr gene sets consisted of all genes up- 
or downregulated by twofold in the Cftr KO mouse. GSEA revealed significant 
correlation, with overlap of gene identity and direction of regulation (Figure 40 and Table 
20; normalized enrichment score (NES) for Cftr KO upregulated genes 1.97, P < 0.001; 
NES for Cftr KO downregulated genes -1.92, P < 0.001). These shared targets included a 
large subset of genes involved in lipid metabolism and, in particular, downregulation of 
genes involved in lipid oxidation. In support of the significance of this overlap, IPA 
analyses of Kcnq1 KO and Cftr KO mice each identified lipid metabolism as a major 
functional category, with oxidation of lipids as the subcategory showing the most 
significant down regulation (Kcnq1, P-value 9.78E-06, activation Z-score, -2.26; Cftr, P-
value 9.37E-09, Z-score, -3.62). Common targets included upregulation of Idi1, involved 
in cholesterol synthesis, and downregulation of Hsd174b and Acaa1b, both involved in 
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fatty acid beta oxidation. Inhibition of fatty acid oxidation is associated with a switch to 
lipogenesis and this switch is characteristic of metabolic remodeling that commonly 
occurs during oncogenesis (DeBerardinis et al. 2008). Also, fatty acid metabolism has 
recently been shown to have a key role in stem cell maintenance with lipogenesis 
associated with more highly proliferating stem cells (Knobloch et al. 2013). Thus, altered 
lipid metabolism may contribute to the development of CRC in Kcnq1 and Cftr KO mice. 
A second group of genes dysregulated in both Kcnq1 KO mice and Cftr KO mice is 
involved in inflammation. Because the intestinal epithelium is constantly exposed to flora 
and foreign substances, it must maintain protective and repair mechanisms. Disruption of 
these protective or homeostatic processes can result in inflammatory changes, which in 
turn are associated with inflammatory bowel disease and increased risk of CRC (Duerkop 
et al. 2009). Genes involved in inflammation are dysregulated in both Kcnq1 KO mice 
and Cftr KO mice. These include upregulation of factors normally produced by intestinal 
epithelial cells to maintain immune homeostasis, including Il7 (Shalapour et al. 2010), 
Reg3g30 and Pglryp1 (Vaishnava et al. 2011, Dziarski et al. 2010). In addition, a number 
of protective genes are downregulated including those involved in detoxification, Gstt1, 
Cyp3a11, Cyp2b10, and others involved in protective signaling, such as Sema7a, which 
promotes Il10 signaling (Kang et al. 2012), and Ace2, which protects against 
inflammation-induced epithelial damage (Hashimoto et al. 2012). Further evidence of 
overlap between KCNQ1 and CFTR was provided by analyzing RNA Seq data from 20 
CRC liver metastases samples for concordance between expression levels of each gene. 
Using Pearson’s correlation analysis of FPKM (fragments per kilobase pair of exon 
model per million fragments mapped) values in the 20 samples, it was found that KCNQ1 
and CFTR were significantly coexpressed, despite up to a 10-fold sample-to-sample 
FPKM variability for each gene (see Figures 40A and B). Finally, both KCNQ1 and 
CFTR are regulated downstream of the serine threonine kinase gene SGK1, which is 
activated by factors including insulin, via the PI3K pathway, under conditions of osmotic 
stress (Lang et al. 2013). SGK1 levels in turn appear to be influenced by the activity of 
both KCNQ1 and CFTR, as Sgk1 expression was upregulated by more than twofold in 
Kcnq1 KO colon (Table 20) and was also upregulated by > 1.6-fold in Cftr KO colon 
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(BLN Than, personal communication). Of further interest, Sgk1 expression levels were 
downregulated by 1.5-fold in the proximal small intestine of Kcnq1 KO mice and 
downregulated by 5.5-fold in the small intestine of Cftr KO mice (Norkina et al. 2004).  
 
 
Figure 40. Results of GSEA showing enrichment scores (ES) of Cftr and Muc2 gene sets 
with respect to the ranked Kcnq1 expression data set. Shown are enrichment plots for gene 
sets consisting of (a) genes upregulated in the small intestine of Cftr KO mice (Norkina et al. 
2004); (b) genes downregulated in the small intestine of Cftr KO mice (Norkina et al. 2004); and 
(c) genes downregulated in the small intestine of Muc2 KO mice (Yang et al. 2008); (d) NES and 
nominal P-value (nom. P-value) are shown for each comparison.  
CFTR export of Cl- and HCO3- maintains extracellular H2O homeostasis, which 
in turn is necessary for hydration and function of the protective lumenal mucin layer (De 
Lisle et al., 2011). Another gene directly involved in maintenance of the mucin layer is 
MUC2, which encodes MUCIN2, one of the major glycoproteins making up this layer. 
As with Kcnq1 and Cftr, Muc2 deficiency is implicated in CRC (Yang et al., 2008). To 
test if common pathways were disrupted by loss of Kcnq1 and Muc2, we compared gene 
expression changes in the Kcnq1 KO mouse with those reported for Muc2 KO mice 
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(Yang et al., 2008). GSEA identified significant overlap in gene expression, with genes 
downregulated in Muc2 KO mice enriched in genes downregulated in Kcnq1 KO mice 
(Figure 40 and Table 22, NES -1.80, P < 0.001). This group included a number of genes 
involved in detoxification, including cytochrome oxidase P450 enzymes and several 
glutathione S-transferases, Gsta2, Gstm2, Gstm4, Gstm6 and Gstt1. Moreover, in a 
separate study (Burger-van Paassen et al., 2012), deficiency for Muc2 in the mouse 
intestine resulted in significant increases in the innate immune responders Reg3g and 
Reg3b, matching our findings in Kcnq1 KO mice. Finally, we found that Areg, an 
epidermal growth factor receptor pathway gene that was upregulated in both the colon 
and proximal small intestine of Kcnq1 KO mice, was also upregulated by >10-fold in the 
colon of Muc2 KO mice (RTC and RJAF, unpublished microarray results) and in the 
colon of Cftr KO mice (BLNT, manuscript in preparation) (see Table 23). 
Loss of Kcnq1 promotes colon organoid development. 
 To investigate a role for Kcnq1 in the intestinal stem cell compartment, we 
created intestinal organoids from the colons of a group of Apc+/+ Kcnq1+/+ and Kcnq1-/- 
age- and gendermatched littermate mice. At days 2–5, organoid growth was monitored 
and organoid number counted on day 5. Loss of Kcnq1 increased the number of colon 
organoids by greater than threefold, confirming a potential regulatory effect of Kcnq1 on 
the intestinal stem cell compartment (Munoz et al., 2012) (Figure 41).  
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Figure 41. Colon organoids. Colon organoids were created from 500 crypt bottoms and plated in 
triplicate in 24-well plates. Crypt bottoms were isolated on separate days from 5 of each, age-, 
gender- and littermate-matched Apc+/+ Kcnq1+/+ and Apc+/+ Kcnq1-/- mice (one matched pair per 
day). Organoids were examined daily and counted at 5 days post plating. *P < 0.05. 
KCNQ1 expression is associated with good prognosis in late-stage human CRC.   
On the basis of our finding that deficiency for Kcnq1 drove the progression of 
intestinal tumors in mice, we tested the hypothesis that low levels of KCNQ1 in human 
CRC would correlate with a worse prognosis. To this end, we evaluated KCNQ1 protein 
expression in tissue microarrays containing samples from more than 500 stage IV CRC 
patients with liver metastases who had undergone hepatic resection. 
Immunohistochemical staining for KCNQ1 expression was evaluated for 311 patients. 
Membranes of neoplastic CRC liver metastasis (CRCLM) epithelium were scored for 
KCNQ1 staining intensity (Figure 42). We found that high KCNQ1 expression was 
related to improved overall survival (OS) (hazard rate ratio (HRR) 0.64; 95% confidence 
interval (CI): 0.45–0.92; P = 0.02). Median OS for patients with high KCNQ1 expression 
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was 60 months, whereas patients with low KCNQ1 levels had a median OS of 37 months, 
indicating a significant 23-month difference in survival (Figure 43).  
 
 
Figure 42. Representative human samples showing the expression pattern of KCNQ1 in the 
epithelium of CRCLM. Staining intensity was evaluated as (a) high or (b) low. Scale bars are 50 
µm. 
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Figure 43. Kaplan–Meier graph depicting OS in months, stratified by intensity of KCNQ1 
expression in CRCLMs. P-values were calculated using the log-rank statistic. 
Next, we performed a multivariate analysis to evaluate whether the prognostic 
value of KCNQ1 protein expression was independent of established prognostic 
clinicopathological variables, that is, primary tumor-to-liver metastasis interval > 12 
months, number of liver metastases > 1, maximal tumor diameter > 5.0 cm, lymph node 
positivity at the time of diagnosis of the primary tumor and serum carcinoembryonic 
level > 200 ng/ml. Upon stepwise backward Cox regression analysis with OS as the 
dependent variable, KCNQ1 expression (HRR, 0.49; 95%: 0.32–0.77; P = 0.002), lymph 
node positivity at the time of diagnosis of the primary tumor (HRR, 1.64; 95% CI: 1.08–
2.48; P = 0.02) and maximal tumor diameter > 5.0 cm (HRR, 1.44; 95% CI: 0.96–2.16; P 
= 0.08) were retained as prognostic variables. Note that the association between maximal 
tumor diameter and survival was not significant; however, the variable was retained in 
the model because we only excluded variables when P > 0.1. 
DISCUSSION 
We first identified Kcnq1 as a potential CRC driver gene in our forward genetic 
screens for GI tract cancer genes. Here, we have followed up with studies using a 
transgenic mouse model and analysis of human CRC tissues that support a tumor 
suppressor role for Kcnq1. We demonstrated the tumor suppressor function of Kcnq1 in 
ApcMin mice, where both hetero- and homozygous inactivation of Kcnq1 resulted in 
significantly more adenomas and, importantly, progression to adenocarcinoma. This was 
especially evident in the proximal small intestine. Furthermore, Kcnq1 deficiency caused 
rectal adenomatous hyperplasia, pyloric tumorigenesis, gastric hyperplasia and pancreatic 
abnormalities. Notably, in human CRC that had metastasized to the liver, low KCNQ1 
protein expression correlated with significantly lower OS, by almost 2 years, compared to 
patients with high KCNQ1 expression. These findings suggest that KCNQ1 expression 
could be a biomarker to help determine eligibility for hepatic resection in CRC patients 
with liver metastases. In addition, newly developed small molecules that enhance K+ ion 
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channel activity (Xiong et al., 2008, Wulff et al., 2009) could potentially be used to treat 
CRC patients with low levels of KCNQ1. 
By what mechanism does loss of KCNQ1 influence cancer processes in the GI 
tract? A promising model is via KCNQ1’s functional interactions with CFTR and MUC2. 
In the healthy intestinal epithelium, KCNQ1 is physiologically linked to the CFTR ion 
channel, with basolateral export of K+ ions by KCNQ1 providing the electrochemical 
driving force for apical export of Cl- ions by CFTR (Preston et al., 2010). Cftr was 
identified as a CRC driver gene in two Sleeping Beauty GI tract forward genetic screens 
(Starr et al., 2009, March et al., 2011), and individuals with cystic fibrosis, caused by 
inactivating mutations in CFTR, are at increased risk for GI cancers including CRC 
(Maisonneuve et al., 2003).  To test if common pathways and genes are disrupted by loss 
of Kcnq1 and Cftr activity, we used GSEA to compare gene sets consisting of genes 
reported to be up- or downregulated in the small intestine of Cftr KO mice to the entire 
ranked Kcnq1 expression data set and found significant correlation (Figure 40). Genes 
upregulated in common include several involved in immune responses and inflammation, 
whereas genes downregulated in common include a subset involved in fatty acid 
metabolism, in particular lipid oxidation. Further evidence of overlap between KCNQ1 
and CFTR was the finding of concordance between KCNQ1 and CFTR expression in 
RNA Seq analysis of 20 CRC liver metastases (Figures 50A and B).  
As with Kcnq1 and Cftr, Muc2 deficiency is implicated in CRC (Yang et al., 
2008). To test if common pathways were disrupted by loss of Kcnq1 and Muc2, we 
compared gene expression changes in the Kcnq1 KO mice with those reported for Muc2 
KO mice. GSEA identified significant overlap in gene expression with genes 
downregulated in Muc2 KO mice enriched in genes downregulated in Kcnq1 KO mice 
(Figure 40). This group included a number of genes involved in detoxification including 
cytochrome oxidase P450 enzymes and several glutathione S transferases, and genes 
involved inflammation. 
These results point to common pathways (inflammation, lipid metabolism, 
detoxification and stress responses) disrupted by Kcnq1, Cftr and Muc2 deficiencies. 
Therefore, we can hypothesize that KCNQ1, like MUC2 and CFTR, may act through one 
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or more of these pathways in preventing cancer in the GI tract. Moreover, precisely 
defining mechanisms of action for KCNQ1 can lead to its use as a prognostic predictor 
for CRC patients and potential therapeutic target. 
MATERIALS AND METHODS 
Mice 
C57BL/6J mice and C57BL/6J-ApcMin mice were obtained from the Jackson Laboratory 
(Bar Harbor, ME, USA). C57BL/6-Kncq1 knockout mice were obtained from Dr Karl 
Pfeifer (NIH, Bethesda, MD, USA) (Casimiro et al., 2001). Details of mouse husbandry 
are as described previously (Fijneman et al., 2012). The genotype of the Apc and Kcnq1 
loci were determined by PCR assays as described previously (Casimiro et al., 2001, 
Fijneman et al., 2012).  
Tumor analysis 
Scoring of GI tumor tissues was performed as described previously (Fijneman et al., 
2012). Two-sided P-values for tumor counts were determined by use of the Wilcoxon 
rank-sum test comparing gender- and age-matched classes produced in the same genetic 
crosses. 
Histopathology 
Histopathological analysis of tumors and adjoining normal tissue was performed on 
formalin-fixed paraffin-embedded tissues by an ACVPcertifie veterinary pathologist 
(MGO0S) from the University of Minnesota Masonic Cancer Comparative Pathology 
Shared Resources facility using protocols as described previously (Fijneman et al., 2012). 
Organoid culture 
Gender- and age-matched littermate C57Bl/6J Kcnq1+/+ and Kcnq1-/- mice were killed 
between 8 and 12 weeks of age. Colons were removed, cut open and washed in cold 
phosphate-buffered saline. Colon organoids were then cultured using the protocol of Sato 
et al. (Sato et al., 2013) following the plating of 500 crypt bottoms per well in triplicate 
per sample. Two-sample t-test was used to determine statistical significance. 
RNA processing for Illumina bead arrays 
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Mouse intestinal tissues were removed, opened longitudinally and rinsed in phosphate-
buffered saline. Colon tissues were processed in RNAlater (Qiagen, Valencia, CA, USA) 
as per the manufacturer’s protocol. The distal quarter of the proximal quarter of the small 
intestine was flash frozen in liquid nitrogen. The tissue was then transferred from liquid 
nitrogen to precooled RNALaterIce (Ambion, Foster City, CA, USA) at -80oC for 30 
min, and later transferred to -20oC for at least 48h. Immediately before RNA isolation, 
tissue in either RNALater or RNALaterIce was placed in 2–4 ml of RLT (guanidine 
thiocyanate buffer)/14.3 M b-mercaptoethanol buffer. The tissue was then homogenized 
using an IKA Ultra-Turrax T25 digital homogenizer (Fisher Scientific, Waltham, MA, 
USA). RNA isolation was then conducted using an RNeasy Mini Kit with an additional 
DNAse Digestion step (Qiagen). RNA sample concentrations were measured using a 
Nanodrop-1000 Spectrophotometer (Thermo Scientific, Rochester, NY, USA). RNA was 
stored at -80oC. 
Illumina bead microarray and data analysis 
RNA labeling, microarray hybridization and scanning were performed at the University 
of Minnesota BioMedical Genomics Center using Illumina MouseWG-6 v.2.0 Expression 
BeadChips (Illumina, San Diego, CA, USA), according to the manufacturer’s 
instructions. Differential expression of genes was quantified by the moderated t-statistic. 
Data were analyzed using GeneData Expressionist Software (GeneData Inc., San 
Francisco, CA, USA); genes that showed statistically significant differences in expression 
between groups were determined using the two-group t-test and analysis of variance. 
Gene expression data has been submitted to the Gene Expression Omnibus, and accession 
number is pending. 
qRT–PCR 
Quantitative RT–PCR was performed as described previously (Starr et al., 2011). 
Significant differences in expression between groups were determined using the two-
group t-test. 
List of primers used: 
All primers were designed using Primer-BLAST (National Center for Biotechnology 
Information) and obtained from Integrated DNA Technologies. 
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Mouse primers 
Ang4: forward, 5’-AGCACACAGCTAGACTCGTCCC-3’; reverse, 5’-ACCAGAC 
CCAGCACGAAGACC-3’; Areg: forward, 5’-GGTCTTAGGCTCAGGCCATTA-3’; 
reverse, 5’-CGCTTATGGTGGAAACCTCTC-3’; Cd55: forward, 5’-GGGGCTATG 
ATCCGTGGGCG-3’; reverse, 5’-TGCCCAAGATTGGCCTGGCA-3’; Clca3: forward, 
5’-CCACACCAAAACGAGAAGGC-3’; reverse, 5’-TGCTTCGGAGATTG 
CATCGT-3’; Clca4: forward, 5’-ACATGGACCGGCCTTTCTAC-3’; reverse, 5’-CG 
ACATCTCCTCGACACACA-3’; Clca6: forward, 5’-GTTCAATCAGAAAAGGCTT 
CCA-3’; reverse, 5’-ACTTCCCAAGTGCTTCTGTAATTG-3’; Gstk1: forward, 
5’-TGGATGCGTGTATGGTCTCG-3’; reverse, 5’-CAGAAAGTGTTGGGCTTGCG- 
3’; Egr1: forward, 5’-CCTCAAGGGGAGCCGAGCG-3’; reverse, 5’-AACCGAGT 
CGTTTGGCTGGG-3’; Fos: forward, 5’-CGGGTTTCAACGCCGACTA-3’; reverse, 
5’-TTGGCACTAGAGACGGACAGA-3’; Id1: forward, 5’-CTCAGCACCCTGAAC 
GGCGA-3’; reverse, 5’-CATCTGGTCCCTCAGTGCGCC-3’; Muc2: forward, 
5’-AACGATGCCTACACCAAGGTC-3’; reverse, 5’-ACTGAACTGTATGCCTTCC 
TCA-3’; Muc3: forward, 5’-CACTACCACCCCAGCACCTA-3’; reverse, 5’-GCCT 
CCATTCTCGCAGTTGA-3’; Muc13: forward, 5’-TTTGGCTACAGCGGGAT 
GAA-3’; reverse, 5’-TCTTTGACCTCGCAGAGACG-3’; Mt1: forward, 5’-AAAC 
CCTTTGCGCCCGGACT-3’; reverse, 5’-AGCAGGAGCAGTTGGGGTCC-3’; Pim3: 
forward, 5’-GCTCATCGACTTCGGCTCGGG-3’; reverse, 5’-AGTGGCAGACCGC 
CCGTGATA-3’; and Retnlb: forward, 5’-AAGCCTACACTGTGTTTCCTTTT-3’; 
reverse, 5’-GCTTCCTTGATCCTTTGATCCAC-3’. 
Pathway analysis 
GSEA. GSEA v.2.0, http://www.broad.mit.edu/gsea/ (Subramanian et al., 2005, Mootha 
et al., 2003). Gene sets analyzed were obtained from published reports and the National 
Center for Biotechnology Information Gene Expression Omnibus database. GSEA 
compared the entire ranked Kcnq1 proximal small intestine KO expression data set to 
Cftr KO25 (twofold change in expression, t  ≤  0.05) and Muc2 KO36 (1.5-fold change in 
the duodenum at 3 or 6 months of age). 
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IPA. Genes showing a 1.5-fold change in expression in whole colon (N = 89) and 
proximal small intestine (N = 345) microarrays were analyzed using IPA (IPA Ingenuity 
Systems). 
Tissue microarrays 
Patient study population. Patients who underwent liver resection with curative intent, 
sometimes with addition of RFA, in one of the seven Dutch hospitals affiliated with the 
DeCoDe PET group were identified by crossreferencing surgery and pathology databases 
using Dutch MeSH terms for ‘colon’, ‘rectum’, ‘carcinoma’, ‘adenocarcinoma’, 
‘colorectal neoplasms’, ‘liver’, ‘neoplasm metastasis’ and ‘(hemi)hepatectomy’. 
Clinicopathological data from 507 patients that were operated on between 1990 and 2010 
were extracted from these databases (see Supplementary Table 22; a manuscript 
describing the patient population in more detail is in preparation). Formalin-fixed 
paraffin-embedded tissue specimens were collected from one CRCLM sample and an 
adjacent control liver sample. Only specimens of patients with histologically confirmed 
CRCLM were included in the study, whereas tissue samples of patients with multiple 
primary tumors were excluded. Collection, storage and use of clinicopathological data 
and tissue specimens were performed in compliance with the ‘Code for Proper Secondary 
Use of Human Tissue in The Netherlands’, and approved in protocol 2011-03 of the 
Department of Pathology (Stichting FMWV Rotterdam 2011).  
Tissue microarrays. A total of 21 tissue microarrays (TMAs) were generated as 
described previously (Simon et al., 2004, Belt et al., 2011). In brief, three tissue core 
biopsies of 0.6mm in diameter were punched from morphologically representative areas 
of all formalin-fixed paraffin-embedded donor blocks, and transferred into TMA 
recipient paraffin blocks using the 3DHISTECH TMA Master (v.1.14, 3DHISTECH Ltd, 
Budapest, Hungary). 
Immunohistochemistry. Four-micrometer sections of TMAs were mounted on glass 
slides, deparaffinized by xylene and rehydrated with a decreasing alcohol series. Staining 
for KCNQ1 was performed upon antigen retrieval by microwave heating in citric acid 
(10mM, pH 6.0) and endogenous peroxidase neutralization in 0.3% hydrogen peroxide in 
methanol for 25 min. The primary rabbit polyclonal antibody directed against human 
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KCNQ1 (sc-20816; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was 
incubated overnight at a 1:200 dilution at 4oC, followed by incubation with anti-rabbit 
secondary antibodies for 30 min at room temperature (Envision Plus; Dako, Heverlee, 
Belgium). Secondary antibodies were visualized by liquid diaminobenzidine substrate 
chromogen system. Slides were counterstained with Mayer’s hematoxylin. Staining of 
formalin-fixed paraffin-embedded colon tissue was used as a positive control, and 
incubation without primary antibody as a negative control. 
Evaluation of KCNQ1 protein expression. Immunohistochemical stainings were 
digitally captured using the Mirax slide scanner system equipped with a x20 objective 
with a numerical aperture of 0.75 (Carl Zeiss BV, Sliedrecht, The Netherlands) and a 
Sony DFW-X710 Fire Wire 1/3 in-type progressive SCAN IT CCD (pixel size 4.65 x 
4.65 µm2). Actual scan resolution at x 20 was 0.23 µm. Computer monitors were 
calibrated using Spyder2PRO software (v.1.0–16; Pantone Colorvision, Regensdorf, 
Switzerland). TMA core biopsies were scored for intensity of KCNQ1 protein expression 
on membranes of neoplastic epithelial cells (categories negative, weak, moderate, strong) 
using dedicated TMA scoring software (v.1.14.25.1; 3DHISTECH Ltd). For facilitating 
scoring, a chart with visual analogue scales of staining patterns was used. Intensity scores 
were dichotomized into low and high KCNQ1 intensities using receiver operating 
characteristic curve analysis (Zlobec et al., 2007).  
Statistical analysis of TMAs. OS was defined as the time in months after surgery until 
death in a follow-up period of 10 years. Patients were excluded from analysis if OS <  2 
months (n = 72), if OS or survival status were unknown (n = 36) or if tissue cores could 
not be evaluated for technical reasons (n = 88). The relation between KCNQ1 expression 
and survival was studied using Kaplan–Meier curves and tested using log-rank statistics. 
HRR was calculated using Cox regression. Multivariate analysis was performed by 
inclusion of KCNQ1 protein expression in a proportional hazards (Cox regression) 
analysis together with established prognostic clinicopathological variables combined in 
the clinical risk score as defined by Fong et al. (Fong et al., 1999) primary tumor-to-liver 
metastasis interval > 12 months, number of liver metastases >  1, maximal tumor diameter >  5.0 cm, lymph node positivity at the time of diagnosis of the primary tumor, serum 
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carcinoembryonic level >  200 ng/ml. Stepwise backward regression was used to exclude 
variables from the model when P > 0.1. All statistical tests were two-sided and executed 
using IBM SPSS Statistics 20.0 software (SPSS Inc., Chicago, IL, USA). P-values <  0.05 
were considered significant. 
Supplemental Information: 
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Figure 44. Rectal Adenomatous Hyperplasia. Panel A. Gross image of rectum. Lines represent 
locations of cross sections taken for histopathological analysis. Panels B, C & D, three cross 
sections of the same tissue showing diffuse crypt hyperplasia. The incidence of abnormal rectums 
was 10 out of 102 ApcMin Kcnq1+/- (79) and ApcMin Kcnq1-/- (23) mice and 0 out of 58 for ApcMin 
Kcnq1+/+ mice, a difference that is highly significant (p = 0.009, Fisher’s Exact Test). 
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Figure 45. Stomach of Apc+/+ Kcnq1-/- mice. Panels A & B, 10X; Panel C, 20X. Severe gastric 
hyperplasia that was characterized by mucosal hyperplasia, with parietal cells increased in size 
and crypt dilation with debris present. Hyperplastic adenomas developed in the pylorus (not 
shown). The incidence of pyloric tumors was 21 out of 23 ApcMin Kcnq1-/- mice and 0 out of 58 
ApcMin Kcnq1+/+ mice, a difference that is highly significant (p < 2.2e-16, Fisher’s Exact Test). 
 
 
 
Figure 46. Pancreas. 20X. Kcnq1 Wildtype, left panels; ApcMin Kcnq1-/- right panels. 
Zymogen granules were less eosinophilic and less prominent. Exocrine cells seemed to be smaller 
and islets appeared to be less prominent (arrows). The incidence of enlarged pancreases was 8 out 
of 23 ApcMin Kcnq1-/- mice and 0 out of 58 in ApcMin Kcnq1+/+ mice, a difference that was high 
significant (p = 1.52e-05, Fisher’s Exact Test). The maximum diameter of a total of 56 pancreatic 
islets was measured, 28 from ApcMin Kcnq1-/- mice and 28 from ApcMin Kcnq1+/+ mice. The mean 
diameter of islets from ApcMin Kcnq1-/- mice was 100 microns and the mean diameter of islets 
from ApcMin Kcnq1+/+ mice was 118 microns. While the difference in means was not significant, 
when the 56 islet diameters were ranked in size the top 7 islets were all from the Kcnq1+/+ group 
(246, 242, 212, 210, 199, 184, and 181 microns), while the largest islet from the Kcnq1-/- group 
was 173 microns. 
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Figure 47. Immunohistochemistry for cellular markers in mouse colon. Age and gender 
matched Kcnq1+/+ and Kcnq1-/- adult littermate mice were sacrificed and FFPE tissues processed 
as previously described (Fijneman et al., 2012). Multiple sections were examined by 
immunostaining for the goblet cell markers Mucin2 and alcian blue (for detection of acidic 
mucopolysaccharides), and the proliferation marker Ki67. No significant differences were 
detected between genotypes. Representative colon section is shown above. Mucin2: Panel A 
(Kcnq1+/+), Panel B (Kcnq1-/-); Alcian Blue: Panel C (Kcnq1+/+), Panel D (Kcnq1-/-); Ki67: Panel 
E (Kcnq1+/+), Panel F (Kcnq1-/-).  Methods. 4 µm formalin-fixed, paraffin-embedded sections of 
small intestine were deparaffinized and rehydrated, followed by antigen retrieval using 10mM 
Citrate buffer pH 6.0 in a steamer. A rabbit polyclonal antibody was used for Mucin 2, Catalog 
number: SC15334, (Santa Cruz Biotechnology). A rabbit monoclonal antibody was used for Ki-
67, Catalog number: CRM325, clone SP6, (Biocare Medical). Detection was achieved using a 
rabbit EnVision™+ Kit (catalog K4011, Dako) with DAB as chromogen. Alcian blue staining 
was performed using a standard protocol. 
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Figure 48. Colon Microarray - Top Functional Networks Identified by IPA 
 
 
 
Figure 49. Proximal Small Intestine Microarray - Top Gene Networks Identified by IPA. 
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Figure 50. Concordance between expression of KCNQ1 and CFTR in colorectal cancer liver 
metastases. Twenty stage IV CRC liver metastases were analyzed by RNA seq, followed by 
Pearson’s Correlation analysis to determine concordance between the expression levels of 
KCNQ1 and CFTR. Panel A. Using all twenty samples. Panel B. removal of two top and bottom 
outliers, N = 18. 
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RNA Seq analysis. Twenty fresh frozen stage IV CRC LM samples were obtained from 
the University of Minnesota BioNet Tissue Procurement facility. The samples were from 
9 males and 11 females, average age 64 years. RNA was isolated using RNA LaterICE 
(Invitrogen) and Qiagen RNAEasy kits, and quantified using a Nanodrop-1000 
Spectrophotometer (Thermo Scientific), and quantity and quality were confirmed using   
The extracted RNA-samples were sent to the University of Minnesota Genomics Center 
(UMGC) for sequencing.  All raw reads that passed the CASAVA 1.8 P/F filter were 
directly deposited at the Minnesota Supercomputing Institute, where the data were 
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analyzed.   Sequence quality was assessed via fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Since the raw sequence 
reads were of sufficient quality, no data trimming or filtering was necessary.  Hence, the 
raw paired-end reads were mapped to human genome (hg19 assembly) using Tophat 
2.0.6 with the iGenomes reference (UCSC human hg19 annotation, downloaded from 
http://cufflinks.cbcb.umd.edu/igenomes.html March 9, 2012). Final mapping percentages 
of the 20 samples range from 92% to 94%.  The mapped samples were then analyzed via 
Cuffdiff (default parameters using the iGenomes UCSC hg19 GTF file previously 
mentioned) to quantify the expression level of each known gene in units of FPKM 
(Fragment mapped per kilobase of exons per million mapped reads).  Additional 
statistical test of Pearson's correlation from R/Bioconductor was applied to selected gene 
pairs to check for expression concordance. 
 
Table 18. List of top known genes 1.5 fold (A) up-regulated and (B) down-regulated in 
Kcnq1 -/- mouse colons, represented as fold change vs control Kcnq1+/+. The asterisk in the Fold 
Change column indicates a P value of 0.05 or less. 
Table 19. List of top known genes 1.5 fold (A) up-regulated and (B) down-regulated in 
Kcnq1-/- mouse small intestines, represented as fold change vs control Kcnq1+/+. The asterisk in 
the Fold Change column indicates a P value of 0.05 or less. 
Table 20. IPA Analysis of Colon Microarray.  
Table 21. IPA Analysis of Proximal Small Intestine Microarray. 
Table 22. Core genes enriched in Kcnq1 KO. 
Table 23.  Expression of Areg. 
Table 18-23 can be found in the supplemental tables. Please see the weblink: 
http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2013350a.html 
 
 
 
 
 
 
  187 
CONFLICT OF INTEREST 
The authors declare no conflict of interest. 
 
ACKNOWLEDGEMENTS 
We thank Dr Karl Pfeifer at the NIH for generously providing Kcnq1 mutant mice and 
reviewing the manuscript. Research was supported by a grant to RC and DL (NCI R01 
CA134759-01A1) and to JG and RF (Center for Translational Molecular Medicine, 
DeCoDe project grant 03O-101) and to TKS (NCI R00 4R00CA151672-02). 
 
Personal Contribution. Lei Zhao isolated RNA samples for Illumina RNA Sequencing 
and analyzed data. 
 
 
 
  188 
APPENDIX 3 
The roles of CNOT1 and CNOT2 in regulating mRNA 
levels of p27kip and CDX2 
Introduction 
Sleeping Beauty (SB) transposon-based screens have identified Cnot1 and Cnot2, 
two subunits of the CNOT complex, as candidate CRC genes (Starr et al., 2009). (See 
introduction for discussion of CNOT1). The TCGA project identified 48 somatic 
mutations in CNOT2 in different types of cancers and 3 of them were discovered in CRC. 
In addition, 47 somatic mutations in CNOT2 were documented in the COSMIC database 
and 76% of them were missense mutations. The presence of somatic DNA mutations in 
CNOT2 provided evidence for a correlation between genetic alterations in CNOT2 and 
CRC. The biological importance of CNOT2 has been reported in several model animals. 
It is critical for yeast survival (Russell et al., 2002). Apoptosis may be occurring in 
CNOT2-depleted C. elegans and D. melanogaster during early embryonic stages (Frolov 
et al., 1998; Sonnichsen et al., 2005). In Hela cells CNOT2 depletion caused apoptotic 
cell death in a caspase-dependent manner (Ito et al., 2011). As for the molecular function 
of CNOT2, accumulating results suggest that it plays a role in regulation of deadenylation 
as a component of the CNOT deadenylase complex and/or in transcriptional regulation 
(Zwartjes et al., 2004). CNOT2 plays an important role in maintaining the integrity of the 
CNOT complex, supported by the fact that CNOT2 mutations affect the structural 
integrity of the complex in yeast (Russell et al., 2002). Mammalian CNOT2 depletion 
also destabilized the CNOT complex and impaired its deadenylase activity. Ito et al 
showed that the disruption of the CNOT complex induced by CNOT2 depletion is 
accompanied by a loss of deadenylase activities (Ito et al., 2011). Furthermore, 
knockdown of CNOT2 inhibits mRNA decay in Drosophila S2 cells (Temme et al. 2004). 
These results suggest that the structural integrity of the complex is apparently important 
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for full deadenylase activity. However, the exact mechanism by which CNOT2 
contributes to the regulation of the deadenylase activity of the CNOT complex remains 
obscure. CNOT2 also acts as a transcriptional repressor of Estrogen Receptor (ER)-
mediated gene expression through direct repression of pol II transcription. The major 
repressive function of CNOT2 is localized in the Not-Box repression domain in the C-
terminus of CNOT2 (Zwartjes et al., 2004). Depletion of deadenylase subunits of the 
CNOT complex was reported to affect cell viability (Ito et al., 2011; Morita et al., 2007), 
suggesting that the deadenylase activity of the CNOT complex is important for regulation 
of cell viability. Thus attenuated deadenylation activity of the CNOT complex may 
contribute to the decreased cell viability caused by CNOT2 depletion.  
Cyclin-dependent kinase inhibitor 1B (CDKN1B, p27Kip) is a well-known cell 
cycle inhibitor which prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 
complexes, and thus arrest cell cycle progression at G1. Cnot6L was shown to contribute 
to the deadenylation and degradation of p27Kip1 mRNA through a 3'UTR ARE-mediated 
mechanism (Morita et al., 2007). The gut-specific homeotic transcription factor caudal 
type homeobox 2 (CDX2) is a crucial regulator of intestinal development and 
homeostasis, which exhibits a tumor suppressor function in CRC (Saandi et al., 2013). 
Cnot1 and Cnot2 silencing was shown to lead to markedly increased expression of Cdx2 
in mouse embryonic stem cells (Zheng et al., 2012). These data suggest that p27Kip1 and 
CDX2 are potential target genes of CNOT1- and CNOT2-mediated deadenylation or 
transcriptional regulation.   
In our study, to investigate the role of CNOT1 and CNOT2 in CRC, we measured 
cell viability following depletion of CNOT1 and CNOT2 in SW480 CRC cells. We then 
studied the role of CNOT1- and CNOT2-mediated deadenylation in regulating p27kip and 
CDX2 mRNA levels and the contribution of these two genes to CNOT1 and CNOT2 
depletion caused cell viability reduction. 
Results 
Depletion of the CNOT Complex Subunits Results in Reduced Cell Viability in 
SW480 Cells 
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As shown in Figure 24 D, depletion of CNOT2 resulted in decreased cell viability 
in SW480 CRC cells, suggesting that CNOT2 may function as an oncogene. In addition, 
cell viability assay revealed that depletion of CNOT6L, CNOT7 and CNOT8 caused 
significant decrease in cell viability (Figure 24 D), suggesting that CNOT1 and CNOT2’s 
effects on cell viability may be mediated by deadenylation activity of these deadenylase 
subunits.  
p27kip and CDX2 mRNA Levels Were Upregulated in SW480 Cells Depleted for 
CNOT1 and CNOT8 
The CNOT deadenylases were reported to mediate deadenylation and subsequent 
degradation of cell cycle inhibitor p27kip and the intestinal differentiation factor CDX2.  
Consistent with published data, we found that p27kip (Figure 51A) and CDX2 (Figure 
51B) mRNA levels were increased by 1.5 and 2.5-fold, respectively, in CNOT1-depleted 
but not changed in CNOT2-depleted cells. To determine which deadenylase subunit 
shares a common phenotype with CNOT1 we examined the effect of their depletion on 
levels of p27kip (Figure 51A) and CDX2 (Figure 51B) mRNA levels. Lack of CNOT8 
caused a 1.5- and 2-fold increase in p27kip and CDX2 mRNA levels, respectively. But 
depletion of other deadenylase subunits did not cause an obvious change in p27kip mRNA 
levels. Interestingly, depletion of CNOT6 and 6L both caused decreased CDX2 mRNA 
levels possibly through indirect mechanisms. These results suggest that CNOT1 and 8 
may works in complexes to regulate the mRNA levels of p27kip and CDX2 through 
deadenylation. 
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A. 
 
B. 
 
Figure 51. p27kip and CDX2 mRNA expression levels in SW480 cells depleted for CNOT 
subunits. SW480 cells were depleted for CNOT1, 2, 6, 6L, 7 and 8, respectively as described 
before. Total RNA was extracted at 48 hours after the second siRNA transfection. mRNA 
expression levels of p27kip (A) and CDX2 (B) were measured by qRT-PCR. Values represent the 
mean ± SD of at least two independent experiments except for CNOT6 (one experiment). 
Statistical significance was determined by a t-test. * = p <0.05. 
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Effects of Depletion for RBPs on Cell Viability and p27kip and CDX2 mRNA Levels  
To test if 3’UTR RNA binding proteins (RBPs) might mediate the phenotype 
shared by CNOT1 and CNOT8 we examined the effect of depletion of several RBPs on 
cell viability and p27kip and CDX2 mRNA levels, including ZFP36, PUM1, PUM2 and 
CELF1. They were knocked down in SW480 cells by transfection of corresponding 
siRNA oligos, which was confirmed by qRT-PCR (Figure 52A). Cell viability was 
reduced in cells depleted for ZFP36, PUM1 and CELF1, but not in cells depleted for 
PUM2 (Figure 52A). mRNA levels of p27kip were increased by 1.35 fold in ZFP36-
depleted cells but not in other cells (Figure 52B). CDX2 mRNA levels were increased by 
1.5 fold in ZFP36 and CELF1-depleted cells but not in other cells (Figure 52C).  
Together, these results suggest that ZFP36 and CELF1 may work with CNOT1 and 8 in 
complexes to regulate cell viability and mRNA levels of p27kip and CDX2 through 
deadenylation.  
A.  
 
B. 
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C. 
 
Figure 52. Cell viability and p27kip and CDX2 mRNA expression levels in SW480 cells 
depleted for RBPs. SW480 cells were depleted for ZFP36, PUM1, PUM2 and CELF1 by siRNA 
transfection as described before. (A) On day 1 after the second transfection SW480 cells were 
plated at 2,500 cells per well in triplicate in 96 well plates. Cell viability was measured by MTT 
assay on day 6 after the second transfection. Relative cell viability represents = absorbance at 595 
nm of cells treated with indicated siRNA/cells treated with non-targeting control. Results 
represent one experiment except for ZFP36 (3 experiments). (B and C) Total RNA was extracted 
48 hours after the second transfection and p27kip (B) and CDX2 (C) mRNA expression levels 
were determined by qRT-PCR. Values represent one experiment except for ZFP36 (mean ± SD of 
3 experiments). Significance of difference was calculated by a t-test. * = p <0.05. 
Depletion of CDX2 Did Not Result in Changes in Cell Viability in SW480 Cells   
To initially investigate whether the decreased cell viability caused by knockdown 
of CNOT1, CNOT8, ZFP36 and CELF1 was due to increased levels of CDX2, we 
depleted CDX2 by transfection of siRNA oligos targeting CDX2 in SW480 cells and 
measured cell viability using the MTT assay. Knockdown of CDX2 was confirmed by 
qRT-PCR (Figure 53A). No obvious difference in cell viability was observed in CDX2 
siRNA transfected cells comparing to control cells (Figure 53B). These results suggest 
that upregulated CDX2 may not be the cause for the reduction in cell viability. However, 
this is the data from only one experiment which was performed in highly malignant 
SW480 cells. Therefore, more assays need to be performed, including overexpression of 
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CDX2 and knocking down CDX2 in normal colon epithelial cell lines, before we can 
draw any conclusions.  
A.                                                                B. 
     
Figure 53. Depletion of CDX2 did not result in changes in cell viability in SW480 cells.  
SW480 cells were depleted for CDX2 by transfection of siRNA oligo targeting CDX2 at 50 nM 
final concentration twice 48 hours apart.  Knockdown of CDX2 was confirmed by qRT-PCR (A) 
and cell viability  (B) was measured by MTT assay. Data represents result of only one 
experiment. Each data point for MTT assay represents the mean ± SD of three replicates in one 
MTT assay. Significance of differences in cell viability on day 6 was determined by one-way 
ANOVA.  
CNOT1 Does Not Regulate p27kip and CDX2 mRNA Levels Through 3’UTR-
Mediated Deadenylation   
To investigate whether CNOT1 regulates p27kip and CDX2 mRNA levels through 
3’UTR-mediated deadenylation we performed a 3’UTR luciferase reporter assay in 
SW480 cells using a Dual-Glo reporter assay system (Promega). The 3’UTR of p27kip 
and CDX2 was cloned downstream of a sequence encoding renilla luciferase in a psi‐
Check2 vector where activity of renilla luciferase is indicative of 3’UTR mediated 
deadenylation. This vector also constitutively encodes the firefly luciferase to normalize 
cell number and transfection efficiency. Results revealed that transfection of CNOT1 
siRNA did not cause a change in luciferase activity of p27kip (Figure. 54A) and CDX2 
(Figure 54B) 3′UTR reporter plasmids compared with cells transfected with control 
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siRNA. This result suggested that CNOT1 might regulate mRNA levels of these two 
genes through mechanisms other than deadenylation. However, the data represent the 
result of only one experiment.  More replicates and more assays need to be done before 
we can draw any conclusions.  
        A.                                                                   B. 
 
Figure 54. CNOT1 does not regulate p27kip and CDX2 mRNA levels through 3’UTR-
mediated deadenylation. A luciferase reporter assay was performed in SW480 cells to 
investigate whether CNOT1 regulates p27kip and CDX2 level through 3’UTR-mediated 
deadenylation. SW480 cells were co-transfected with 50 ng of luciferase reporter plasmid 
containing either p27kip or CDX2 3’UTR together with 50 nM CNOT1 siRNA or control siRNA. 
Firefly and renilla luciferase activity was measured at 48 hours post‐transfection using the Dual-
Glo reporter assay system (Promega). Luciferase activity was analyzed by the ratio of 
renilla/firefly illuminance to normalize cell number and transfection efficiency. The luciferase 
activity of p27kip (A) and CDX2 (B) reporter was not obviously changed in CNOT1 siRNA 
transfected cells comparing to control cells. The data represent the result of only one experiment 
in which each treatment was performed in duplicates. 
Discussion 
Consistent with published studies, knockdown of CNOT1 and CNOT2 in SW480 
CRC cells highly reduced cell viability, suggesting that CNOT1 and 2 may function as an 
oncogene in CRC and that the integrity of the CNOT complex is important in maintaining 
cell viability. It has been shown that the attenuated deadenylase activity of the CNOT 
complex could cause reduced cell viability (Ito et al., 2012; Morita et al., 2007). 
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Therefore, the suppression of deadenylation activity caused by CNOT1 and CNOT2 
depletion might be responsible for the decreased cell viability. To test this hypothesis we 
depleted deadenylase subunits in SW480 cells and measured cell viability. We found that 
cell viabilities in CNOT6L, 7 and 8-depleted cells were highly reduced, suggesting that 
decreased cell viability induced by CNOT1 and 2 depletion might be due to suppressed 
deadenylation. 
p27kip and CDX2 are two well-known cell cycle inhibitors and are potential target 
genes of CNOT1 and 2 mediated deadenylation. We investigated the mRNA levels of 
these two genes in both CNOT1- and CNOT2-depleted SW480 cells. The results showed 
that mRNA levels of these two genes were upregulated in CNOT1-depleted cells but had 
no obvious change in CNOT2-depleted cells, suggesting that CNOT2 may not participate 
in regulation of these two genes. These results also revealed that CNOT1 and CNOT2 
might have different roles in deadenylation mediated by the CNOT complex. Next, to 
initially study whether deadenylation contribute the regulation of p27kip and CDX2 
mRNA levels by CNOT1 we measured the mRNA levels of these two genes in SW480 
cells depleted for deadenylase subunits. We found that lack of CNOT8 caused an increase 
in p27kip and CDX2 mRNA levels. But depletion of other deadenylase subunits did not 
result in obvious changes in p27kip mRNA levels. Interestingly, depletion of CNOT6 and 
6L both caused decreased CDX2 mRNA levels, suggesting an indirect effect. Together, 
these results suggest that CNOT1 and 8 may participate in a complex that regulates 
mRNA levels of p27kip and CDX2 by deadenylation. These findings also revealed that 
deadenylase subunits have specificity in targets or that their distribution and abundance 
might be different in cell lines.  
RNA binding proteins (RBPs) promote deadenylation of target RNA transcripts 
by binding to AREs in their 3'UTRs. They recruit the deadenylases to the target mRNAs 
through direct binding to CNOT1 that in turn provides a platform to recruit the 
deadenylases and thereby trigger decay of target mRNAs. SB-based screens have 
identified several RBPs as potential CRC cancer genes, including Pum1, Pum2, Elavl1 
and Celf1. To test if these RBPs might mediate the phenotype shared by CNOT1 and 
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CNOT8 we examined the effect of depletion of several RBPs on cell viability and p27kip 
and CDX2 mRNA levels. Cell viability was reduced in cells depleted for ZFP36, PUM1 
and CELF1 but not in cells depleted for PUM2. mRNA levels of p27kip were increased 
only in ZFP36-depleted cells. CDX2 mRNA levels were increased by 1.5 fold in ZFP36, 
and CELF1-depleted cells. Together, these results suggest that ZFP36 and CELF1 may 
work with CNOT1 and 8 in complexes to regulate cell viability and mRNA levels of 
p27kip or CDX2 through deadenylation. 
Two important questions are whether CNOT1 regulates p27kip and CDX2 mRNA 
levels through deadenylation and whether upregulated levels of these two genes were 
responsible for the reduced cell viability in CNOT1 insufficient cells. To answer the first 
question we performed a 3’UTR luciferase reporter assay. The results revealed that lack 
of CNOT1 did not result in a change in luciferase activity of p27kip and CDX2 3′UTR 
reporter plasmids. This result suggested that CNOT1 might regulate the mRNA levels of 
these two genes through mechanisms other than deadenylation. It is also possible that the 
assay was not able to detect the changes in deadenylation possibly due to the reporter 
plasmids, so we may need to construct new reporter plasmids, such as a plasmid 
containing concatemers of targeting sites of known microRNAs that destabilizes these 
two genes. To answer the second question we depleted CDX2 in SW480 cells. But no 
obvious change in cell viability was observed. These results suggest that upregulated 
CDX2 may not be the cause for reduction in cell viability caused by CNOT1 depletion. 
However, this experiment was carried out in highly malignant SW480 cells. Therefore we 
need to knock down CDX2 in a normal colon epithelial cell line and perform an 
overexpression study of CDX2, before we can draw any conclusions.  
In this study we failed to provide evidence that CNOT1 and CNOT2 could 
regulate p27kip and CDX2 mRNA levels through deadenylation and that upregulated 
CDX2 levels could be responsible for decreased cell viability following CNOT1 and 
CNOT2 depletion.  However, there were several obvious limitations in this study. Some 
of the experiments were performed only once, thus the results need to be confirmed by 
more replicates. Knockdown of CDX2 was performed in a highly malignant CRC cell 
line, possibly making the acceleration in cell proliferation impossible to be observed. 
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Thus a less malignant cell line and overexpression studies are necessary. The 3’UTR 
reporter assay may not work for our purpose, so a new strategy to design reporter 
plasmids may be needed. It is also possible that upregulation of p27kip and CDX2 do not 
contribute to decreased cell viability caused by CNOT1 and CNOT2 depletion. 
Upregulation of other genes or a combination of other genes may be the reason.  
Material and methods 
siRNA transfection, MTT assay, RNA isolation, cDNA synthesis, qRT-PCR were 
performed as described in previous sections.  
Luciferase Reporter Plasmids Construction and Luciferase Assay  
Clones containing complete 3’UTR of p27kip (clone ID: 3458141) and CDX2 (clone ID: 
4867859) were obtained from Openbiosystem. PCR primers containing restriction sites 
for XhoI and NotI were designed to amplify the complete 3’UTR of p27kip and CDX2. 
p27kip: forward, 5’- CAACTCGAGATGACCCACCGGGGTCTGCAG-3’; reverse, 5’- 
CAAGCGGCCGCATCTGGAAAGCTCATTTATCT-3’; CDX2: forward, 5’- 
CAACTCGAGATAAACAGCTCGAATTAAGAAT-3’; reverse, 5’- 
CAAGCGGCCGCATAGCTATGGAAGTTTTCTT-3’. PCR was carried out using a 
Phusion High-Fidelity DNA Polymerase (New England Biolabs) with the following 
reaction mix: 8 µl of 5 x Phusion HF buffer, 0.4 µl Phusion DNA Polymerase, 200 µM of 
each dNTP, 1 µl of each primer (final concentration 0.5 µM), 100 ng of DNA template, 
and corresponding amount of H20 to make a 40 µl volume. Cycling conditions were 95°C 
for 5 minutes, then 35 cycles of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 
seconds, and finally 72°C for 10 minutes. PCR products was digested with XhoI and NotI 
and inserted between the corresponding restriction sites on a psiCHECK-2 vector 
(Promega) to generate 3’UTR reporter plasmids. psiCHECK-2 vector contains both the 
synthetic firefly luciferase (Fluc) gene and the synthetic renilla luciferase (hRluc) gene, 
each with its own promoter and poly(A)-addition sites. The correctness of all constructs 
was confirmed by sequencing. 
To perform luciferase reporter assays, SW480 cells were plated at 2 x 104/well on 
96 well plates and co-transfected with 50 ng of 3’UTR luciferase reporter plasmids for 
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p27kip or CDX2 together with 50 nM CNOT1 siRNA or a control siRNA. Firefly and 
renilla luciferase activities were measured at 48 hours post‐transfection using a Dual-Glo 
reporter assay system (Promega) according to manufacturer's instructions. Briefly, 96 
well plates was changed with 75 µl DMEM medium and then added with 75 µl of Dual-
Glo luciferase reagent containing the firefly luciferase substrate. Incubate plates for 15 
minutes to allow for cell lysis to occur, and then measure the firefly luminescence in a 
luminometer (Biotek). Add 75 µl of Dual-Glo Stop & Glo reagent that contains the 
inhibitor of firefly luciferase and substrate for renilla luciferase. Incubate for 15 minutes, 
and then measure renilla luminescence in the same plate order as the firefly 
luminescence. Total renilla luciferase activity was normalized to firefly luciferase activity 
in order to correct for differences in transfection efficiency.   
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APPENDIX 4 
Construction of CNOT1 mutant plasmids 
As discussed in the introduction, multiple somatic mutations in CNOT1 have been 
identified in various types of human cancers, in particular CRC that has the highest 
CNOT1 mutation rate among cancers (~8%). Furthermore, several recurrent mutations 
also have been documented, for example, R1733H and R1640Q. These results suggest 
that genetic mutations in CNOT1 may contribute to the development of CRC. To further 
study the potential contribution of CNOT1 somatic mutations to CRC we have began to 
create constructs that contain the documented mutations in CNOT1 to study their effects 
on CRC in cell culture as well as in mouse models. To start with we selected nine somatic 
mutations in CRC identified by the TCGA project (Table 24). Among these mutations, 
seven have been documented more than once in the COSMIC database and all of them 
are predicted to have a medium level impact on CNOT1 function. The distribution of 
these mutations in CNOT1 protein is illustrated (Figure 55).  
 
Table 24. The 9 selected mutations in CNOT1. COSMIC indicates the number of times this 
mutation has been documented in the COSMIC database. FIS (Functional Impact Score): the 
predicted functional impact for missense mutations calculated by Mutation Assessor. 
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Figure 55. The distribution of selected mutations in the CNOT1 protein. Each dot represents 
a mutation. 
Clones encoding CNOT1S (NM_206999.2) ORF (BC040523) in a pBluescriptR 
vector were obtained from Open Biosystem (Clone Id: 5266600). The CNOT1S ORF was 
inserted between the Xho1 and BamH1 sites from 5’ to 3’ (Figure 57). These nine 
somatic mutations were introduced into the ORF of CNOT1S via using a Transformer 
Site-Directed Mutagenesis Kit (Clontech). The general procedure of this method is 
illustrated in Figure 56. The mutagenic primer introduces the desired mutation and the 
selection primer mutates a unique restriction site in the plasmid for selection of mutated 
plasmids. These two primers are simultaneously annealed to one strand of a denatured 
double-stranded template and both mutations are incorporated in the same newly 
synthesized strand after elongation by T4 DNA polymerase. The mixture of original and 
mutated DNA is then digested with a restriction enzyme that cuts at the original 
restriction site and is used to transform E. coli. BMH 71-18 mutS, which is mismatch 
repair deficient, to propagate the mutated plasmid. The uncut, mutated DNA has much 
higher transformation efficiency than linear DNA with no mutations, so the product of 
the first round of transformation will be mutated plasmids with the two mutations on one 
of the two strands. Then the DNA will be digested with the same restrictive enzyme again 
and used to transform a regular E. coli. strain. The final product will be a mixture of 
original plasmids and mutated plasmids with the two mutations on both strands. Two 
rounds of DNA digestion and transformation ensure that a very high frequency of 
transformants carry the mutated plasmid, which nearly always contains both mutations. 
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Figure 56. The general procedure of making site-directed mutations using a TransformerR 
Site-Directed Mutagenesis Kit. (From Clontech website: http://www.clontech.com) 
 
The nine CNOT1 mutants were constructed following the protocol below.  
 
A. Design selection and mutagenic primers (Table 25). The selection primer deletes 
the single Sca1 site on pBluescriptR-CNOT1s plasmid. And the mutagenic primers bear 
the nine desired point mutations in CNOT1. 
 
Table 25. The sequence of selection and mutagenic primers. 
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Figure 57. The map of pBluescriptR-CNOT1 plasmid and the location of mutagenic and 
selection primers on the plasmid. 
B. Denaturation of plasmids and annealing of primers to the DNA template. 
Set up the primer/plasmid reaction system in a 0.5 ml microcentrifuge tube, as follows:   
 
Incubate at 100°C for 3 minutes.  
Chill immediately in an ice and water bath (0°C) for 5 minutes.    
C. Synthesis of the mutant DNA strands.  
To the primer/plasmid annealing reaction from last step add: 
  204 
 
Incubate at 37°C for 2 hours. 
Heat the reaction at 70°C for 5 minutes to inactivate the enzymes. 
D. Primary selection for mutant plasmids by restriction digestion. This step will 
selectively linearize the parental DNA to increases the percentage of mutant plasmids 
present in the pool of the first transformation. 
 
Incubate at 37°C for 2 hours. 
Heat the reaction at 70°C for 5 minutes to inactivate the enzymes. 
E. First Transformation.  
Transform the BMH 71-18 mutS cells with digest reaction from step D to propagate the 
heterozygous mutant plasmids.  
 
Put on ice 30 minutes, incubate at 42°C for 1 minute, transfer to ice for 5 minutes. 
Add 1 ml of S.O.C (with no antibiotic) to each tube. Incubate at 37°C for 60 minutes with 
shaking at 220 rpm to let cells recover. 
Add 4 ml of LB medium containing ampicillin at 100 µg/ml to each tube. 
Incubate the culture at 37°C overnight with shaking at 220 rpm. 
F. Isolation of the mixed plasmid pool using a Qiagen Miniprep Kit. 
Nanodrop the harvested plasmids and adjust the concentration to ≈ 100 ng/µl. 
G. Selection of the mutant plasmids. 
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Incubate at 37°C for 2 hours. 
Add an additional 0.5 µl Sca1-HF, and continue incubation at 37°C for another 1 hour. 
Heat the reaction at 70°C for 5 minutes to inactivate the enzymes. 
H. Final Transformation 
Transform the NEB5α high efficiency cell with digest reaction from step G to propagate 
the final mutant plasmids. 
 
Put on ice 30 minutes, incubate at 42°C for 1 minute, transfer to ice for 5 minutes. 
Add 450 µl S.O.C medium (with no antibiotic) to each tube. Incubate at 37°C for 60 
minutes with shaking at 220 rpm to let cell recover. 
Use 50 µl, 100 µl and 350 µl cell suspension to streak three LB plates containing 50 
µg/ml ampcillin for each mutant.  
Incubate plate at 37°C overnight. 
I. Propagate cells and harvest final plasmids.  
Pick 3 clones from each plate and grow cells in 2.5 ml LB containing 100 µg/ml 
ampcillin at 37°C overnight with shaking at 220 rpm. 
Isolate final plasmids from 4 clones for each mutant using a Qiagen Miniprep Kit 
(Qiagen).  
J. Confirm the mutations by Sanger sequencing.  
The sequencing primers for confirming introduced mutations are listed in table 26.  
  206 
                  
Table 26. The sequencing primers used for validation of mutations. 
Set up the reaction in a 0.5 ml eppendorf tube for Sanger sequencing as follows: 
 
Send the tubes for sequencing to the University of Minnesota BioMedical Genomic 
Center. The sequencing results revealed that all nine mutations except for #6 were 
successfully introduced into the CNOT1S ORF in the pBluescriptR vector (Figure 58). 
 
Figure 58. Validation of introduced mutations by Sanger sequencing. The mutated nucleic 
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acids were marked out in gray. 
K. Construction of plasmids expressing CNOT1 mutants.  
The pBluescriptR vector is non-expressing. Therefore, to ectopically express the 
CNOT1 mutants in cells we transferred the mutated CNOT1 ORF into a pcDNA3 vector 
(Life Technologies) that can be expressed in mammalian cells. The eight CNOT1 mutant 
constructs were digested with Apa1 and Not1 and inserted between the corresponding 
restriction sites on a pcDNA3 vector to generate pcDNA3-CNOT1SΔ. The final plasmids 
were propagated by transforming NEB5α cells and confirmed by restrictive digestion and 
agarose gel electrophoresis.  
Discussion 
Multiple somatic mutations in CNOT1 have been documented in different types of 
cancers, in particular CRC. To characterize these mutations in CRC ectopic expression of 
CNOT1 bearing these mutations in cell lines represents a direct means to test the function 
of these mutations in vitro. The CNOT1 mutations in CRC span the whole CNOT1 
protein and no obvious cluster was discovered. Due to a lack of understanding of CNOT1 
structure, it is difficult to predict which mutations may have more influence than others. 
Therefore, we selected 9 mutations spanning the short CNOT1 isoform to make CNOT1 
mutants. There are several methods in introducing a site-specific mutation into a 
construct. We employed Clontech’s Transformer Site-Directed Mutagenesis method to 
introduce the 9 mutations into the CNOT1S ORF. Finally, we successfully constructed 8 
CNOT1 mutants, confirmed by Sanger sequencing. These results suggested that this 
method is an effective way to introduce a mutation into a plasmid construct of 8kb in 
length. We note that the short CNOT1 isoform lacks the amino acids after 1478 aa 
including part of the deadenylase binding domain and the NOT1 domain on the C-
terminal region. Since long CNOT1 isoforms are the complete and predominant isoforms 
and may have different functions, we now need to make the mutated long CNOT1 
isoforms bearing the same mutations in ways described in material and methods section. 
We also need to introduce the mutations discovered in the C-terminal region of CNOT1 
into the construct for long CNOT1 isoforms. In the future, we will express these CNOT1 
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mutants in CRC and normal colon epithelial cells to study their effects on oncogenic 
phenotypes, assembly of the CNOT complex and deadenylation of target mRNA 
transcripts. If necessary, we can introduce another mutation to these CNOT1 mutants to 
silence the sites targeted by siRNA oligos used to deplete endogenous CNOT1. 
Furthermore, we may carry out in vivo studies by producing transgenic mice bearing 
CNOT1 mutations that show strong phenotypes in cell line based studies. These studies 
will be helpful in determining the role of CNOT1 in CRC and in understanding the 
structure and functions of CNOT1. 
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APPENDIX 5 
Identification of fusion mRNA transcripts in human 
colorectal cancer and normal colon epithelial 
tissues using RNA seq 
 
Introduction 
A gene fusion is formed by combining a part of one gene with a segment of 
another. Until recently, most fusion genes were discovered in neoplasms having 
hematopoietic and mesenchymal origins (Li et al., 2008), such as leukemia, lymphoma 
and sarcoma. Recurrent and characteristic gene fusions are a common feature of these 
neoplasms (Li et al., 2008) that together represent only 10% of all human cancers, such 
as BCR-ABL1 in chronic myelogenous leukemia (CML) (Nowell et al, 2007), NPM1-
ALK in lymphomas (Falini et al., 1999) and EWS-FLI-1 in Ewing's sarcoma (May et al., 
1993). Recurrent gene fusions are widely used for disease classification, diagnosis, and 
therapeutic targets. For example, treatment of CML with Gleevec, a tyrosine kinase 
inhibitor specifically targeting the BCR-ABL chimeric protein, has been proved to 
increase the survival rate of CML patients (Deininger et al., 2005). 
However, detection of cancer-specific, recurrent gene fusions was rare in common 
types of epithelial carcinomas, which account for 80% of cancer-related deaths. This 
apparent discrepancy is mainly due to the inherent complexity of the solid cancer genome 
and technical limitations rather than fundamental genetic differences between 
hematological malignancies and solid cancers. With the application of new technological 
approaches, in particular the next-generation sequencing (NGS) techniques, and software 
for analyzing sequencing data, increasing numbers of gene fusions were being identified 
in solid tumors, such as TMPRSS2-ERG in prostate cancers (Taylor et al., 2010, 
Ishkanian et al., 2009), EML4-ALK in non-small cell lung cancer (NSCLC) (Soda et al., 
2007) and VAPB-IKZF3 in breast cancer cell lines (Edgren et al., 2011). These results 
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have changed our views regarding the presence and frequency of fusion genes in solid 
tumors, sparking a revitalization of the quest to identify novel gene fusions in epithelial 
malignancies.  
The Mechanisms for Formation of Fusion Gene Transcripts 
A fusion gene transcript is a chimeric RNA joining the transcripts of two or more 
different genes. The fusion transcripts can be produced by different mechanisms.  
Chromosomal rearrangement is a most common cause of gene fusions, which can 
cause translocations, deletions and inversions. The best-known example of a gene fusion 
caused by chromosomal translocation is the BCR-ABL fusion gene in CML (Wong and 
Witte, 2004). 
In addition to chromosomal rearrangements, fusion transcripts can also be 
produced due to aberrant RNA splicing at the transcript level, including transcription-
induced chimeras (TICs) and trans-splicing (Figure 59).  
A TIC is a specialized cis-splicing event that results from read-through 
transcription of two adjacent, independent genes that share the same orientation. In this 
process, RNA polymerase II keeps transcribing over multiple polyadenylation sites, 
where transcripts are normally cleaved and processed. Most of these fusion transcripts are 
generated from tandem genes that are physically located within ~50 kb of each other and 
the median distance is ~8.5 kb, indicating the spatial proximity might be a prerequisite 
for forming TICs (Akiva et al., 2006). TICs were previously reported in isolated cases 
and thought to be a rare event in mammals. Recent studies, however, incorporating 
systematic in silico analyses of ESTs and cDNAs in the NCBI databases, found that as 
much as 5% of the tandem gene pairs in the human genome is comprised of chimeric 
sequences, indicating TICs could be quite frequent. (Parra et al., 2006, Unneberg et al., 
2007). Despite the prevalence, the regulation and function of most TIC-induced fusion 
transcripts remains largely uncharacterized (Wang et al., 2007, Akiva et al., 2006). Some 
of these chimeric transcripts are thought to be produced as ‘noise’ in the transcription 
process, while some could encode chimeric proteins or have a logical function inferred. 
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For example, the RBM6-RBM5 TIC expression levels were associated with elevated 
levels of RBM6 and RBM5 mRNA, and with increased tumor size in breast tumor tissue 
(Wang et al., 2007).  In addition, two tissue-specific TICs fusing tyrosine hydroxylase 
(TH) and insulin (INS) genes were reported to encode two TH protein isoforms whose 
functionality was somewhat diminished with respect to the canonical TH, providing an 
additional aspect in the control of TH/insulin gene expression. (Hernández-Sánchez et al., 
2006, Mansilla et al., 2005). 
Trans-splicing can generate chimeric mRNAs between pre-mRNAs originating 
from two different genes. It is a special form of RNA processing where exons from two 
different primary RNA transcripts are joined end to end and ligated (Figure 59). This 
process was found to follow similar mechanisms as cis-splicing of RNA, which is also 
catalyzed by the spliceosome (Faustino et al., 2003). Juxtaposition of the loci encoding 
the RNAs that participate in trans-splicing seems to be essential for some pre-mRNA 
substrates but not for some other ones (Kristi et al., 2008). Some resultant fusion 
transcripts may have functional effects. An example is the cyclin D1 (CCND1)-tumor-
associated calcium signal transducer 2 (TROP2) fusion transcript detected in a variety of 
human cancers (Guerra et al., 2008). This RNA transcript did not encode a chimeric 
protein, but rather led to elevated levels of CCND1 in that the 3' UTR in the CCND1 
mRNA was deleted due to trans-splicing with TROP2 pre-RNA. Removal of the 3’UTR 
stabilizes the chimeric RNA transcript relative to normal CCND1 mRNA. In addition, the 
chimeric RNA was reported to be oncogenic as it could transform primary cells in culture 
and induce aggressive tumor formation in cooperation with activated RAS in both 
cultured cells and transgenic mice. These findings have turned the view of trans-splicing 
in higher eukaryotes from a bizarre phenomenon to a biological event that is attaining 
stronger recognition (Mansfield et al., 2004, Garcia-Blanco et al., 2003).  
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Figure 59. RNA splicing mechanisms in eukaryotes. (Anderson et al., 2008) (a) Canonical pre-
mRNA cis-splicing yielding mRNA from pre-mRNA composed of two exons (orange boxes) and 
an intron (black line). (b) A transcription-induced chimera generated by read-through 
transcription from one gene (blue) into a downstream gene (red), followed by cis-splicing. (c) 
Trans-splicing of exons from two distinct pre-mRNAs (red and blue boxes). 
The Biological Effects of Gene Fusions  
Previous studies suggested that the consequence of gene fusions could be either 
generation of a truncated or chimeric protein with a different function or an alteration of 
gene expression (Tomlins et al., 2005). In most cases, gene fusions occur within introns, 
giving rise to the expression of truncated or chimeric proteins with a new or altered 
activity (Mitelman et al., 2007), such as BCR-ABL chimeric protein which has 
constitutive tyrosine kinase activity (Wong and Witte, 2004). Some of the resultant 
chimeric proteins are abnormal, tumor-specific products that may provide tumor cells 
with a growth and/or survival advantage (Li et al., 2008, Mitelman et al., 2007). Besides 
encoding chimeric proteins, formation of gene fusions can affect gene expression (Lin et 
al., 2012). In some cases, gene fusion occurs between the coding region of a gene and the 
transcriptionally active promoter or enhancer region of another gene, which may lead to 
upregulated expression of the former gene. Examples include TMPRSS2-ERG and 
TMPRSS2-ETV1 gene fusions where expression of ERG or ETV1 genes are dramatically 
up-regulated due to their repositioning after the TMPRSS2 transcription start site which is 
actively transcribed in prostate cancer (Tomlins et al., 2005). Another type of gene fusion 
involves recombination between the coding region of one gene with the non-coding 
regulatory region, such as 3’UTR, of the second gene, which may alter the post-
transcriptional regulation of the former gene. One example is the chimera between 
CCND1 mRNA with TROP2 pre-RNA, which led to the deletion of 3' UTR of CCND1 
mRNA transcript. The CCND1-TROP2 fusion transcript stabilized CCND1 mRNA levels 
and consequently resulted in elevated CCND1 levels, promoting cells to pass the G1 
phase of the cell cycle (Guerra et al., 2008).  
Next Generation Sequencing and RNA Sequencing 
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Next generation sequencing (NGS) technology is a fundamentally novel approach 
to DNA sequencing, which can sequence the fragments of a DNA template in a 
massively parallel fashion, producing thousands or millions of sequences concurrently. 
This advance enables rapid sequencing of large stretches of DNA base pairs spanning 
entire genomes (Hall et al., 2007, Church et al., 2006). Whole-genome DNA sequencing 
can be used to identify potential fusion-gene-creating rearrangements. However, only a 
fraction of gene fusions predicted based on DNA sequencing is expected to generate an 
expressed fusion mRNA, making this approach tedious to discover activated, oncogenic 
fusion gene events. In contrast, RNA sequencing (RNA-seq) using next-generation 
sequencing instruments directly identifies only those fusion genes that are expressed, 
providing an efficient tool to identify candidate oncogenic fusions (Edgren et al., 2011). 
RNA-seq also facilitates comprehensive characterization of cellular transcriptomes.  
In a standard RNA-seq procedure, RNA sample (total or polyA+ enriched) is 
converted to cDNA through reverse transcription, which is then broken into a library of 
small fragments. Oligonucleotide adapters are then attached to a cDNA library on one or 
both ends. Finally the adaptor-ligated cDNA library is sequenced on a high-throughput 
platform either single-ended (single-end sequencing) or pair-ended (pair-end sequencing) 
(Martin et al., 2011). This process usually generates millions of short (30-400 bp) reads 
which can be analyzed by a variety of bioinformatics tools. The methods for inferring the 
sequencing data are generally classified as two types. In one approach the reads are 
aligned and mapped to a reference genome either of the organism itself (whose 
transcriptome is being studied) or of a closely related species. The other approach, de 
novo transcriptome assembly, uses bioinformatics tools to assemble the transcriptome 
directly from short sequence reads without referring to a reference genome (Wang et al., 
2009). Generally speaking, the results of RNA-Seq have shown high levels of 
reproducibility, for both technical and biological replicates (Cloonan et al., 2008). The 
general procedure of RNA sequencing is summarized in Figure 60. Paired-end RNA-seq, 
where 36 to 100 bp are sequenced from both ends of 200 to 500 bp long cDNA 
molecules, is especially suitable for identification of chimeric mRNA transcripts. The 
employment of the paired-end RNA-seq, combined with effective analytic pipelines 
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enable the discovery of fusion RNA transcripts in breast cancer (Edgren et al., 2011, 
Asmann et al., 2012), lung cancer (Lin et al., 2009), colon cancer (Chu et al., 2011), and 
other types of solid tumors with high confidence.   
 
Figure 60. The procedure of RNA-seq. (Solar home http://cmb.molgen.mpg.de) 
Fusion Genes in CRC 
The first recurrent fusion gene in CRC was reported by Lin et al in 2009 (Lin et 
al., 2009). They performed an exon array for the global search of gene rearrangements in 
a large collection of breast cancer, CRC and non-small cell lung cancer (NSCLC) 
samples and identified the echinoderm microtubule associated protein like 4 (EML4)-
anaplastic lymphoma receptor tyrosine kinase (ALK) fusion in multiple samples. An RT-
PCR assay was then used to screen a collection of tumor samples for the presence of the 
EML4-ALK fusion transcript, leading to detection of the EML4-ALK fusion in 2.4% of 
breast cancer (5 of 209), 2.4% of CRC (2 of 83), and 11.3% of NSCLC (12 of 106), 
which was confirmed by subsequent sequencing of PCR products. The presence of EML-
ALK rearrangement was further verified by identifying genomic fusion points in tumor 
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samples using long-range genomic PCR. A FISH assay was used to confirm the EML4-
ALK translocation in tumor samples and tumor-derived cell lines positive for the fusion 
transcript. The functional role of the EML4-ALK fusion in cell growth and proliferation 
was assessed by measuring cell viability following siRNA-mediated silencing of EML4 
and ALK. Cell growth inhibition was not observed in control cell lines lacking the EML4-
ALK fusion. On the contrary, significant growth inhibition was observed in lung and 
breast cancer cell lines but not in CRC cell lines harboring the EML4-ALK fusion, failing 
to show the functionality of this fusion in CRC (Lin et al., 2009).  
Next generation sequencing provides the capacity for doing a deeper analysis of 
the entire genomes of CRC tumors. In the first study using NGS to discover gene fusions 
in CRC, Bass et al performed whole genome sequencing of 9 CRCs and paired non-
neoplastic tissues (Bass et al., 2011). They found 11 chromosomal rearrangements that 
could give rise to in-frame fusion transcripts, including a fusion of vesicle transport 
through interaction with t-SNAREs 1A (VTI1A) and transcription factor 7-like 2 
(TCF7L2). By screening cDNA from a panel of 97 primary CRCs, they found that the in-
frame VTI1A-TCF7L2 fusion was recurrently expressed in 3 of 97 cases. The VTI1A-
TCF7L2 chimeric transcript fuses the first three exons of VTI1A to the fourth exon of 
TCF7L2. VTI1A encodes a v-SNARE protein mediating fusion of intracellular vesicles 
within the Golgi complex 21 (Kreykenbohm et al., 2002). TCF7L2 encodes a 
transcriptional factor belonging to the TCF/LEF family 4 (Clevers et al., 2006, Waterman 
et al., 2004). TCF7L2 is known to have a significant role in CRC in collaboration with 
beta-catenin. To test the functional importance of the VTI1A-TCF7L2 fusion gene in 
CRC, they knocked down the fusion gene through RNAi targeting the sequence spanning 
the fusion, which caused a dramatic reduction in the anchorage-independent growth of 
NCI-H508 cells, suggesting the fusion gene has a substantial role in cancer cell survival. 
This paper provides an excellent example of employment of NGS technology in 
identification of important genomic rearrangements and fusion events occurring in CRC.   
Using RNA-seq, Wu et al profiled the whole transcriptomes of CRC tissue, 
adjacent non-tumor tissue and distant normal tissue from a stage III CRC patient (Wu et 
  216 
al., 2012). They identified a cancer-specific gene fusion between the prostaglandin F2 
receptor inhibitor (PTGFRN) and NOTCH2 (NOTCH2) using two algorithms, deFuse 
and TopHat-Fusion, which was confirmed by RT-PCR and Sanger sequencing. NOTCH2 
is a homolog of NOTCH1 and plays a role in a variety of developmental processes by 
controlling cell fate decisions. NOTCH2 expression has been shown to be a prognostic 
predictor and is related to tumor differentiation status in CRC (Chu et al., 2011). In the 
PTGFRN-NOTCH2 gene fusion the first intron of PTGFRN is fused with the 3′ junction 
of the 17th exon of NOTCH2, thus the fusion gene is under the control of the promoter of 
NOTCH2. The predicted protein encodes the first 917 aa of NOTCH2, lacking some 
essential domains in NOTCH2, such as NOTCH domain, and appearing to act like a loss-
of-function mutation. This study employed RNA-Seq to successfully identify the tumor-
specific PTGFRN-NOTCH2 fusion gene in CRC. However, this study only included one 
tumor sample and did not show the functional significance of the PTGFRN-NOTCH2 
gene fusion. Therefore, a study using RNA-seq in larger group of CRC samples is 
necessary to identify recurrent gene fusions in CRC. 
In another large scale study of fusion genes in CRC, Seshagiri et al (Seshagiri et 
al., 2012) applied exome sequencing and RNA-seq to 70 pairs of primary human CRC 
and normal tissues to characterize their exomes, transcriptomes and copy-number 
alterations. 36 chromosomal rearrangements that result in gene fusions were identified 
using RNA-seq. Among these gene fusions, recurrent gene fusions involving R-spondin 
family members R-spondin 2 homolog (RSPO2) (3%; 2 out of 68) and R-spondin 3 
homolog  (RSPO3) (8%; 5 out of 68) were discovered. R-spondins are secreted proteins 
that can potentiate canonical WNT signaling (Yoon et al., 2012). The recurrent RSPO2 
fusion involves eukaryotic translation initiation factor 3, subunit E (EIF3E) exon 1 and 
RSPO2 exon 2, which is expected to produce a functional RSPO2 protein driven by the 
EIF3E promoter. Two different RSPO3 fusion variants were identified where either exon 
1 or exon 7 of protein tyrosine phosphatase, receptor type, K (PTPRK) (5’) was fused to 
exon 2 of RSPO3 (3’). The PTPRK (e1)–RSPO3 (e2) transcript found in four samples is 
an in-frame fusion that preserves the entire coding sequence of RSPO3 and replaces its 
secretion signal sequence with that of PTPRK. The PTPRK (e7)-RSPO3 (e2) fusion, 
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detected in one sample, is also an in-frame fusion that potentially encodes a 70 kD 
protein consisting of the first 387 amino acids of PTPRK, including its secretion signal 
sequence, and the RSPO3 amino acids 34-272 lacking its native signal peptide. In studies 
of the biological activity of the R-spondin fusions, they showed that the RSPO fusion 
proteins were capable of potentiating WNT signaling in both 293T and HT-29 cells using 
a WNT-responsive luciferase reporter assay.  
Furthermore, TCGA has comprehensively examined in genomic alterations in 
CRC, providing the most integrated view of CRC cancer genes to date (Cancer Genome 
Atlas Network, 2012). To identify new chromosomal translocations, they performed low-
pass, paired-end, whole-genome sequencing on 97 tumors with matched normal samples. 
Despite the low genome coverage, they detected 250 candidate interchromosomal 
translocation events (0–10 per tumor). Among these events, 212 had one or both 
breakpoints in an intergenic region, whereas the remaining 38 juxtaposed coding regions 
of two genes in putative fusion events, of which 18 were predicted to code for in-frame 
events. They also found three separate cases (3%) in which the first two exons of the 
neuron navigator 2 (NAV2) gene are joined with the 3′ coding portion of transcription 
factor 7 like 1 (TCF7L1) through an interstitial deletion. TCF7L1 encodes TCF3, a 
member of the TCF/LEF class of transcription factors that heterodimerize with nuclear β-
catenin to enable β-catenin-mediated transcriptional regulation. However, the predicted 
NAV2–TCF7L1 fusion protein lacks the TCF3 β-catenin-binding domain, suggesting a 
loss of function truncation. They also observed 21 cases of translocation involving 
tetratricopeptide repeat domain 28 (TTC28) that was identified as a target of P53 and an 
inhibitor of tumor cell growth (Brady et al., 2011). In all cases the fusions are predicted 
to lead to inactivation of TTC28.  
These studies provided examples for employment of next-generation sequencing 
and RNA-seq in identification of recurrent and functional gene fusions in CRC as well as 
other solid tumors. Identification of these genomic rearrangements and fusion events will 
be beneficial in further understanding the mechanisms of CRC formation and developing 
novel therapeutic strategies targeting these gene fusions or their product.  
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All the published studies in gene fusions in CRC were performed using primary 
CRC samples. To study the fusion transcripts that are associated with advanced stage 
CRC and potentially involved in cancer progression we studied the fusion transcripts in 
20 liver metastasis of stage IV CRC and 5 normal colon samples using RNA-seq and 
analyzed the sequencing data via deFuse software.   
Results 
In the 20 CRC samples, we discovered 414 fusion transcripts involving 737 
genes, among which 289 fusion transcripts were unique, 42 were in-frame fusions, and 
137 occurred between adjacent genes, suggesting that these fusion transcripts were 
transcriptional read-throughs, also known as TICs, rather than actual genome 
rearrangements. In addition, the number and characteristics of fusion transcripts vary 
from sample to sample. On average, each CRC sample had 33 fusion transcripts (range 
15-51), 0.7 in-frame fusions (range 0-3), 18 TICs (range 9-31), and 5 fusion transcripts 
(range 1-12) which had a predicted probability ≥ 0.85, suggesting the presence of these 
fusions are highly possible (Figure 61, table 27, 35 and 36, Sue Rathe, unpublished data). 
These results suggest that fusion transcripts and TICs are prevalent in CRC samples. 
However, the in-frame fusions that potentially encode chimeric proteins are rare.   
In the 5 normal colon samples, 54 fusion events were discovered among which 37 
were unique fusion transcripts, none was an in-frame fusion, and 24 were caused by TIC. 
On average, each normal colon sample had 10.8 fusion transcripts (range 9-14), no in-
frame fusion, 7 TICs (range 6-8), and 1 fusion transcripts (0-2) having a predicted 
probability ≥ 0.85 (Figure 62, table 28, 37 and 38). These results suggest that fusion 
transcripts and TICs also exist in normal colon samples, while the numbers are lower 
than in CRCs.  
We then compared the lists of fusion transcripts discovered in both CRC and 
normal samples to identify the fusions occurring in both types of samples. We found that 
20 unique transcripts were discovered in both CRC and normal colon samples, among 
which 17 were the same fusion transcripts and 3 were formed by same partners but with 
  219 
different breakpoints. None of these fusions were in-frame and 15 of them were TICs 
(Figure 63, Table 39).  
Follow-up filtering using a stringent threshold for in-frame fusions resulted in a 
workable set of 12 fusion candidates that we are testing in in vitro assays. The criteria for 
selection of candidate fusion transcripts are: probability ≥ 0.85, in coding regions, and in-
frame. All the 12 fusion transcripts were validated by RT-PCR followed by DNA 
sequencing except four which were validated by RT-PCR only. Interestingly, 6 of these 
fusion transcripts were also discovered in normal colon samples by RT-PCR, although 
none of them were predicted by the RNA seq data. In addition, 7 of the candidate fusion 
transcripts were TICs and 3 of them were found to be cancer-specific (Table 29).  
 
Figure 61. The map of fusion transcripts in 20 CRC liver metastasis. The thickness of the 
edges corresponds to the times that the same fusion was detected. 
 (A)  
# fusions 414 
# unique fusion transcripts 289 
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# in-frame 42 
# TIC 137 
(B) 
Per sample Range Average 
# fusions 15--51 33 
# in-frame 0--3 0.7 
# TIC 9--31 18 
# prob≥0.85 1--12 5 
Table 27. Summary of fusion transcripts discovered in 20 CRC samples. (A) Characteristics 
of fusion transcripts. (B) Fusion transcripts discovered in per sample. # in-frame: number of the 
fusion transcripts remaining an open reading frame; # TICs: number of fusion transcripts 
predicted to be TICs; # probability ≥ 0.85: number of fusions having predicted probability ≥ 0.85.  
 
 
Figure 62. The map of fusion transcripts in 5 normal colon samples. The thickness of the 
edges corresponds to the times that the same fusion was detected. 
(A)  
# fusions 54 
# unique fusion transcripts 37 
# in-frame 0 
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# TIC 24 
(B) 
Per sample Range Average 
# fusion 9--14 10.8 
# in-frame 0 0 
# TIC 6--8 7 
# prob≥0.85 0--2 1 
Table 28. Summary of fusion transcripts discovered in 5 normal colon samples. (A) 
Characteristics of fusion transcripts. (B) Fusion transcripts discovered in per sample. # in-frame: 
number of the fusion transcripts remaining an open reading frame; # TICs: number of fusion 
transcripts predicted to be TICs; # probability ≥ 0.85: number of fusions having predicted 
probability ≥ 0.85.  
 
 
Figure 63. The overlapping fusion transcripts discovered in both CRC and normal samples.   
Gene1 Gene2 #Sample Probability TIC PCR 
Sequen
cing 
Cancer 
specific 
KISS1 GOLT1A 13 0.978 Y Y Y N 
OSGIN1 NECAB2 2 0.971 Y Y Y Y 
CDH1 CDH3 1 0.965 N Y Y N 
IGSF5 PCP4 1 0.959 Y Y N N 
ADCK4 NUMBL 3 0.957 Y Y Y N 
GFER ZNRF2 1 0.941 N Y Y Y 
UBXN11 AIM1L 1 0.929 Y Y N Y 
EHMT2 MIF 1 0.914 N Y Y N 
RGN RP2 1 0.882 Y Y N N 
WFDC3 TNNC2 4 0.870 Y Y N Y 
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NUP155 WDR70 1 0.854 N Y Y Y 
KDM2A SYT12 1 0.854 N Y Y Y 
Table 29. Lists of the fusions that have been validated by PCR and Sanger Sequencing. 
 
Discussion 
Given that common gene fusions are rare in CRC (Bass et al., 2011), identifying 
case-specific gene fusions can help to understand the complexity of the molecular basis 
of CRC development. In addition, all the published studies of gene fusions in CRC were 
performed using primary CRC samples. Therefore, we used 20 liver metastasis of stage 
IV CRC to study the fusion transcripts in advanced stage CRC. Since only 1 of the 5 
normal colon samples matches one of the CRC samples, we are not able to compare the 
fusions in paired samples to identify fusion transcripts potentially involved in CRC 
progression. However, the fusion transcripts discovered in CRC samples provide some 
candidate fusion transcripts for functional characterization. The RNA-seq dataset was 
analyzed for presence of fusion transcripts by using deFuse which is a bioinformatics tool 
for discovering fusion transcripts from RNA seq data. In the 20 CRC samples, we 
discovered 414 fusion events and 289 unique fusion transcripts. The majority of gene 
fusions were only found in a single patient, however, several were highly recurrent. The 
number of fusion genes varies from sample to sample (15 to 51 fusions per sample). Only 
42 fusion transcripts retained an open reading frame, suggesting that majority of fusion 
transcripts do not encode chimeric proteins and they may function through other 
mechanisms. About half of the fusion transcripts (137/289) occured between adjacent 
genes, suggesting that these fusion transcripts were transcriptional read-throughs or TICs 
rather than actual genome rearrangements. This result suggested that TICs are an 
important mechanism in forming fusion transcripts in CRC. Together, these results 
indicated that fusion transcripts and TICs are prevalent in CRC samples, while the in-
frame fusions that potentially encode chimeric proteins are rare. In the 5 normal colon 
samples, 54 fusion events were discovered and 37 were unique fusion transcripts. On 
average, each sample had 10.8 fusion transcripts that was a lower number than CRC 
samples. Among the 37 unique fusion transcripts 24 were caused by TICs, suggesting 
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that TICs are also widely involved in formation of fusion transcripts in normal colon 
tissues. In consistent with the low occurrence of in-frame fusions in CRC samples, none 
of these fusion transcripts was in-frame. These results suggest that fusion transcripts and 
TICs also exist in normal colon samples, while the numbers were lower than in CRCs.  
12 fusion candidates that meet the criteria of probability ≥ 0.85, in coding regions, 
and in-frame were validated by RT-PCR followed by DNA sequencing, suggesting the 
predicted probability ≥ 0.85 is a good predictor for the presence of a fusion transcript.  6 
of these fusion transcripts were also discovered in normal colon samples by RT-PCR, 
although none of them were predicted by the RNA-seq data. This result suggests that 
RNA-seq may not be able to pick all the fusion transcripts in a specific sample. 7 of these 
fusion transcripts were TICs consistent with RNA-seq data that about 50% fusions were 
formed by TICs, suggesting that TICs are an important mechanism in formation of fusion 
transcripts. We also found that 3 of these TICs were cancer-specific, which were reported 
for the first time.   
In ongoing studies, we will functionally characterize some of the fusion 
transcripts, especially cancer-specific TICs, to reveal the influence of fusion transcripts in 
tumor formation and to identify potential targets for novel therapies.  
Material and methods 
Tumor and Normal Colon Samples 
The liver metastasis of 20 stage IV colon cancer patients and 5 normal colon samples 
were obtained from the Biological Materials Procurement Network (BioNet) at the 
University of Minnesota. All tumor and normal tissues were snap frozen in liquid 
nitrogen at the time of surgical resection, and delivered to us on dry ice, and transferred 
into liquid nitrogen immediately upon they were received. The clinico-pathological 
profile of the 20 CRC (Table 30) and 5 normal colon samples (Table 31) are listed below.  
Table 30. Summery of clinico-pathological profile of the 20 CRC patients 
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Median Range 
Age,yr 
 
59.5 (36-90) 
    Variable 
 
n % 
Gender 
   Male 
 
11 55 
Female 
 
9 45 
Histology 
   AD 
 
19 95 
Adenocarcinoid 
 
1 5 
Differentiation* 
   Well 
 
2 25 
Moderate 
 
6 75 
Poor 
 
0 0 
Stage 
   IV 
 
20 1 
                        * Differentiation was not available for 12 cases.       
   Two patients received chemotherapy, but drugs were unknown.  
   AD = Adenocarcinoma.    
 
Table 31. Summery of clinico-pathological profile of the 5 normal colon samples 
  Median Range 
Age,yr  68 (49-77) 
    
Variable  n % 
Gender    
Male  3 60 
Female  2 40 
    Location    
Left colon  0  
Right colon  4 80 
Rectum  1 20 
 
RNA Isolation 
Total RNA was isolated from 20 fresh frozen CRC samples and 5 fresh frozen normal 
colon tissues as described in chapter 4. RNA integrity was assessed by capillary 
electrophoresis and the RNA Integrity Number (RIN) for each sample is listed as below 
(Table 32).  
Table 32. RIN of the total 25 RNA samples 
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 Sample name RIN 
Cancer 
samples 
T980321 9.0 
T010314 8.9 
T001683 8.7 
T000418 8.1 
T970244 7.9 
T021380 7.8 
T021606 7.8 
T990569 7.8 
T970192 7.6 
T000447 7.5 
T010902 7.4 
T020556 7.3 
T980748 7.3 
T020193 7.2 
T980429 7.2 
T001090 7.1 
T010004 6.9 
T020201 6.8 
T990896 6.1 
T970854 5.8 
Normal 
tissue 
T022437 8.3 
T011145 7.3 
T020627 7.1 
T020613 7.0 
T020447 6.6 
 
Experimental Validation of Fusion Transcripts 
We used RT-PCR followed by DNA sequencing to validate the presence of fusion genes 
transcripts in RNA samples.  
cDNA synthesis was performed as described before.  
PCR. All standard PCR was carried out with HotStarTaq DNA Polymerase using a 
HotStarTaq Master Mix Kit (Qiagen) with the following reaction mix: 25 µl of 2 X 
HotStarTaq Master Mix (2.5 units HotStarTaq DNA Polymerase, 1 x PCR Buffer, 200 
µM of each dNTP), 10 µl of each primer (final concentration 0.2 µM), and 5 µl of cDNA 
template in a 50 µl volume. Cycling conditions were 95°C for 5 minutes, then 35 cycles 
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of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute per kb of target, and 
finally 72°C for 10 minutes. The primers used for PCR are listed (Table 33). 
Fusion Forward primer Reverse primer 
KISS1-GOLT1A GCAACTTAACCAAGGGTCAGC GCAGTAGCTGCCAAGAAACC 
OSGIN1-NECAB2 CAAGAAGGGTCTGGGGCATA TCCACATGGTTGGTGTTGTCA 
CDH1-CDH3 GTCTCCTCTTGGCTCTGCC CTTTCCTGGACTGTCTCGCC 
IGSF5-PCP4 AAAGACCACAGACACCGCTT ACTGAGACTGAATGGCCACC 
ADCK4-NUMBL TACATCGAGGTGGTGAAGGC GTAACTTGTTCATGGTGCCCG 
GFER-ZNRF2 CTTACCAGCTCACCTCTCGC CCAGCGCTCATCCACTTTTG 
UBXN11-AIM1L ACTGGAGACGATGTGTGTGC TTTCATGTCCTCCACATGGTCC 
EHMT2-MIF CCAGAGTTTGGCTATGAGGCT GCTTGCTGTAGGAGCGGTT 
RP2-RGN AATATCCCGGGGTCAGAGACA TTGTGGTCTAGCGACCAATCC 
WFDC3-TNNC2 CTTCCGCATCTTCGACAGGA TCATCCATCACACAGCCAACA 
NUP155-WDR70 TCCTTGTTCCTTCCTTGCTACA TTTTTGCCTTGCATCGTCCG 
KDM2A-SYT12 CAGCCCTGGAGTGGTTTCTT GACTTCCGGAGGGTCCCATA 
Table 33.   List of primers used for validation of candidate fusion transcripts. 
Gel extraction. PCR products were subjected to electrophorisis using a 1% low melting 
agarose (LMT) gel with 0.05% ethidium bromide. The desired bands on gel were excised 
from the gel using a sterile scalpel and the PCR products were then extracted from the gel 
slice using the QIAquick Gel extraction kit (Qiagen) following the manufacturer’s 
instructions. The extracted DNA was quantified using Nanodrop.  
Sanger sequencing. The reaction mix comprises 50 ng DNA extracted from LMT gel, 
1.6 µl of 2 µM sequencing primer stock and H20 to make a final volume of 12 µl. The 
reactions were sent to the University of Minnesota BioMedical Genomics Center for 
sequencing by using an ABI 3730 DNA sequencer (Applied Biosystems). Results were 
screened by eye using the Applied Biosystems software packages Sequence Scanner 
version 1.0 (Applied Biosystems). Sequencing results were compared with the RNA seq 
data to confirm the fusion transcripts. The sequencing primers are listed in Table 34. 
Fusion Sequencing primer 
GOLT1A-KISS1  CAAGGGTCAGCTTCCCGT 
OSGIN1-NECAB2 CTGGGGCATAACTTTGTGTC 
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CDH1-CDH3  CCTCTTGGCTCTGCCAGG 
IGSF5-PCP4  ACCACAGACACCGCTTCTCT 
ADCK4-NUMBL  TGTATGATGCCTCCAGCCA 
GFRE-ZNRF2  ATCGGCTCCTTACCAGCTC 
UBXN11-AIM1L  CAGTGACTATGGCCTGCAGT 
EHMT2-MIF TGAGTATGCCAGGAGCCC 
RGN-RP2  TCCCGGGGTCAGAGACAG 
WFDC3-TNNC2  CGCATCTTCGACAGGAATG 
KDM2A-SYT12  GTTGCAATCTGGTTCCTAAGGA 
Table 34. List of sequencing primers for validation of candidate fusion transcripts. 
Illumina RNA-Sequencing was performed as described in chapter 4. 
deFuse. Fusion transcript discovery was performed using deFuse 
(http://compbio.bccrc.ca). Briefly, deFuse identifies fusion transcripts by clustering 
discordantly aligning paired-end reads as potential evidence of reads that span a fusion 
breakpoint. Clusters of discordantly aligning reads are then used to inform a targeted 
search for reads split by fusion breakpoints. The results produced by deFuse are further 
filtered to reduce the number of false positives. After these series of filters are applied, a 
candidate list of fusions is carried forward for further analysis (McPherson et al., 2011). 
 
Supplemental information 
Table 35.  Summary of fusion transcripts discovered in each CRC sample 
Sample # Fusions # In Frame # Adjacent # prob≥0.85 
T980429-5 51 3 31 7 
T020556-4 49 2 25 11 
T980321-1 49 8 26 8 
T020201-4 48 8 20 4 
T010314 45 5 29 12 
T001683 42 3 15 8 
T001090 38 2 26 10 
T970192-5 35 0 17 5 
T990896-2 33 2 16 3 
T021380 32 2 22 12 
T010004 31 2 19 2 
T970854-6 29 3 14 3 
T990569-2 26 3 13 5 
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T020193-2 25 2 13 1 
T000418-2 24 4 12 3 
T970244-7 22 1 14 1 
T980748 22 0 10 6 
T010902-3 21 4 14 3 
T021606-3 16 1 9 1 
T000447 15 0 12 3 
# Fusion number of gene fusions discovered in each sample 
# In-frame number of the fusion transcript remainning an open reading frame 
# Adjacent number of the two genes which are located in adjacent 
# Probability ≥ 0.85 number of fusions having predicted probability ≥ 0.85 
 
Table 36. Summary of fusion transcripts discovered in the 20 CRC samples 
Gene1 Gene2 #Sample (20 total) In Frame Adjacent 
Probability 
≥0.85 
RP11-150O12.3 RP11-150O12.5 14 N Y 0.35 
GOLT1A KISS1 13 0.23_Y Y 0.67 
MT1P1 RP11-435O5.2 13 N Y 0.26 
ANO1 RP11-626H12.1 12 N N 0.4 
NME4 Z97634.5 11 N Y 0.67 
AC036222.1 HOXB9 11 N Y 0.57 
AC022098.2 PALM3 11 N Y 0.28 
AL360181.1 RP11-108K14.4 10 N Y 0.62 
BAG6 C6orf47 10 N Y 0.5 
AC017074.2 ACR 10 N N 0.46 
PAQR6 SMG5 9 N Y 0.36 
PPP1R1B STARD3 8 N Y 0.67 
GSK3B NR1I2 8 N Y 0.61 
C19orf63 JOSD2 8 N Y 0.44 
C2orf49 FHL2 8 N Y 0.15 
AC007405.7 Y_RNA.703 7 N Y 0.67 
AC036222.1 HOXB7 7 N Y 0.62 
AC011383.1 SYNPO 7 N Y 0.55 
C5orf32 CTB-131B5.5 7 N Y 0.36 
MICAL2 MICALCL 6 N Y 0.86 
HOTAIRM1 HOXA3 6 N N 0.5 
AP003774.1 CCDC88B 6 N Y 0.25 
MRPS36P2 RP11-11N5.1 6 N Y 0.2 
AC036222.1 CTD-2377D24.6 5 N N 0.44 
TNNC2 WFDC3 4 Y N 0.83 
AKR1A1 PRDX1 4 N N 0.67 
CDC42EP2 POLA2 4 N Y 0.5 
MORN1 RP4-740C4.4 4 N Y 0.5 
AC018717.1 AC019330.1 4 N Y 0.46 
AC090425.1 NDUFB5 4 N Y 0.43 
CALM3 PTGIR 4 N Y 0.4 
HADH RP11-286E11.1 4 N Y 0.2 
RP11-11N5.1 RP11-217E13.1 4 N N 0.15 
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MIR633 TANC2 4 N Y 1 
RP11-191N8.2 RP11-815M8.1 3 N Y 0.83 
CLDN10 DZIP1 3 N Y 0.67 
CKAP5 F2 3 N Y 0.6 
ADCK4 NUMBL 3 Y Y 0.5 
AL049836.1 DIO3 3 N Y 0.4 
AC100791.3 TBC1D16 3 N N 0.4 
ARSD GYG2P1 3 N N 0.25 
CARD10 MFNG 3 N Y 1 
RP1-10C16.1 RP11-375F2.2 2 N N 0.8 
NCBP2 PIGZ 2 N Y 0.75 
ATAD5 EIF5A 2 N N 0.75 
AFM RP11-622A1.2 2 N Y 0.71 
ACOT12 ZCCHC9 2 N Y 0.67 
PFKFB3 Y_RNA.738 2 N Y 0.67 
AL137145.2 PFKFB3 2 0.33_Y N 0.67 
METTL11A RP11-492E3.2 2 N N 0.5 
MAP6D1 PARL 2 N Y 0.5 
AC087699.1 CUX1 2 N N 0.5 
AC079080.2 RP11-162O12.2 2 N Y 0.5 
RP11-255B23.3 RP11-255B23.4 2 N Y 0.5 
AL139815.1 MSRB2 2 N Y 0.5 
DUS3L FUT6 2 N N 0.5 
PITPNA YWHAE 2 N N 0.5 
ACE2 BMX 2 N Y 0.4 
AC007405.6 Y_RNA.703 2 N Y 0.33 
TTLL12 TTLL12 2 Y N 0.33 
NECAB2 OSGIN1 2 0.33_Y Y 1 
TNFRSF9 UBE4B 2 N N 1 
TBC1D5 ZMAT3 1 N N 0.8 
CDH1 CDH3 1 0.40_Y Y 0.8 
NFS1 RBM39 1 N Y 0.75 
CEACAM7 RPS19 1 N N 0.75 
IGSF5 PCP4 1 0.50_Y Y 0.75 
SCN2A SCN3A 1 N Y 0.75 
C17orf99 SYNGR2 1 0.25_Y Y 0.75 
CIITA DEXI 1 N Y 0.67 
TBC1D5 Y_RNA.191 1 N N 0.67 
OAZ2 ZNF609 1 N Y 0.67 
ATXN10 RP4-695O20__B.10 1 N N 0.67 
RP11-142A23.1 RP11-656G20.1 1 N Y 0.67 
SLC25A33 SPSB1 1 N N 0.67 
DCBLD2 MINA 1 N N 0.5 
HSP90AB1 SLC29A1 1 Y Y 0.5 
AMPD2 STXBP3 1 Y N 0.5 
AQP5 AQP6 1 Y Y 0.5 
CAPRIN2 FAR2 1 N N 0.5 
SERINC2 WASF2 1 N N 0.5 
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FAM19A1 PTPRG 1 N N 0.5 
TBL3 ZNRF2 1 Y N 0.5 
KIF16B RP3-410C9.1 1 N N 0.5 
MND1 TRIM2 1 0.50_Y Y 0.5 
BLM RCCD1 1 Y N 0.5 
SYT8 TNNI2 1 Y Y 0.5 
RP5-1024N4.1 SKINTL 1 N Y 0.5 
L2HGDH MAP4K5 1 Y N 0.5 
EIF2C2 WDR67 1 Y N 0.5 
ACAP2 VPS8 1 Y N 0.5 
BCL2L13 RP11-14C22.6 1 N N 0.5 
C1orf21 RNF2 1 N N 0.5 
RGN RP2 1 0.50_Y N 0.5 
PLCE1 SLC5A11 1 N N 0.5 
RP11-285C1.2 TRIM2 1 N Y 0.5 
BCLAF1 ENC1 1 N N 0.5 
SMTNL1 TIMM10 1 N Y 0.5 
RP4-610C12.1 SMUG1 1 N N 0.5 
AC093768.1 SLC29A1 1 N N 0.5 
GLG1 STAC2 1 Y N 0.5 
MYOM1 NEDD4L 1 N N 0.5 
NPR2 RP11-112J3.16 1 N Y 0.5 
AC005682.6 MAP4 1 N N 0.5 
CEP63 RP11-680B3.2 1 N N 0.5 
ATP6V1H PLEKHA2 1 Y N 0.5 
AL591415.1 RP11-543D5.1 1 N Y 0.5 
DTD1 RP11-379J5.2 1 N Y 0.5 
CBX1 RP11-390F4.6 1 N N 0.5 
ATP5G1P7 TSPAN15 1 N Y 0.5 
AP001610.9 AP006748.1 1 N Y 0.5 
GGT1 IGSF3 1 N N 0.5 
TPD52 U6.413 1 N N 0.5 
AC091849.1 CTD-2245E15.3 1 N Y 0.5 
CACNB1 RPL19 1 N Y 0.5 
LRPPRC SPDYA 1 Y N 0.5 
BCL7C MGRN1 1 N N 0.5 
RP11-1L12.3 SLC5A12 1 N N 0.5 
CDC45 PARVB 1 Y N 0.5 
AF064860.7 IGSF5 1 N Y 0.5 
CTB-63M22.1 PLEKHM3 1 N N 0.5 
SPAG17 WARS2 1 N N 0.5 
BDP1 NAIP 1 Y N 0.5 
AC011897.2 NBAS 1 N N 0.5 
CTNND2 SRFBP1 1 N N 0.5 
C4orf3 FABP2 1 N Y 0.5 
AC019181.2 SLC38A11 1 N N 0.5 
GLS STAT4 1 Y Y 0.5 
CDH1 TMCO7 1 Y Y 0.5 
NCAPH2 NPTXR 1 0.10_Y N 0.2 
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C17orf37 GRB7 1 N Y 0.17 
PLEKHO1 VPS45 1 N Y 1 
RP11-439A17.7 SRGAP2 1 N N 1 
CDC37 KISS1R 1 Y N 1 
AIM1L UBXN11 1 Y Y 1 
TEX9 USP3 1 N N 1 
HOXC5 HOXC9 1 N Y 1 
ATP6V1B1 VAX2 1 N Y 1 
RP1-154K9.2 U6.507 1 N Y 1 
SMAP1 TPBG 1 N N 1 
RP11-322M19.1 VTI1A 1 N N 1 
NUP155 WDR70 1 Y N 1 
THOP1 ZNF554 1 N Y 1 
KDM2A SYT12 1 Y N 1 
ARFGEF1 KCNB2 1 N N 1 
5S_rRNA.78 PMM2 1 N N 1 
C1orf94 KIAA1522 1 N N 1 
GFER ZNRF2 1 Y N 1 
AC004066.3 PPA2 1 N N 1 
C20orf26 NINL 1 N N 1 
CXorf31 PHF16 1 N Y 1 
CORO7 HMOX2 1 N N 1 
RNF38 RP11-84P7.2 4 N N 0 
AC005532.5 C1GALT1 3 N Y 0 
ATF1 CSRNP2 2 N N 0 
FGB RP5-857K21.4 2 N N 0 
RP5-857K21.6 RPS18 2 N N 0 
ATIC FN1 2 N Y 0 
FABP1 SMAD2 2 N N 0 
PPDPF PTK6 1 N Y 0 
AC006008.1 ACTR3B 1 N N 0 
KRT18 LOH12CR1 1 N N 0 
BCL7C PLCE1 1 N N 0 
SKAP1 Y_RNA.493 1 N Y 0 
METTL4 SMCHD1 1 N N 0 
AC091172.1 WNT3 1 N N 0 
FBXL6 ZNF252 1 N N 0 
ABLIM3 CTC-529P8.1 1 N N 0 
GSDMD RP11-661A12.5 1 N Y 0 
RP11-113G13.2 USO1 1 N N 0 
C1orf94 CSMD2 1 N Y 0 
AC091320.2 RP11-328J2.1 1 N N 0 
EDARADD ERP44 1 N N 0 
C9orf163 SEC16A 1 N Y 0 
CR381670.1 PHF20 1 N N 0 
NBAS RP11-339A11.1 1 N N 0 
PTGR1 RNASE10 1 N N 0 
RGS20 RP11-419C23.1 1 N N 0 
GDAP1L1 HNF4A 1 Y N 0 
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LIMA1 NIPAL2 1 N N 0 
MIR1268 TMEM87A 1 N N 0 
EFHA1 ZDHHC20 1 N N 0 
CPSF1 WWOX 1 N N 0 
RP11-504G3.1 UEVLD 20 N N 0 
C19orf21 PALM 17 N Y 0 
ANKDD1A SPG21 16 N Y 0 
PLCB3 RP11-783K16.13 16 N Y 0 
AP000963.2 CXADR 13 N Y 0 
EDF1 PHPT1 12 N Y 0 
CCDC162 RP11-425D10.1 11 N N 0 
C4orf48 WHSC2 11 N Y 0 
AC016735.1 AC016735.2 10 N Y 0 
LRRC25 SSBP4 8 N N 0 
CTA-398F10.2 TSPAN15 7 N N 0 
GRIN2D KDELR1 6 N Y 0 
PDE4DIP RP11-289I10.2 6 N N 0 
BLCAP RPL7AP14 6 N Y 0 
RP11-395P17.3 SLC25A25 5 N Y 0 
FAM83H RP11-429J17.6 5 N Y 0 
AF064858.11 AF064858.8 5 N Y 0 
PLCH2 RP4-740C4.4 5 N Y 0 
CEACAM5 CEACAM7 5 0.12_Y Y 0 
CFTR CTTNBP2 4 N Y 0 
ACTR8 IL17RB 4 N Y 0 
KIAA1274 PRF1 4 N Y 0 
NLRP6 RP11-326C3.2 4 N Y 0 
DPPA2P1 UTY 4 N Y 0 
MT-ATP6 MT-ND4 3 0.33_Y N 0 
GBP4 GBP7 3 N Y 0 
CTC-537E7.1 CTC-537E7.2 3 N Y 0 
CTAGE5 MIA2 3 Y Y 0 
GRPR RP11-431J24.2 3 N Y 0 
ITIH1 NEK4 3 N Y 0 
RP5-857K21.8 TPT1 3 N N 0 
ATP5F1 C1orf162 3 N Y 0 
PDE4DIP RP11-277L2.2 3 N N 0 
AHSG CT45A6 3 N N 0 
AC012363.4 EPB41L5 2 N Y 0 
CATSPERG KCNK6 2 N Y 0 
CTD-2165H16.1 SMAD2 2 N N 0 
DNAH2 KDM6B 2 N Y 0 
CCDC102A GPR114 2 N Y 0 
CCNO DHX29 2 N Y 0 
AC083849.1 CNTNAP2 2 N Y 0 
MT-ATP6 MT-CYB 2 0.50_Y N 0 
DMBX1 RP5-1109J22.3 2 N Y 0 
AC091814.3 DENND3 2 N N 0 
MT-ATP6 MT-ND6 2 N N 0 
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FDPSP8 NEK2 2 N Y 0 
AC022201.4 BRD7P6 2 N Y 0 
KNDC1 VENTX 2 N N 0 
CTD-3035D6.1 RP5-857K21.6 2 N N 0 
FSIP1 THBS1 2 N Y 0 
NCRNA00106 SLC25A6 2 N Y 0 
MALT1 U6.282 2 N Y 0 
NCOA3 SULF2 2 N Y 0 
EPCAM RP5-857K21.4 2 N N 0 
AP001187.1 AP001187.9 2 N N 0 
FPR3 ZNF577 2 N Y 0 
RP5-857K21.4 RPL8 2 N N 0 
MT-ND4 MT-ND6 2 N N 0 
AC006000.4 AC011288.2 2 N Y 0 
LYPLAL1 RP11-135J2.3 2 N Y 0 
MT-CYB MT-ND2 2 0.40_Y N 0 
AVL9 DPY19L1 2 N N 0 
SERPINF2 WDR81 2 0.33_Y Y 0 
HPGD RP11-440I14.2 1 N Y 0 
AAGAB GRINL1A 1 N N 0 
AP2B1 PIPOX 1 N N 0 
RP11-434D9.2 RP11-44F21.4 1 N N 0 
AC013564.1 SMAD6 1 N Y 0 
J01415.25 MT-ND6 1 N N 0 
CTD-2151A2.1 WDR70 1 N N 0 
KDM6A RP11-185O17.3 1 N N 0 
MT-ATP6 MT-ND2 1 N N 0 
ATPBD4 NIT1 1 N N 0 
AAK1 AC092431.3 1 N Y 0 
ACTR3B RP11-728K20.1 1 N N 0 
KCTD8 STXBP3 1 N N 0 
HMGN3 Y_RNA.293 1 N N 0 
ERBB2 WDR59 1 N N 0 
ATP8A2 GTF2F2 1 N N 0 
BTBD8 KIAA1107 1 Y Y 0 
RP11-834C11.5 SMUG1 1 N N 0 
ABCC1 ARID1B 1 N N 0 
ARL13A TRMT2B 1 N N 0 
5S_rRNA.160 PEX5L 1 N Y 0 
TOP1 U2.20 1 N Y 0 
KDM5B MACF1 1 N N 0 
BGN SLC25A6 1 N N 0 
CACNB1 RYR2 1 N N 0 
GATA1 U6.681 1 N Y 0 
HPCAL1 ODC1 1 N Y 0 
CEP70 MRPS22 1 N N 0 
GPR35 PLA2G6 1 Y N 0 
RP4-779E11.3 SMOX 1 N Y 0 
LCTL SMAD6 1 N N 0 
  234 
PVT1 RP11-473O4.5 1 N N 0 
AL049836.1 AL049836.1 1 N N 0 
DIAPH3 RPL13AP25 1 N N 0 
HNRNPA1P27 NOX1 1 N Y 0 
HCP5 SBF2 1 N N 0 
NCL RP5-857K21.8 1 N N 0 
MT-CO3 MT-ND6 1 N N 0 
RP11-391M1.3 SATB1 1 N N 0 
GABPB1 PARP15 1 N N 0 
HNRNPA1P27 XKRX 1 N N 0 
HP RP5-857K21.8 1 N N 0 
HP RP5-857K21.4 1 N N 0 
                # Samples        number of samples this gene fusions has been discovered in  
   In-frame         if the fusion transcript remains an open reading frame 
   Adjacent if  the two genes are located in adjacent 
                Probability≥0.85 percentage of this fusions having predicted probability≥0.85 
 
Table 37.  Summary of fusion transcripts discovered in each normal sample 
Sample # Fusions # In Frame # Adjacent # prob≥0.85 
T011145-9 14 0 7 2 
T020447-3 10 0 8 0 
T020613-1 9 0 8 2 
T020627-1 12 0 7 1 
T022437-2 9 0 6 0 
# Fusion number of gene fusions discovered in each sample 
# In-frame number of the fusion transcript remainning an open reading frame 
# Adjacent number of the two genes which are located in adjacent 
# Probability ≥ 0.85 number of fusions having predicted probability ≥ 0.85 
 
Table 38.  Summary of fusion transcripts discovered in 5 normal samples 
Gene1 Gene2 #Sample (5 total) In Frame Adjacent 
Probability 
≥0.85 
AP001187.1 AP001187.9 3 N N 0 
SYNPO AC011383.1 4 N Y 0 
FABP2 C4orf3 3 N Y 0 
AP001610.9 AP006748.1 1 N Y 0.5 
BAG6 C6orf47 2 N Y 0 
EPS15 CALR4P 2 N Y 0 
GIMAP2 ATP8B1 2 N N 0 
HOXB7 AC036222.1 3 N Y 0.33 
KDM6B DNAH2 1 N Y 0 
RP11-
286E11.1 HADH 2 N Y 0 
RP11-504G3.1 UEVLD 2 N N 0 
AC036222.1 HOXB9 1 N Y 1 
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ACR AC017074.2 1 N N 0 
ANKDD1A SPG21 1 N Y 0 
AP000963.2 CXADR 1 N Y 0 
BCDIN3D RP11-202D20.1 1 N N 0 
CD200 RP11-231E6.1 1 N Y 0 
CORO1C Y_RNA.117 1 N Y 0 
CTD-
2165H16.1 SMAD2 1 N N 1 
EDF1 PHPT1 1 N Y 0 
EPCAM PCBD2 1 N N 0 
GADD45GIP1 DAND5 1 N Y 0 
GSDMD RP11-661A12.5 1 N Y 0 
MEP1A MEP1AP4 1 N N 0 
MICAL2 MICALCL 1 N Y 1 
MT-ATP6 MT-ND6 1 N N 0 
MTCH2 MED15 1 N N 0 
MYH11 AC092024.2 1 N N 0 
NME4 Z97634.5 1 N Y 0 
RP11-
230B22.1 ATG4C 1 N Y 0 
RP11-271E2.1 FGD5 1 N N 0 
RP11-
783K16.13 PLCB3 1 N Y 0 
RP5-857K21.4 RP11-433O3.1 1 N N 0 
SGMS2 HADH 1 N Y 0 
SLC25A25 RP11-395P17.3 1 N Y 0 
SLC25A45 FRMD8 1 N Y 0 
UTY DPPA2P1 1 N Y 0 
               # Samples         number of samples this gene fusions has been discovered in  
   In-frame          if the fusion transcript remains an open reading frame 
  Adjacent  if the two genes are located in adjacent 
               Probability ≥ 0.85 percentage of this fusions having predicted probability ≥ 0.85 
 
Table 39. The overlapping fusion transcripts in CRC and normal samples 
Gene1 Gene2 # In CRC # In normal 
AC011383.1 SYNPO 7 4 
AC017074.2 ACR 10 1 
AC036222.1 HOXB7 7 3 
ANKDD1A SPG21 16 1 
AP000963.2 CXADR 13 1 
AP001187.1 AP001187.9 2 3 
BAG6 C6orf47 10 2 
C4orf3 FABP2 1 3 
CTD-2165H16.1 SMAD2 2 1 
DNAH2 KDM6B 2 1 
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DPPA2P1 UTY 4 1 
EDF1 PHPT1 12 1 
GSDMD RP11-661A12.5 1 1 
HADH RP11-286E11.1 4 2 
MICAL2 MICALCL 6 1 
MT-ATP6 MT-ND6 2 1 
NME4 Z97634.5 11 1 
PLCB3 RP11-783K16.13 16 1 
RP11-395P17.3 SLC25A25 5 1 
RP11-504G3.1 UEVLD 20 2 
# In CRC     numer of CRC samples this fusion has been discovered in 
# In normal  numer of normal samples this fusion has been discovered in 
 
 
 
 
 
